<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Nebulised hypertonic saline for cystic fibrosis - Wark, P - 2023 | Cochrane Library</title> <meta content="Nebulised hypertonic saline for cystic fibrosis - Wark, P - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001506.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Nebulised hypertonic saline for cystic fibrosis - Wark, P - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001506.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001506.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Nebulised hypertonic saline for cystic fibrosis" name="citation_title"/> <meta content="Peter Wark" name="citation_author"/> <meta content="Hunter Medical Research Institute, University of Newcastle" name="citation_author_institution"/> <meta content="peter.wark@newcastle.edu.au" name="citation_author_email"/> <meta content="Vanessa M McDonald" name="citation_author"/> <meta content="The University of Newcastle" name="citation_author_institution"/> <meta content="Sherie Smith" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD001506.pub5" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001506.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001506.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001506.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Amiloride [therapeutic use]; *Cystic Fibrosis [drug therapy]; Mannitol [therapeutic use]; Saline Solution, Hypertonic [therapeutic use]; Sodium; Xylitol [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001506.pub5&amp;doi=10.1002/14651858.CD001506.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001506\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001506\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","fa","th","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001506.pub5",title:"Nebulised hypertonic saline for cystic fibrosis",firstPublishedDate:"Jun 14, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001506.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001506.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001506.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001506.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001506.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001506.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001506.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001506.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001506.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001506.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3127 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001506.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-sec-0212"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-sec-0198"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/appendices#CD001506-sec-0217"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/supinfo/CD001506-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/supinfo/CD001506-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Nebulised hypertonic saline for cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information#CD001506-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Peter Wark</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information#CD001506-cr-0005">Vanessa M McDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information#CD001506-cr-0006">Sherie Smith</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information/en#CD001506-sec-0222">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001506.pub5">https://doi.org/10.1002/14651858.CD001506.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001506-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001506-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001506-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001506-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001506-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD001506-abs-0006">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001506-abs-0001" lang="en"> <section id="CD001506-sec-0001"> <h3 class="title" id="CD001506-sec-0001">Background</h3> <p>Hypertonic saline enhances mucociliary clearance and may lessen the destructive inflammatory process in the airways. This is an update of a previously published review. </p> </section> <section id="CD001506-sec-0002"> <h3 class="title" id="CD001506-sec-0002">Objectives</h3> <p>To investigate efficacy and tolerability of nebulised hypertonic saline treatment in people with cystic fibrosis (CF) compared to placebo or other treatments that enhance mucociliary clearance. </p> </section> <section id="CD001506-sec-0003"> <h3 class="title" id="CD001506-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register, comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We also searched ongoing trials databases. </p> <p>Most recent search: 25 April 2022.</p> </section> <section id="CD001506-sec-0004"> <h3 class="title" id="CD001506-sec-0004">Selection criteria</h3> <p>We included randomised and quasi‐randomised controlled trials assessing hypertonic saline compared to placebo or other mucolytic therapy, for any duration or dose regimen in people with CF (any age or disease severity). </p> </section> <section id="CD001506-sec-0005"> <h3 class="title" id="CD001506-sec-0005">Data collection and analysis</h3> <p>Two authors independently reviewed all identified trials and data, and assessed trial quality. We assessed the certainty of the evidence using GRADE. For cross‐over trials we stipulated a one‐week washout period. We planned to use results from a paired analysis in the review, but this was only possible in one trial. For other cross‐over trials, we chose to treat the trials as if they were parallel. </p> </section> <section id="CD001506-sec-0006"> <h3 class="title" id="CD001506-sec-0006">Main results</h3> <p>We included 24 trials (1318 participants, aged one month to 56 years); we excluded 29 trials, two trials are ongoing and six are awaiting classification. We judged 15 of the 24 included trials to have a high risk of bias due to participants' ability to discern the taste of the solutions. </p> <p>Hypertonic saline 3% to 7% versus placebo (stable disease) </p> <p>We are uncertain whether the regular use of nebulised hypertonic saline in stable lung disease leads to an improvement in forced expiratory volume in one second (FEV<sub>1</sub>) % predicted at four weeks, (mean difference (MD) 3.30%, 95% confidence interval (CI) 0.71 to 5.89; 4 trials, 246 participants; very low‐certainty evidence). In preschool children we found no difference in lung clearance index (LCI) at four weeks, but a small improvement after 48 weeks of treatment with hypertonic saline compared to isotonic saline (MD ‐0.60, 95% CI ‐1.00 to ‐0.19; 2 trials, 192 participants). We are also uncertain whether hypertonic saline made a difference to mucociliary clearance, pulmonary exacerbations or adverse events compared to placebo. </p> <p>Hypertonic saline versus control (acute exacerbation) </p> <p>Two trials compared hypertonic saline to control, but only one provided data. There may be little or no difference in lung function measured by FEV<sub>1</sub> % predicted after hypertonic saline compared to isotonic saline (MD 5.10%, 95% CI ‐14.67 to 24.87; 1 trial, 130 participants). Neither trial reported any deaths or measures of sputum clearance. There were no serious adverse events. </p> <p>Hypertonic saline versus rhDNase </p> <p>Three trials compared a similar dose of hypertonic saline to recombinant deoxyribonuclease (rhDNase); two trials (61 participants) provided data for inclusion in the review. We are uncertain whether there was an effect of hypertonic saline on FEV<sub>1</sub> % predicted after three weeks (MD 1.60%, 95% CI ‐7.96 to 11.16; 1 trial, 14 participants; very low‐certainty evidence). At three months, rhDNase may lead to a greater increase in FEV<sub>1</sub> % predicted than hypertonic saline (5 mL twice daily) at 12 weeks in participants with moderate to severe lung disease (MD 8.00%, 95% CI 2.00 to 14.00; low‐certainty evidence). We are uncertain whether adverse events differed between the two treatments. No deaths were reported. </p> <p>Hypertonic saline versus amiloride </p> <p>One trial (12 participants) compared hypertonic saline to amiloride but did not report on most of our outcomes. The trial found that there was no difference between treatments in measures of sputum clearance (very low‐certainty evidence). </p> <p>Hypertonic saline compared with sodium‐2‐mercaptoethane sulphonate (Mistabron®) </p> <p>One trial (29 participants) compared hypertonic saline to sodium‐2‐mercaptoethane sulphonate. The trial did not measure our primary outcomes. There was no difference between treatments in any measures of sputum clearance, courses of antibiotics or adverse events (very low‐certainty evidence). </p> <p>Hypertonic saline versus mannitol </p> <p>One trial (12 participants) compared hypertonic saline to mannitol, but did not report lung function at relevant time points for this review; there were no differences in sputum clearance, but mannitol was reported to be more 'irritating' (very low‐certainty evidence). </p> <p>Hypertonic saline versus xylitol </p> <p>Two trials compared hypertonic saline to xylitol, but we are uncertain whether there is any difference in FEV<sub>1</sub> % predicted or median time to exacerbation between groups (very low‐certainty evidence). No other outcomes were reported in the review. </p> <p>Hypertonic saline 7% versus hypertonic saline 3% </p> <p>We are uncertain whether there was an improvement in FEV<sub>1</sub> % predicted after treatment with 7% hypertonic saline compared with 3% (very low‐certainty evidence). </p> </section> <section id="CD001506-sec-0007"> <h3 class="title" id="CD001506-sec-0007">Authors' conclusions</h3> <p>We are very uncertain if regular use of nebulised hypertonic saline by adults and children over the age of 12 years with CF results in an improvement in lung function after four weeks (three trials; very low‐certainty evidence); there was no difference seen at 48 weeks (one trial; low‐certainty evidence). Hypertonic saline improved LCI modestly in children under the age of six years. </p> <p>Evidence from one small cross‐over trial in children indicates that rhDNase may lead to better lung function than hypertonic saline at three months; qualifying this, we highlight that while the study did demonstrate that the improvement in FEV<sub>1</sub> was greater with daily rhDNase, there were no differences seen in any of the secondary outcomes. </p> <p>Hypertonic saline does appear to be an effective adjunct to physiotherapy during acute exacerbations of lung disease in adults. However, for the outcomes assessed, the certainty of the evidence ranged from very low to low at best, according to the GRADE criteria. </p> <p>The role of hypertonic saline in conjunction with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy now needs to be considered, and future research needs to focus on this aspect. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001506-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001506-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001506-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001506-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001506-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001506-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD001506-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001506-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001506-abs-0002" lang="en"> <h3>Hypertonic saline (salt water with at least 3% salt) nebulised as a fine mist through a mask or mouthpiece for cystic fibrosis </h3> <p><b>Review question</b> </p> <p>Is inhaling hypertonic saline (salt water with at least 3% salt) as a mist through a mask or mouthpiece better for improving mucus clearance in the lungs of people with cystic fibrosis (CF) than a placebo (a mist with no or very little salt) or other agents? </p> <p><b>Background</b> </p> <p>People with CF produce large amounts of thick mucus which is difficult to clear and blocks up their airways. Chest physiotherapy or medication, e.g. hypertonic saline, or both combined, are used to try and clear this mucus from the airways. Hypertonic saline is water with a concentration of 3% to 7% salt and is inhaled as a fine mist. This is an update of an earlier review. </p> <p><b>Key messages</b> </p> <p>• We are uncertain whether inhaling nebulised hypertonic saline regularly improves lung function compared to placebo. </p> <p>• Nebulised hypertonic saline does seem to work well as an add‐on to physiotherapy.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at the use of nebulised hypertonic saline compared to either a placebo or a different type of treatment for clearing mucus from the lungs. We compared the size and methods of the studies and stated how confident we were in the results. </p> <p><b>What did we find?</b> </p> <p>We included 24 trials with 1318 people with CF aged between one month and 56 years. Two thirds of the trials compared hypertonic saline to a placebo (a dummy treatment); the remaining trials compared hypertonic saline to another type of mucus clearing treatment (including mannitol; rhDNase (Pulmozyme®); amiloride; Mistabron®; xylitol); and one trial compared 7% hypertonic saline with 3% hypertonic saline. Trials assessed different concentrations of hypertonic saline with different nebulisers and different treatment schedules; the most common treatment was twice‐daily 7% hypertonic saline and the most common nebuliser was ultrasonic. Most trials treated people with a bronchodilator to widen the airways before giving the hypertonic saline. </p> <p><b>Main results</b> </p> <p><b><i>Hypertonic saline 3% to 7% versus placebo</i> </b> </p> <p>We are not sure whether hypertonic saline leads to an improvement in lung function in stable disease after four weeks. Two trials showed that there may be a small improvement in lung function (measured using the lung clearance index) with hypertonic saline compared to placebo in preschool children. We are also unsure whether hypertonic saline makes a difference to clearing mucus from the lungs, exacerbations or side effects compared to placebo. </p> <p>During exacerbations, we found that there may be little or no difference in lung function after hypertonic saline compared to placebo. The trials did not report any serious side effects and there were no deaths. </p> <p>One study compared 7% hypertonic saline with a lower concentration of hypertonic saline (3%); we are uncertain whether the higher concentration improved lung function. </p> <p><b><i>Hypertonic saline versus mucus mobilising treatments</i> </b> </p> <p>Three trials compared hypertonic saline with rhDNase and found that rhDNase may lead to an improvement in lung function compared to hypertonic saline after three months. We are unsure whether there is any difference in side effects. </p> <p>One trial compared hypertonic saline to amiloride and a further trial compared hypertonic saline to sodium‐2‐mercaptoethane sulphonate (Mistabron®), but neither of the trials gave information about the effect of the treatments on lung function. </p> <p>Similarly, a trial comparing hypertonic saline with mannitol did not give information about the effects on lung function, but they did report that there was no difference between treatments in clearing mucus from the lungs. People taking mannitol said it was more irritating than hypertonic saline. </p> <p>Two trials compared hypertonic saline with xylitol, but we are unsure if there is any difference in lung function and none of our other outcomes were measured. </p> <p><b>What are the limitations of this evidence?</b> </p> <p>We are not confident in the evidence from these trials. There is a high risk that people knew which treatment they were receiving in half the trials as they could taste the difference between the solutions. </p> <p>Other factors that made us unsure of the results were the small numbers of people taking part in the trials combined with a wide variation in results; also, some trials limited participants to those who could tolerate hypertonic saline or to certain age groups. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is current to 25 April 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001506-sec-0212" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001506-sec-0212"></div> <h3 class="title" id="CD001506-sec-0213">Implications for practice</h3> <section id="CD001506-sec-0213"> <p>There is low to very low‐certainty evidence showing the benefits of hypertonic saline compared to placebo in those over the age of 12 years with cystic fibrosis (CF) in terms of improvement in lung function, at least in the short term, but it should not be used in preference to dornase alfa (rhDNase). At this stage the benefit appears to be a modest reduction in frequency of pulmonary exacerbations, and an improvement in chest symptoms, though evidence does not exist to say in whom it works best. In children under the age of 12 years we have not found sufficient evidence to justify its routine use. In those over the age of six years, an improvement in exacerbation frequency was not seen, and in this cohort of children with milder lung disease, the modest benefits seen with hypertonic saline in earlier trials could not be detected. One small cross‐over trial in 10 children reported a small improvement, but this was not seen in our analysis (very low‐certainty evidence). </p> <p>In preschool children, hypertonic saline led to an improvement in lung clearance index (LCI). It has been argued that, in this age group, LCI is a surrogate clinical predictor of early lung disease; it is a test that can readily be performed in the clinic and is more responsive to change than other parameters of infant lung function ‐ an effect that is consistent with our analysis. The effect size in change in LCI, while positive, was also modest. The implication that this may have for longer‐term outcomes such as decline in lung function is unclear. </p> <p>An important consideration now is the place of therapy with hypertonic saline in the context of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use. Especially in those individuals with minimal bronchiectasis and sputum production, the place for additional inhalational therapies to improve mucus clearance is now uncertain. </p> <p>The variation in response seen in individuals to both rhDNase and hypertonic saline raises the possibility that certain individuals will respond better to one agent compared to the other. In order to assess the individual response to therapy, it would therefore be reasonable to conduct a modified N of 1 trial in people with CF where the person acts as their own control, on and off treatment. Suitable individuals to consider therapy are those in the clinic who fail to respond, are ineligible or are unable to tolerate rhDNase; with hypertonic saline used as an alternative agent to increase mucociliary clearance. Unfortunately, there are no data on the effects of hypertonic saline in combination with rhDNase. </p> <p>In the majority of trials hypertonic saline was used after pretreatment with bronchodilators and as an adjunct to chest physiotherapy; in both cases this may be important to ensure its efficacy. When delivered following a bronchodilator, hypertonic saline is an inexpensive and safe therapy for people with CF. </p> </section> <h3 class="title" id="CD001506-sec-0214">Implications for research</h3> <section id="CD001506-sec-0214"> <p>The effect hypertonic saline has on mucus clearance, and consequently short‐term improvements in lung function, is relatively small in all age groups. The most relevant consideration now is the place of therapy with hypertonic saline in people with CF on CFTR modulators. Important questions now to consider would include: what is their benefit, if any, in the context of modulator use? Who should be targeted in therapy? And when should hypertonic saline be considered? Finally, when can mucus clearance therapies be safely withdrawn? Considering the clear benefit of modulator therapy in those who are suitable, these are now the most important questions to consider regarding the use of all mucus clearance therapies. </p> <p>Future assessments of efficacy for agents that improve mucociliary clearance should be assessed in robust longer‐term randomised controlled trial designs. These should consider alternative primary outcomes, such as pulmonary exacerbations or validated quality of life (QoL) measures, as these appear to be more responsive to change for this intervention than conventional lung function tests. Measurement of pulmonary exacerbation rates are difficult and would benefit from tighter clinical definitions, especially around milder exacerbations. The emergence of more sensitive measures of early disease, such as LCI or chest computer tomography (CT), may provide novel outcomes that are a more sensitive index to change, as has been the case in preschool children. However, their role in terms of clinical outcomes in the long term remains less certain. It may be possible to obtain these data in retrospect from national data registries. Equally, it will be important to determine the impact that CFTR modulators have on the use of these therapies, their uptake and adherence. </p> <p>There is also a good case for undertaking equivalence trials comparing hypertonic saline to other interventions, as hypertonic saline is likely to remain less costly, especially where new treatments tend to be associated with increased costs. </p> <p>Consideration should be given to defining whether there are groups of individuals who will respond better to hypertonic saline or other mucociliary clearance agents, especially rhDNase, to better tailor treatment. Any future trials of hypertonic saline should determine who will benefit most from this intervention. Trials that combine mucociliary agents or physical therapy, or both, also need to be considered to assess efficacy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001506-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001506-sec-0008"></div> <div class="table" id="CD001506-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (stable lung disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (stable lung disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis (stable lung disease) </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline 3% to 7% </p> <p><b>Comparison:</b> isotonic saline </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Isotonic saline</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 3% to 7%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (% predicted) ranged from ‐1.42 to 2.8 in the isotonic saline groups. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (% predicted) was 3.30 higher (0.71 higher to 5.89 higher) in the hypertonic saline group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246</p> <p>(4 trials)<b><sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c,d,e</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> <p> </p> <p>Follow‐up: 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (% predicted) was 2.44 in the isotonic saline group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (% predicted) was 2.31 higher (2.72 lower to 7.34 higher) in the hypertonic saline group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,e</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial also measured change in FEV<sub>1</sub> (% predicted) at: </p> <p>12 weeks, MD 4.10 (95% CI ‐0.08 to 8.28); 24 weeks, MD 5.37 (95% CI 1.03 to 9.71); and 36 weeks, MD 3.63 (95% CI ‐1.56 to 8.82). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> <p> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean LCI was 8.89 in the isotonic saline group.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean LCI was 1.03 lower (2.76 lower to 0.70 higher) in the hypertonic saline group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>f,g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design.</p> <p>2 trials reported change from baseline in LCI at 12 months in preschool children and found a slight difference between groups favouring hypertonic saline MD ‐0.60 (95% CI ‐1.00 to ‐0.19). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: up to 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The trials used radio‐labelled aerosol clearance and an 'area under the curve' measure to assess mucociliary clearance. </p> <p>Both measures significantly favoured treatment with hypertonic saline.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,e,f</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All trials had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: up to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 trial showed that there were fewer exacerbations per year requiring intravenous antibiotic therapy in the hypertonic saline group than in the isotonic saline group and that the interval during which participants remained free of exacerbations was also significantly longer in the hypertonic saline group. </p> <p> </p> <p>The second trial found no difference in the mean number of exacerbations per year or hospitalisation rates between the hypertonic saline group and the controls. </p> <p> </p> <p>2 further trials reported the rate of exacerbations in preschool children and found no difference between groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>607</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>very low<sup>e,h,i</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: up to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no differences between treatment groups in most adverse events including cough,chest tightness, pharyngitis, haemoptysis, sinusitis, sneezing, tonsillitis and vomiting. </p> <p>Fever was slightly more common in the isotonic saline group whilst rhinorrhoea was more common in the hypertonic saline group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further trial reported adverse events at this time point, but reported number of events rather than number of participants experiencing adverse events and we have not included these data in the analysis. </p> <p>Adverse events were also reported in shorter‐term trials.</p> <p>Single‐dose trials: there was little difference in the drop in FEV<sub>1</sub> within 5 minutes of receiving hypertonic saline (MD 5.20%, 95% CI ‐0.59 to 10.99; 1 trial, 12 participants) but participants reported throat irritation, shortness of breath and chest tightness related to inhalation of hypertonic saline. </p> <p>Medium‐term trials: 3 trials reported at 2 to 4 weeks and no differences were reported for cough, hoarseness, chest pain, pharyngitis, haemoptysis, wheezing, or nasal congestion. 1 trial reported more adverse events in the hypertonic saline group for fever, rhinorrhoea, malaise and ear infections (P = 0.003). The same trial reported increased sputum production in the hypertonic saline group whilst the remaining 2 trials did not report this adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second;<b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA:</b> not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>1 trial (n = 19) was of a cross‐over design.<br/><sup>b</sup>Downgraded once due to risk of bias arising from participants being able to discern the taste of the intervention and limited information about trial methods.<br/><sup>c</sup>Downgraded once due to imprecision caused by wide CIs.<br/><sup>d</sup>Downgraded once due to inconsistency as there was substantial heterogeneity (I<sup>2</sup> = 51%) which may have originated from different age groups recruited in the trials or different baseline levels of lung function.<br/><sup>e</sup>Downgraded once due to indirectness as the results only apply to those who can tolerate hypertonic saline.<br/><sup>f</sup>Downgraded twice due to imprecision: cross‐over trial analysed as a parallel trial (due to available data) which is likely to over‐estimate the within‐trial variability and increase imprecision, and small number of participants.<br/><sup>g</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline and the trial only included children aged 6 to 18 years, so results may not apply to adults.<br/><sup>h</sup>Downgraded once due to risk of bias: 1 trial was at high risk of detection bias as participants could discern the taste of the intervention.<br/><sup>i</sup>Downgraded once for inconsistency as there was heterogeneity in the results of the trials. Three out of the four trials reported no difference whilst one trial found a slight difference in favour of hypertonic saline. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001506-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (during acute exacerbations of lung disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (during acute exacerbations of lung disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis (during acute exacerbations of lung disease) </p> <p><b>Settings:</b> hospitalised patients and outpatients </p> <p><b>Intervention:</b> hypertonic saline 3% to 7% </p> <p><b>Comparison:</b> isotonic saline </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Isotonic saline</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 3% to 7%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: approximately 14 days (at time of hospital discharge)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % change in FEV<sub>1</sub> (% predicted) was 32.3% in the isotonic saline group. </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % change in FEV<sub>1</sub> (% predicted) was 5.10% higher (14.67% lower to 24.87% higher) in the hypertonic saline 3% to 7% group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths were reported in either trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no significant difference between the groups in time until the next pulmonary exacerbation requiring hospitalisation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.86 (95% CI 0.57 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Adverse events reported were cough and wheeze.</p> <p>No serious adverse events were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>HR</b> : hazard ratio;<b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias: high risk of selection bias due to sequential allocation.<br/><sup>b</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline, and the trial included only adults so results may not apply to children.<br/><sup>c</sup>Downgraded once due to risk of bias: first trial was at high risk of detection bias as participants could discern the taste of the intervention, second trial was at high risk of selection bias due to sequential allocation.<br/><sup>d</sup>Downgraded once due to imprecision: no numerical data provided and small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001506-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hypertonic saline compared with rhDNase with for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with rhDNase with for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline (daily) </p> <p><b>Comparison:</b> rhDNase (daily)<sup>a</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>rhDNase</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: 3 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change from baseline in FEV<sub>1</sub> (% predicted) was 1.6% higher (7.96% lower to 11.16% higher) in the hypertonic saline group compared to the daily rhDNase group.<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>c,d,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design.</p> <p> </p> <p>No significant difference in the primary outcome (lung function) at this time‐point, with improvements only in secondary outcomes. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> <p> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change from baseline in FEV<sub>1</sub> (% predicted) was 8% higher (2% higher to 14% higher) in the hypertonic saline group compared to the daily rhDNase group.<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,f,g</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design.</p> <p>An additional cross‐over trial of 18 participants found no difference between treatments in FEV<sub>1</sub> after 10 weeks (no data presented). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of sputum clearance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>15 episodes occurred during treatment with hypertonic saline and 18 with daily rhDNase. There was no statistical difference between treatments (see comment). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,f,g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design.</p> <p>Number of episodes reported rather than the number of participants with exacerbations (leading to a unit of analysis issue) so data not entered into the analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Increased cough was reported in 13 participants using hypertonic saline and 17 on daily rhDNase. There were similar rates of other adverse events between treatment arms (see comment). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,f,g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design, so data not entered into analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>An alternate day rhDNase group was also included in 1 trial (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>), but to allow a comparison across the trials, only results from the rhDNase daily group are presented in the tables.<br/><sup>b</sup>Data analysed as MD between treatment groups via generic inverse variance due to cross‐over design of the trial; therefore, an estimate of the assumed risk is not available.<br/><sup>c</sup>Downgraded once due to risk of bias: high risk of detection bias as participants could discern the taste of the intervention and limited information was provided about the methodological design of the trial.<br/><sup>d</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline.<br/><sup>e</sup>Downgraded once due to imprecision: cross‐over trial analysed as a parallel trial due to available data, this approach is likely to over‐estimate the within study variability and increase imprecision; also small sample size.<br/><sup>f</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline, and the trial included only participants under the age of 18 so results may not apply to adults.<br/><sup>g</sup>Downgraded once due to imprecision: small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001506-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hypertonic saline compared with amiloride for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with amiloride for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline </p> <p><b>Comparison:</b> amiloride </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Amiloride</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: change from baseline, short‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: change from baseline, long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: 60 minutes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no significant difference between treatment groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>LCI</b> : lung clearance index; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias: high risk of detection bias as participants could discern the taste of the intervention and limited information was provided about the trial methods (including whether a washout period was used).<br/><sup>b</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline, and the trial included only adults so results may not apply to children.<br/><sup>c</sup>Downgraded once due to imprecision: no numerical data provided and small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001506-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Hypertonic saline compared with sodium‐2‐mercaptoethane sulphonate (Mistabron®) for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with sodium‐2‐mercaptoethane sulphonate (Mistabron®) for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline </p> <p><b>Comparison:</b> sodium‐2‐mercaptoethane sulphonate </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sodium‐2‐mercaptoethane sulphonate</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: short‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant difference in sputum volume, colour or cough frequency between the groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> <p>The only information provided relevant to this outcome was that there was no change in the number of courses of antibiotics prescribed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> <p>Participants in both treatment groups described coughing at the beginning of their inhalations. </p> <p>No serious adverse events occurred during the trial.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>LCI</b> : lung clearance index; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias: high risk of detection bias as participants could discern the taste of the intervention and limited information was provided about the trial design.<br/><sup>b</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline and the trial included only children aged 6 to 15 years so results may not apply to other age groups.<br/><sup>c</sup>Downgraded once due to imprecision: no numerical data provided and small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001506-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Hypertonic saline compared with mannitol for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with mannitol for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline </p> <p><b>Comparison:</b> mannitol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mannitol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: short‐term </p> <p> </p> <p>Follow‐up: up to 95 minutes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> <p>FEV<sub>1</sub> was assessed in the included trial at 5 minutes and 95 minutes postintervention. These very short‐term time‐points are not of clinical relevance to this review. </p> <p>Change from baseline within‐groups was reported but no between‐group data.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: up to 95 minutes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no significant difference between treatment groups for matched voluntary cough. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: up to 95 minutes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> <p>Mannitol was considered to be a more 'irritating' treatment than other treatments (4‐armed trial); no specific data given. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>LCI</b> : lung clearance index; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias: high risk of detection bias as participants could discern the taste of the intervention and no washout period was used.<br/><sup>b</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline, and the trial included only participants over the age of 16 so results may not apply to younger children.<br/><sup>c</sup>Downgraded once due to applicability: the outcome measured only at very short‐term time points (minutes after intervention), which are not of clinical relevance to this review.<br/><sup>d</sup>Downgraded once due to imprecision: no numerical data provided and small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001506-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Hypertonic saline 7% versus xylitol for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline 7% versus xylitol for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline 7% </p> <p><b>Comparison:</b> aerosolised xylitol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Xylitol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 7%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub> % predicted ranged from ‐0.1 to 8.8. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub> % predicted was 1.89% higher in the hypertonic saline </p> <p>(0.8% lower to 4.58% higher).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths were reported in either trial.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of sputum clearance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference in median time to exacerbation between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were presented as a graph and we have reported narratively</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> serious adverse events </p> <p> </p> <p>Follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference between groups in relation to serious adverse events, RR 4.07 (95% CI 0.47 to 35.34). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no differences between treatment groups in specific adverse events including gastro‐intestinal disorders, hepato‐biliary disorders, bronchospasm, haemoptysis or vascular disorders. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second;<b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA:</b> not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias due to trial methods being unclear in one trial and the risk of participants being able to discern the taste of the interventions due to their sweet and salty taste.<br/><sup>b</sup>Downgraded once due to imprecision caused by small participant numbers.<br/><sup>c</sup>Downgraded once due to indirectness as the trials were only carried out in adults and the results may not be applicable to children.<br/><sup>d</sup>Downgraded once due to imprecision caused by low participant numbers, low event rates and wide CIs. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001506-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Hypertonic saline 7% versus hypertonic saline 3% for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline 7% versus hypertonic saline 3% for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline 7% </p> <p><b>Comparison:</b> hypertonic saline 3% </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 3%</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 7%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in FEV<sub>1</sub> % predicted was 12.53% (20.04). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV1 % predicted was 13.00% lower in the hypertonic saline 7% group</p> <p>(25.20% lower to 0.73% lower).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a, b, c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial was seriously underpowered and was carried out as a pilot study (sample size calculation stated that 394 participants were needed and the pilot trial included 30). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of sputum clearance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second;<b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA:</b> not applicable; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias due to the trial being seriously underpowered.<br/><sup>b</sup>Downgraded once due to imprecision caused by small participant numbers.<br/><sup>c</sup>Downgraded once due to indirectness as the trials were only carried out in children and the results may not be applicable to adults. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001506-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001506-sec-0009"></div> <section id="CD001506-sec-0010"> <h3 class="title" id="CD001506-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is the most common life‐limiting autosomal recessive genetic disorder in populations of Northern European descent (<a href="./references#CD001506-bbs2-0062" title="BobadillaJL , MacekM , FineJP , FarrellPM . Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Human Mutation2002;19(6):575-606.">Bobadilla  2002</a>). In 1989, the gene responsible was identified on the long arm of chromosome 7 (<a href="./references#CD001506-bbs2-0071" title="KeremB , RommensJM , BuchananJA , MarkiewiczD , CoxTK , ChakravartiA , BuchwaldM , Tsui LC. Identification of the cystic fibrosis gene: Genetic analysis. Science1989;245:1073-1080.">Kerem 1989</a>). This gene encodes for a protein named the cystic fibrosis transmembrane conductance regulator (CFTR), which functions as a chloride channel on the surface of epithelial cells. The altered CFTR is thought to result in defects of electrolyte transport which then cause increased water reabsorption across respiratory epithelia. This may lead to dehydration of the airway surface liquid, which in turn may prevent normal clearance of mucus (<a href="./references#CD001506-bbs2-0065" title="DavisP , DrummM , KonstanW . Cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(5):1229-56.">Davis 1996</a>), although the precise mechanism by which CFTR causes abnormal mucus is still unknown. </p> </section> <section id="CD001506-sec-0011"> <h3 class="title" id="CD001506-sec-0011">Description of the intervention</h3> <p>Improvement of sputum clearance is a major therapeutic aim in CF. Treatments to improve mucus clearance in CF include chest physiotherapy, with and without the addition of agents that enhance mucus clearance. Treatment with nebulised recombinant deoxyribonuclease (rhDNase) has been widely accepted to be of benefit in CF (<a href="./references#CD001506-bbs2-0076" title="YangC , MontgomeryM . Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD001127. [DOI: 10.1002/14651858.CD001127.pub5]">Yang 2021</a>), and is thought to exert its major effect by enhancing sputum clearance. However, treatment with rhDNase is relatively expensive and its use in most countries is restricted as a consequence. Hypertonic saline may represent a potential alternative or supplementary therapy to improve mucociliary clearance in the context of long‐term maintenance therapy or during times of acute worsening of lung disease in CF. </p> </section> <section id="CD001506-sec-0012"> <h3 class="title" id="CD001506-sec-0012">How the intervention might work</h3> <p>In vitro deposition of hypertonic saline onto the airway surface improves mucus clearance. Dasgupta demonstrated that the addition of 3% hypertonic saline improved measures of sputum clearance and that hypertonic saline had a greater effect on mucus clearance in vitro than rhDNase (<a href="./references#CD001506-bbs2-0064" title="DasguptaB , TomkiewiczRP , BrownNE , KingM . Combined effects of hypertonic saline and rhDNase on cystic fibrosis sputum in-vitro. Pediatric Pulmonology1995;20(Suppl 12):A201-A236.">Dasgupta 1995</a>). The postulated molecular mechanism of this effect is as follows: </p> <p> <ol id="CD001506-list-0001"> <li> <p>hypertonic saline breaks the ionic bonds within the mucus gel, which could reduce the degree of cross‐linking and entanglements and lower viscosity and elasticity (<a href="./references#CD001506-bbs2-0077" title="ZimentI . Respiratory pharmacology and therapeutics. Philadelphia: WB Saunders, 1978.">Ziment 1978</a>); </p> </li> <li> <p>with chronic infection the mucin macromolecules develop fixed negative charges, causing increased repulsion; the addition of hypertonic saline increases the ionic concentration of the mucus and causes a conformational change by shielding the negative charges and thereby reducing repulsion ‐ this would result in a more compact mucus macromolecule that would allow more effective clearance (<a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>); </p> </li> <li> <p>in addition hypertonic saline induces an osmotic flow of water into the mucus layer, rehydrating secretions and thereby improving mucus rheology (<a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>). </p> </li> </ol> </p> </section> <section id="CD001506-sec-0013"> <h3 class="title" id="CD001506-sec-0013">Why it is important to do this review</h3> <p>In the long term, improvement in mucociliary function may reduce bacterial load and chronic inflammation within the airways and therefore reduce the decline in lung function that is consequent to this. Hypertonic saline is easy and inexpensive to produce. Therefore, it is important to determine if nebulised hypertonic saline improves outcomes in CF, and to determine the frequency of adverse effects. This is an update of a previously published review (<a href="./references#CD001506-bbs2-0078" title="WarkP , McDonaldV . Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews1999, Issue 2. Art. No: CD001506. [DOI: 10.1002/14651858.CD001506]">Wark 1999</a>; <a href="./references#CD001506-bbs2-0079" title="WarkP , McDonaldV . Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews2000, Issue 2. Art. No: CD001506. [DOI: 10.1002/14651858.CD001506]">Wark 2000</a>; <a href="./references#CD001506-bbs2-0080" title="WarkP , McDonaldV . Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews2003, Issue 1. Art. No: CD001506. [DOI: 10.1002/14651858.CD001506.pub2]">Wark 2003</a>; <a href="./references#CD001506-bbs2-0081" title="Wark, P, McDonaldVM . Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews2009, Issue 2. Art. No: CD001506. [DOI: 10.1002/14651858.CD001506.pub3]">Wark 2009</a>; <a href="./references#CD001506-bbs2-0082" title="WarkP , McDonaldVM . Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 9. Art. No: CD001506. [DOI: 10.1002/14651858.CD001506.pub4]">Wark 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001506-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001506-sec-0014"></div> <p>To investigate efficacy and tolerability of nebulised hypertonic saline treatment in people with CF compared to placebo or other treatments that enhance mucociliary clearance. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001506-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001506-sec-0015"></div> <section id="CD001506-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001506-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included controlled clinical trials, both random allocation and quasi‐random allocation (e.g. where there is alternate allocation to treatment and control groups). </p> </section> <section id="CD001506-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of all ages and of both sexes with CF diagnosed clinically or by sweat and genetic testing, including all degrees of disease severity, were eligible. </p> </section> <section id="CD001506-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies of nebulised hypertonic saline (defined as any concentration of saline greater than or equal to 3% delivered via a mask or mouthpiece with a nebuliser pump) compared to either placebo or usual treatment or any other mucus‐mobilising treatments (including, but not limited to, physical airway clearance techniques and medications which demonstrate improved mucus clearance e.g. rhDNase) or other concentrations of hypertonic saline. The minimum treatment duration considered in this review was a single dose. We planned to consider trials comparing hypertonic saline used in conjunction with another intervention if the comparator group also received the second intervention. </p> </section> <section id="CD001506-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We planned to assess the following outcome measures.</p> <section id="CD001506-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001506-list-0002"> <li> <p>Lung function (absolute change and change in per cent (%) predicted)</p> <ol id="CD001506-list-0003"> <li> <p>forced expiratory volume at one second (FEV<sub>1</sub>) </p> </li> <li> <p>forced vital capacity (FVC)</p> </li> <li> <p>lung volume (residual volume (RV) and total lung capacity (TLC))</p> </li> <li> <p>FEV<sub>0.5</sub> </p> </li> <li> <p>lung clearance index (LCI)</p> </li> </ol> </li> <li> <p>Mortality</p> </li> </ol> </p> </section> <section id="CD001506-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001506-list-0004"> <li> <p>Measures of sputum clearance (including measures of mucociliary clearance)</p> </li> <li> <p>Measures of exercise capacity</p> </li> <li> <p>Measures of quality of life (QoL) and symptoms</p> </li> <li> <p>Pulmonary exacerbations (where a clear definition is described demonstrating an increase in symptoms or a decline in pulmonary function) </p> <ol id="CD001506-list-0005"> <li> <p>frequency</p> </li> <li> <p>admission to hospital</p> </li> <li> <p>duration of hospital stay (post hoc change)</p> </li> <li> <p>outpatient treatments (hospital in the home, unscheduled visits to the doctor)</p> </li> <li> <p>use of antibiotics, either intravenous, oral or inhalational</p> </li> </ol> </li> <li> <p>Medication delivery time (minutes)</p> </li> <li> <p>Cost of treatment</p> </li> <li> <p>Adherence to treatment with hypertonic saline along with other treatments after hypertonic saline is added </p> </li> <li> <p>Bacteriology in pulmonary secretions, including sputum culture, culture from cough swab or bronchial lavage (post hoc change) </p> </li> <li> <p>Adverse effects such as bronchospasm, cough and acute decline in pulmonary function (acute decline was limited to the immediate phase of receiving treatment with hypertonic saline to within the first three hours, and described separately to longer‐term lung function data as it represents acute bronchospasm provoked by hypertonic saline) </p> </li> </ol> </p> </section> </section> </section> <section id="CD001506-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD001506-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register using the term: hypertonic saline. </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the <i>Cochrane Library</i> ), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 25 April 2022. </p> <p>We also searched the following trials registries:</p> <p> <ol id="CD001506-list-0006"> <li> <p>US National Institutes of Health Ongoing Trials Register Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 18 May 2022); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 18 May 2022). </p> </li> </ol> </p> <p>For details of our search strategies, please see <a href="./appendices#CD001506-sec-0218">Appendix 1</a>. </p> </section> <section id="CD001506-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials and any relevant systematic reviews identified for further references to relevant trials. </p> </section> </section> <section id="CD001506-sec-0026"> <h3 class="title" id="CD001506-sec-0026">Data collection and analysis</h3> <section id="CD001506-sec-0027"> <h4 class="title">Selection of studies</h4> <p>The authors (PW, VMM, SS) independently selected the abstracts found during the searches. They then discussed potential and excluded abstracts to reach consensus. If trials were only in abstract form, the review authors contacted the trial authors for additional information. Two review authors then independently reviewed the full trials and, by consensus with the third author, included them if they were suitable or excluded them, documenting reasons for exclusion. </p> </section> <section id="CD001506-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two authors (PW, VMM or SS) independently extracted data on trial characteristics and results using standard data acquisition forms. The authors entered the data into the Review Manager software (<a href="./references#CD001506-bbs2-0075" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p>The authors considered data reported up to and including three months to be short term and data reported at over three months to be long term. </p> <p>The authors obtained additional data for one trial from the original investigators (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). Where an author of this Cochrane Review was a co‐author on an included trial, a third party performed the data extraction and assessment of quality (both risk of bias and GRADE) for that trial. This occurred when both the current review authors were co‐investigators in the National Hypertonic Saline in Cystic Fibrosis Study trial, and Ashley Jones and a second person from the editorial base extracted the data and assessed the risk of bias (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). This was also the case when one author (PW) was an author on one further trial, when VP and a second person from the editorial base extracted the data and assessed the risk of bias (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). </p> </section> <section id="CD001506-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors assessed the risk of bias of each trial using the Cochrane risk of bias tool described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001506-bbs2-0070" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>) (PW, VMM or SS). In particular, they examined details of the generation of allocation sequence, the concealment of treatment allocation schedule, whether the trial was blinded, whether intention‐to‐treat (ITT) analyses were possible from available data, and if the number of participants lost to follow‐up or subsequently excluded from the trial was recorded. </p> </section> <section id="CD001506-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>If the review authors found that trials did not use an ITT analysis, then they sought data on the number of participants with each outcome event, by allocated treated group, irrespective of adherence and whether the participant was later thought to be ineligible or otherwise excluded from treatment or follow‐up. Regarding dichotomous outcome measures, currently none of the trials report on mortality. For adverse event data, the authors have calculated a pooled estimate of the treatment effect for each outcome across the studies and determined the risk ratio (RR). For the outcome of an improvement of over 10% in FEV<sub>1</sub> reported by two cross‐over trials, the authors used the generic inverse variance to analyse the data and present the odds ratio (OR). </p> <p>For continuous outcomes, the authors recorded either a mean change from baseline for each group or mean post‐treatment or post‐intervention values and standard deviation (SD) for each group. They calculated a pooled estimate of treatment effect for each of these individually by calculating the mean difference (MD) and 95% confidence intervals (CIs) where appropriate. Where the SD was not reported or available to use, we used the MD and 95% CI for each group to calculate the SDs. </p> <p>The review authors reported costs of treatment narratively.</p> </section> <section id="CD001506-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Where trials measured data longitudinally, the authors based the analysis on the final time point results. Methods do exist to carry out a meta‐analysis of aggregate longitudinal data, where individual patient data (IPD) are not available, but these are not available at the moment in RevMan. </p> <p>For trials with a cross‐over design, at least one week was required to allow sufficient washout of effect, at least for the measures of short‐term outcomes. For these trials of cross‐over design, the authors planned to carry out the analysis using results from a paired analysis, as recommended by <a href="./references#CD001506-bbs2-0066" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>. This was only possible in one trial (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). For the remaining cross‐over trials, the data that were provided in the trial report were not sufficient to carry out this type of analysis. For these trials, we chose to ignore the cross‐over design and treat the results from the two periods as if they were independent (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). Elbourne reported that using this approach is conservative, due to the fact that it ignores the within‐patient correlation (<a href="./references#CD001506-bbs2-0066" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). </p> </section> <section id="CD001506-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>The authors originally planned to include missing participants due to dropouts in an ITT analysis. The authors attempted to obtain any missing statistics (such as SDs or correlation coefficients) from the trial authors, or they obtained the original data and determined the statistics. The authors were only able to obtain additional data from two trials (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). The review authors made two attempts to contact trial authors for missing data before accepting that the additional data would not be made available. However, if the trial authors contact us with data in the future, we will add the information to the review at the following update. </p> </section> <section id="CD001506-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>The authors tested for heterogeneity between studies using a standard Chi² test and I² statistic (<a href="./references#CD001506-bbs2-0069" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). The Chi² test is a statistical test for heterogeneity, whereas I² assesses the quantity of inconsistency across studies in the meta‐analysis. The authors accepted a P value of below 0.1. They used the following I² ranges to interpret heterogeneity: </p> <p> <ol id="CD001506-list-0007"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ol> </p> </section> <section id="CD001506-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Due to the chronic nature of the disease, in many CF trials investigators collect data longitudinally at different time points throughout the course of the trial. In all the trials the authors examined when data were collected during the trial and also which data were reported in the trial publication. If it appeared that time points were missing that the review authors would expect to have been reported (based on clinical and biologic plausibility), the review authors would have reported this. The authors also planned to assess publication bias by constructing funnel plots if they had been able to include a sufficient number of trials. </p> </section> <section id="CD001506-sec-0035"> <h4 class="title">Data synthesis</h4> <p>The authors have used fixed‐effect analyses in this review. For future updates, when appropriate, where between‐trial variability is statistically significant, the authors plan to carry out random‐effects analyses. </p> </section> <section id="CD001506-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For future updates, where possible, the authors plan to investigate heterogeneity using subgroup analysis if the I² statistic is over 40%; they will consider the following subgroups: </p> <p> <ol id="CD001506-list-0008"> <li> <p>strength of hypertonic saline (comparing a concentration of 3% to 7% versus a concentration greater than 7%); </p> </li> <li> <p>volume of hypertonic saline (less than 5 mL versus 5 mL to 10 mL versus more than 10 mL). </p> </li> </ol> </p> </section> <section id="CD001506-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>For a future update, when possible, the authors plan to perform a sensitivity analysis based on risk of bias of the trials, excluding those with a high risk of performance bias and including and excluding quasi‐randomised trials. </p> </section> <section id="CD001506-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>In a post hoc change in line with current Cochrane guidance, at the 2018 update we added a summary of findings table for each comparison presented in the review (<a href="./full#CD001506-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD001506-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001506-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001506-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD001506-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD001506-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD001506-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD001506-tbl-0008">summary of findings Table 8</a>). We selected the following seven outcomes to report (chosen based on relevance to clinicians and consumers). </p> <p> <ol id="CD001506-list-0009"> <li> <p>FEV<sub>1</sub> (short‐term change (up to and including three months)) </p> </li> <li> <p>FEV<sub>1</sub> (long‐term change (longer than three months)) </p> </li> <li> <p>LCI</p> </li> <li> <p>Mortality</p> </li> <li> <p>Measures of sputum clearance</p> </li> <li> <p>Pulmonary exacerbations</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> <p>We determined the certainty of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if we considered the limitation to be serious and by two levels if very serious. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001506-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001506-sec-0039"></div> <section id="CD001506-sec-0040"> <h3 class="title">Description of studies</h3> <p>The trials included in this review were heterogenous in terms of age, severity of underlying lung disease, colonisation of micro‐organisms, other interventions, as well as the dose, timing and delivery of hypertonic saline. </p> <section id="CD001506-sec-0041"> <h4 class="title">Results of the search</h4> <p>The searches identified 61 potentially eligible trials (159 references). We included 24 trials (84 references) (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>: <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>) and excluded 29 trials (59 references) (<a href="./references#CD001506-bbs2-0025" title="ACTRN12619001681145. Effect of the MetaNeb® on measures of lung clearance index, other measures of lung function and patient reported outcomes in individuals admitted to hospital for an acute exacerbation of their Cystic Fibrosis: a randomised controlled trial. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619001681145 (first posted 18 September 2019). [CFGD REGISTER: PE354a] ">ACTRN12619001681145</a>; <a href="./references#CD001506-bbs2-0026" title="ACTRN12621000855820. Immediate effects of the MetaNeb® on regional lung perfusion, ventilation and other measures of lung function compared to those of huff and cough in adults with stable cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12621000855820 (first posted 12 July 2021). ">ACTRN12621000855820</a>; <a href="./references#CD001506-bbs2-0027" title="AquinoES , GotoDM , SantosAS , CoelhoCC , FuccioMB , SaldivaPHN , et al. Effects of hypertonic saline solution and continuous positive airway pressure on respiratory mucus contact angle and mucus transportability by cough in cystic fibrosis patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:Poster #G7. [CENTRAL: CN-00679594] [CFGD REGISTER: PE199b] AquinoES , ShimuraF , SantosAS , GotoDM , CoelhoCC , deFuccioMB , et al. CPAP has no effect on clearance, sputum properties, or expectorated volume in cystic fibrosis. Respiratory Care2012;57(11):1914-9. [CFGD REGISTER: PE199a] ">Aquino 2012</a>; <a href="./references#CD001506-bbs2-0028" title="BrivioA , CerutiC , GambazzaS , ColomboC . Randomized double-blind monocentric trial on tolerability, acceptability and efficacy of two formulations of inhaled 7% hypertonic saline with and without hyaluronic acid in reducing airways inflammation in patients with cystic fibrosis - preliminary results. Journal of Cystic Fibrosis2013;12 Suppl 1:S104. [ABSTRACT NO.: 217] [CENTRAL: 999881] [CFGD REGISTER: BD208a] BrivioA , ConeseM , GambazzaS , BiffiA , TirelliAS , RussoM , et al. Pilot Randomized Controlled Trial Evaluating the Effect of Hypertonic Saline With and Without Hyaluronic Acid in Reducing Inflammation in Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2016;29(6):482-9. [CENTRAL: 1155400] [CFGD REGISTER: BD208b] [PMID: 27149365]">Brivio 2016</a>; <a href="./references#CD001506-bbs2-0029" title="BrownAW , LaubeBL , ZemanK , LechtzinN , SharplessG , WuJ , et al. Durability of hypertonic saline for enhancing mucociliary clearance in cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:303. [ABSTRACT NO.: 237] [CFGD REGISTER: BD173] 5500100000010577 TrimbleAT , Whitney BrownA , LaubeBL , LechtzinN , ZemanKL , WuJ , et al. Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis. Journal of Cystic Fibrosis2018;17(5):650-6. [CENTRAL: CN-01645710] [CFGD REGISTER: BD173c] [EMBASE: 620273897]">Brown 2010</a>; <a href="./references#CD001506-bbs2-0030" title='BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Advances in Therapy2010;27(11):870-8. [CENTRAL: 781252] [CFGD REGISTER: BD156c] [EMBASE: 2010642492] [PMID: 20953746]BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Hyaluronic acid improves tolerability of hypertonic saline in CF patients. Journal of Cystic Fibrosis2010;9 Suppl 1:S63. [ABSTRACT NO.: 245] [CENTRAL: 775087] [CFGD REGISTER: BD156b] BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Inhaled hyaluronic acid improves pleasantness and tolerability of nebulised hypertonic saline in patients with cystic fibrosis. Pediatric Pulmonology2009;44 Suppl 32:243. [ABSTRACT NO.: 93] [CFGD REGISTER: BD156a] NCT01658449. Comparison of the tolerability of two formulations of hypertonic saline in cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT01658449 (first posted 7 August 2012). '>Buonpensiero 2010</a>; <a href="./references#CD001506-bbs2-0031" title="CorcoranTE , GodovchikJE , DonnKH , BusickDR , GoralskiJ , LockeLW , et al. Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis. Pediatric Pulmonology2017;52(9):1142-9. [CFGD REGISTER: BD207] [CTG: NCT02141191]NCT02141191. A study of lung clearance after hypertonic saline delivery using the tpad device [A randomized crossover mucociliary clearance study of aerosolized 7% NACL solution administered overnight by the tpad device to subjects with cystic fibrosis]. clinicaltrials.gov/show/nct02141191 (first posted 19 May 2014). [CENTRAL: CN-01596846] [CFGD REGISTER: BD207b] ">Corcoran 2017</a>; <a href="./references#CD001506-bbs2-0032" title="De ConoN , SchelstraeteP , HaerynckF , Van daeleS , SandersM , De BaetsF . Hypertonic saline: effect on mucus rheology and spirometry. Journal of Cystic Fibrosis2008;7(Suppl 2):S24. [ABSTRACT NO.: 93] [CFGD REGISTER: BD130] ">DeCono 2008</a>; <a href="./references#CD001506-bbs2-0033" title='ACTRN12611000673943. A randomised trial of the effect of timing of nebulised hypertonic saline in relation to airway clearance physiotherapy, in people with cystic fibrosis lung disease [Randomised trial of the effect of timing of nebulised hypertonic saline in relation to airway clearance physiotherapy, on subjective efficacy, tolerability and overall satisfaction, and lung function parameters in adults with cystic fibrosis lung disease]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000673943 (first registered 4 July 2011). [CFGD REGISTER: BD160e] DenticeR , ElkinsM , ByeP . Hypertonic saline before vs during vs after physiotherapy techniques for airway clearance in people with cystic fibrosis: A randomised trial. Physiotherapy2011;97:eS308-9. [ABSTRACT NO.: RR-PL-3136] [CENTRAL: 1089301] [CFGD REGISTER: BD160d] [EMBASE: 71882596]DenticeR , ElkinsMR , ByePT . A randomised trial of the effect of timing of hypertonic saline inhalation in relation to airway clearance physiotherapy in adults with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:384. [ABSTRACT NO.: 459] [CFGD REGISTER: BD160a] DenticeRL , ElkinsMR , ByeP . Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial. Journal of Physiotherapy2012;58(1):33-40. [CFGD REGISTER: BD160b] DenticeRL , ElkinsMR , ByePT . Online Supplementary Material - Table 3: Individual outcome data to "Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial" [online]. Journal of Physiotherapy2012;58(1):33-40 Online. [CFGD REGISTER: BD160c] '>Dentice 2012</a>; <a href="./references#CD001506-bbs2-0034" title="DonaldsonSH , BennettW , ZemanK , KnowlesMR , BoucherRC . Efficacy of amiloride and hypertonic saline in cystic fibrosis. Pediatric Pulmonology2003;Suppl 25:251. [CFGD REGISTER: BD110a] DonaldsonSH , BennettWD , ZemanKL , KnowlesMR , TarranR , BoucherRC . Mucus clearance and lung function in cystic fibrosis with hypertonic saline. New England Journal of Medicine2006;354(3):241-50. [CFGD REGISTER: BD110b] DonaldsonSH , BennettWD , ZemanKL , KnowlesMR , TarranR , BoucherRC . Online supplement to 'Mucus clearance and lung function in cystic fibrosis with hypertonic saline'. New England Journal of Medicine2006;354(3):241-50 Online. [CFGD REGISTER: BD110c] NCT00274391. Efficacy of amiloride and hypertonic saline in cystic fibrosis [Efficacy of amiloride and hypertonic saline in cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00274391 (first posted 10 January 2006). ">Donaldson 2006</a>; <a href="./references#CD001506-bbs2-0035" title="ACTRN12606000053527. Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with cystic fibrosis [Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with cystic fibrosis]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12606000053527 (first registered 7 February 2006). [CFGD REGISTER: BD124b] ElkinsMR , TingpejP , MoriartyCP , YozghatlianV , RoseBR , HarbourC , et al. Tolerability of hypertonic saline when delivered rapidly via the Eflow® rapid nebulizer in subjects with cystic fibrosis. Pediatric Pulmonlogy2006;41 (Suppl 29):292. [CFGD REGISTER: BD124a] ">Elkins 2006b</a>; <a href="./references#CD001506-bbs2-0036" title="EUCTR2007-002707-40-BE. The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in cystic fibrosis patients. www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002707-40 (first registered 28 June 2007). ">EUCTR2007‐002707‐40‐BE</a>; <a href="./references#CD001506-bbs2-0037" title="GenkovaN , BoshevaM , IvanchevaD . Inhaled hypertonic saline solution in cystic fibrosis. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998. ">Genkova 1998</a>; <a href="./references#CD001506-bbs2-0038" title="GrasemannH , TullisE , RatjenF . A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis. Journal of Cystic Fibrosis2013;12(5):468-74. [CFGD REGISTER: GN233b] GrasemannH , TullisE , RatjenF . A randomized placebo controlled study on the effects of L-arginine inhalation in patients with cystic fibrosis . Pediatric Pulmonology 2011;46 Suppl 34:293-4. [CFGD REGISTER: GN233c] GrasemannH , TullisE , RatjenF . Inhaled L-arginine in patients with cystic fibrosis - a randomized controlled trial. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO.: 81] [CFGD REGISTER: GN233a] NCT00405665. The short term safety and efficacy of inhaled L-arginine in patients with cystic fibrosis [Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis]. clinicaltrials.gov/ct2/show/NCT00405665 (first posted 30 November 2006). ">Grasemann 2013</a>; <a href="./references#CD001506-bbs2-0039" title="IRCT20180307038994N1. Comparison of the nebulized mannitol with nebulized hypertonic saline on pulmonary function in patients with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20180307038994N1 (first received 15 April 2018). ">IRCT20180307038994N1</a>; <a href="./references#CD001506-bbs2-0040" title="IRCT20191112045413N2. Study the Effectiveness of Outpatient treatment in Cystic Fibrosis Patients in Exacerbation Phase. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20191112045413N2 (first registered 14 February 2020). ">IRCT20191112045413N2</a>; <a href="./references#CD001506-bbs2-0041" title="IRCT20201017049055N1. Evaluation of the effectiveness of 7% plus hypertonic saline in comparison with 7% hypertonic saline in reducing the growth of Pseudomonas aeruginosa in lung of the patient with cystic fibrosis disease. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20201017049055N1 (first registered 23 April 2021). ">IRCT20201017049055N1</a>; <a href="./references#CD001506-bbs2-0042" title="KingM , DasguptaB , TomkiewiczRP , BrownNE . Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease. American Journal of Respiratory and Critical Care Medicine1997;156(1):173-7. ">King 1997</a>; <a href="./references#CD001506-bbs2-0043" title="KobylyanskyVI , GembitskayaTE . Study of the mucociliary and cough clearance in patients with mucoviscidosis and evaluation of hypertonic sodium chorlide solution influence on them. European Respiratory Journal2000;16(Suppl 31):121S. [CFGD REGISTER: BD111] 5500100000002413 ">Kobylyansky 2000</a>; <a href="./references#CD001506-bbs2-0044" title="NCT01094704. Durability of hypertonic saline for enhancing mucociliary clearance in cystic fibrosis. clinicaltrials.gov/show/NCT01094704 (first posted 29 March 2010). ">NCT01094704</a>; <a href="./references#CD001506-bbs2-0045" title="ISRCTN13412080. Effects of inhaled hypertonic saline in children with cystic fibrosis [Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: a crossover, randomized clinical trial]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13412080 (first registered 6 July 2016). NennaR , MidullaF , LambiaseC , De CastroG , ZicariAM , IndinnimeoL , et al. Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial. Italian Journal of Pediatrics2017;43(1):60. [CFGD REGISTER: BD238] [DOI: 10.1186/s13052-017-0376-6]">Nenna 2017</a>; <a href="./references#CD001506-bbs2-0046" title="NCT01753869. Timing of hypertonic saline inhalation relative to airways clearance in cystic fibrosis [Timing of hypertonic saline inhalation relative to airways clearance in cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01753869 (first posted 20 December 2012). [CFGD REGISTER: BD231c] O'NeillK , MoranF , TunneyMM , ElbornJS , BradburyI , DowneyDG , et al. Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study. BMJ Open Respiratory Research2017;4(1):e000168. [CFGD REGISTER: BD231b] [DOI: 10.1136/bmjresp-2016-000168]O’NeillK , MoranF , BradburyI , DowneyDG , RendallJ , TunneyMM , et al. Exploring the timing of hypertonic saline (HTS) and airways clearance techniques (ACT) in cystic fibrosis (CF): a cross over study. Thorax2016;71(Suppl 3):A134-5. [CFGD REGISTER: BD231a] ">O'Neill 2017</a>; <a href="./references#CD001506-bbs2-0047" title="RosM , CasciaroR , LuccaF , AlatriF , SaloniniE , FavilliF , et al. Tolerability and acceptability in patients with cystic fibrosis (CF) of two formulations of 7% hypertonic saline: a prospective multicenter clinical study. Pediatric Pulmonology2012;47(S35):364. [ABSTRACT NO.: 390] [CFGD REGISTER: BD181a] 5500100000011650 RosM , CasciaroR , LuccaF , TroianiP , SaloniniE , FavilliF , et al. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery2014;27(2):133-7. [CFGD REGISTER: BD181b] ">Ros 2012</a>; <a href="./references#CD001506-bbs2-0048" title="NCT01377792. Study of long-term treatment with hypertonic saline in patients with cystic fibrosis [Phase 4 study of the efficacy of long-term treatment with hypertonic saline on pulmonary exacerbations in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01377792 (first received 21 June 2011). [CFGD REGISTER: BD182b] Ruiz de Valbuena MaizM , LamasA , MaizL , GironR , BarrioM , delCampoR , et al. Study of the efficacy of long-term treatment with high volume compared to standard volume of hypertonic saline on pulmonary exacerbations in patients with cystic fibrosis. Pediatric Pulmonology2012;47 (S35):360. [ABSTRACT NO: 379: 379] [CFGD REGISTER: BD182a] ">Ruiz de Valbuena Maiz 2012</a>; <a href="./references#CD001506-bbs2-0049" title="Herrero CortinaB , San Miguel PagolaM , Cebria i RanzoMA , Gomez RomeroM , Diaz GutierrezF , ReychlerG . Short-term effects of hypertonic saline nebulization combined with oscillatory positive expiratory pressure in cystic fibrosis:randomised crossover trial. Journal of Cystic fibrosis2016;15 Suppl 1:S33. [ABSTRACT NO.: WS21.3] [CFGD REGISTER: BD229a] NCT02303808. Positive expiratory pressure during inhalation of hypertonic saline in patients with cystic fibrosis [Effect of introducing a positive expiratory pressure device during inhalation of hypertonic saline in patients with cystic fibrosis: a randomized crossover trial]. clinicaltrials.gov/ct2/show/NCT02303808 (first received 01 December 2014). San Miguel PagolaM , Herrero CortinaB , Cebria i IranzoMA , Gomez RomeroM , Diaz GutierrezF , ReychlerG . Hypertonic saline nebulization combined with oscillatory positive expiratory pressure accelerate sputum clearance in cystic fibrosis: A randomised crossover trial. European Respiratory Journal2016;48(Suppl 60):PA1369. [CFGD REGISTER: BD229b] San Miguel-PagolaM , ReychlerG , Cebria i IranzoMA , Gomez-RomeroM , Diaz-GutierrezF , Herrero-CortinaB . Impact of hypertonic saline nebulisation combined with oscillatory positive expiratory pressure on sputum expectoration and related symptoms in cystic fibrosis: a randomised crossover trial. Physiotherapy2020;107:243-51. [CFGD REGISTER: BD229d] ">San Miguel‐Pagola 2016</a>; <a href="./references#CD001506-bbs2-0050" title="ACTRN12615001067561. Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT) [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks on lung structure in patients with cystic fibrosis at 3-6 years of age, in parallel with the North American SHIP clinical trial, as measured by computed tomography (CT)]. apps.who.int/trialsearch/Trial3.aspx?trialid=ACTRN12615001067561 (first received 13 October 2015). EUCTR2015-004143-39-NL. Saline hypertonic in preschoolers and lung structure as measured by computed tomography [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-004143-39-NL (first received 21 December 2015). [CENTRAL: CN-01854740] [CFGD REGISTER: BD262c] ISRCTN13083896. Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT). trialsearch.who.int/Trial2.aspx?TrialID=NTR5502 (date first registered 29 September 2015). [CFGD REGISTER: BD262g] NCT02950883. Saline hypertonic in preschoolers + CT (SHIP-CT) [Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT)]. clinicaltrials.gov/ct2/show/NCT02950883 (first received 01 November 2016). NTR5502. Saline hypertonic in preschoolers and lung structure as measured by computed tomography [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study]. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR55022015. [CENTRAL: CN-01880673] [CFGD REGISTER: BD262d] TiddensH , ChenY , AndrinopoulouE , DavisS , RosenfeldM , StukovskyK , et al. Effect of inhaled hypertonic saline on structural lung disease in preschool children with cystic fibrosis. The SHIP-CT study. Journal of Cystic Fibrosis2021;20 Suppl 2:S255. [CFGD REGISTER: BD262e] TiddensHA , ChenY , AndrinopoulouER , DavisSD , RosenfeldM , RatjenF , et al. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. The Lancet. Respiratory Medicine 2022 March 11 [Epub ahead of print];S2213-2600(21):00546-4. [DOI: 10.1016/S2213-2600(21)00546-4] [FGD REGISTER: BD262f]TiddensHA , ChenY , DavisSD , RosenfeldM , RatjenF , Hinckley StukovskyKD , et al. The effect of hypertonic saline treatment in pre-schoolers with cystic fibrosis on lung structure as measured by chest computed tomography. SHIP-CT study. Journal of Cystic Fibrosis2021;20 Suppl 1:S56. [CFGD REGISTER: BD262h] ">Tiddens 2022</a>; <a href="./references#CD001506-bbs2-0051" title="Van GinderdeurenF , VerbanckS , Van CauwelaertK , VanlaethemS , SchuermansD , VinckenW , et al. Chest physiotherapy in cystic fibrosis: short-term effects of autogenic drainage preceded by wet inhalation of saline versus autogenic drainage preceded by intrapulmonary percussive ventilation with saline. Respiration2008;76(2):175-80. [CFGD REGISTER: BD178] ">Van Ginderdeuren 2008</a>; <a href="./references#CD001506-bbs2-0052" title="Van GinderdeurenF , VanlaethemS , EynsH , De SchutterI , DewachterE , MalfrootA . Influence of inhaled hypertonic saline (NaCl 6%) before or during autogenic drainage on sputum weight, oxygen saturation, heart frequency and dyspnea in cystic fibrosis patients. Journal of Cystic Fibrosis2011;10(Suppl 1):S62. [CFGD REGISTER: BD164] ">Van Ginderdeuren 2011</a>; <a href="./references#CD001506-bbs2-0053" title="VanlaethemS , Van GinderdeurenF , EynsH , MalfrootA . Influence of inhaled hypertonic saline combined with airway clearance on SpO2, heart rate, dyspnoea and wet sputum weight in hospitalised CF patients. Journal of Cystic Fibrosis2008;7(Suppl 2):S71. [CENTRAL: 643104] [CFGD REGISTER: BD129] ">Vanlaethem 2008</a>). There are six trials (11 references) currently listed as 'Awaiting classification' until more information is available to allow a judgement regarding eligibility (<a href="./references#CD001506-bbs2-0054" title="BalinottiJ , RodriguezV , ZaragozaS , LubovichS , KofmanC , Garcia BournissenF . Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with cystic fibrosis diagnosed by neonatal screening. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A3342. [CENTRAL: 1127230] [CFGD REGISTER: BD227b] TeperA , BalinottiJ , RodriguezV , Zaragoza S LubovichS , KofmanC , Garcia BournissenF . Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with cystic fibrosis (CF) diagnosed by neonatal screening. Journal of Cystic Fibrosis2015;14 Suppl 1:S49. [ABSTRACT NO.: ePS04.8] [CFGD REGISTER: BD227a] ">Balinotti 2015</a>; <a href="./references#CD001506-bbs2-0055" title="ACTRN12610000754044. Trial of different concentrations of nebulised saline for cystic fibrosis saline at lower tonicity in cystic fibrosis (SALTI-CF) trial [The effect of nebulised 0.9% vs 3% vs 6% saline on lung function and quality of life in people with cystic fibrosis]. apps.who.int/trialsearch/Trial3.aspx?trialid=ACTRN12610000754044 (first received 13 September 2010). DwyerT , ElkinsM , DenticeR , ForbesS , MacArthurM , CooperP , et al. Saline at a lower tonicity in cystic fibrosis (SALTI-CF) trial - a randomised controlled trial comparing 0.9% v 3% v 6% nebulised saline. Journal of Cystic Fibrosis2013;12 Suppl 1:S19. [ABSTRACT NO.: WS9.5] [CFGD REGISTER: BD186] ">Dwyer 2013</a>; <a href="./references#CD001506-bbs2-0056" title="HofmannT , SenierI , ZierschA , GeidelC , RegnisJ , LindemannH . Additive effects of amiloride and hypertonic saline on respiratory ion transport in cystic fibrosis [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:119. [CFGD REGISTER: BD75] ">Hofmann 1997</a>; <a href="./references#CD001506-bbs2-0057" title="LennoxA , BrownS , CorcoranTE , MyerburgMM , PilewskiJM . Pilot study of inhaled sodium bicarbonate: safety and ph changes after 1-2 doses. Pediatric Pulmonology2016;51 (Suppl 45):281. [ABSTRACT NO.: 236] [CFGD REGISTER: BD255a] NCT03391414. Effects of inhaled bicarbonate on airway pH in cystic fibrosis. clinicaltrials.gov/show/NCT03391414 (first posted 5 January 2018). [CFGD REGISTER: BD255b] ">Lennox 2016</a>; <a href="./references#CD001506-bbs2-0058" title="PalacioS , GiugnoH , Diaz CasauxA , LuceroB , SmithS , GiorgettiM , et al. Inhaled 7% hypertonic saline treatment in preschool children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S7, Abstract no: WS3.5. [CENTRAL: 1000053] [CFGD REGISTER: BD205] ">Palacio 2014</a>; <a href="./references#CD001506-bbs2-0059" title="Mayer-HamblettN , NicholsDP , Odem-DavisK , RiekertKA , SawickiGS , DonaldsonSH , et al. Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY Clinical Trial Study Design. Annals of the American Thorac Society2021;18(8):1397-405. [CFGD REGISTER: BD315b] [DOI: 10.1513/AnnalsATS.202010-1336SD]Mayer-HamblettN , RatjenF , RussellR , DonaldsonSH , RiekertKA , SawickiGS , et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respiratory Medicine 2022 Nov 4 [Epub ahead of print]:S2213-2600(22)00434-9. [CFGD REGISTER: BD315c] [DOI: 10.1016/S2213-2600(22)00434-9]NCT04378153. Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY). clinicaltrials.gov/ct2/show/NCT04378153 (first posted 7 May 2020). [CFGD REGISTER: BD315a] ">SIMPLIFY 2022</a>) and two trials are ongoing (<a href="./references#CD001506-bbs2-0060" title="ISRCTN14081521. A randomised open-label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies (the CF STORM trial). trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN14081521 (first posted 31 March 2021). ">ISRCTN14081521</a>; <a href="./references#CD001506-bbs2-0061" title="NCT02343445. Clearing lungs with ENAC inhibition in cystic fibrosis (CLEAN-CF) [A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of P-1037 solution for inhalation in patients with cystic fibrosis (CF)]. clinicaltrials.gov/ct2/show/NCT02343445 (first posted 22 January 2015). ">NCT02343445</a>). The study flow chart is presented as a figure (<a href="#CD001506-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD001506-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow chart" data-id="CD001506-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow chart</p> </div> </div> </div> </section> <section id="CD001506-sec-0042"> <h4 class="title">Included studies</h4> <p>There were 24 trials which met the inclusion criteria, with a total of 1318 participants (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>: <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>: <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). Of these, 18 were published as full papers, one was published only as a trial registration document (with results) (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>) and four were reported in abstract form only (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>), but additional data were provided by one of these investigators (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>). </p> <section id="CD001506-sec-0043"> <h5 class="title">Trial design</h5> <p>There were 10 trials of parallel design (<a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). There were 14 trials that were of cross‐over design (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>, <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>) and two of these had a four‐arm cross‐over design (<a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). A washout period was not stated in four cross‐over trials (<a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>); there was no washout (interventions given on single days consecutively) in one trial (<a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>). Where there was a washout period described, this ranged from one week (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>) up to eight weeks (<a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). </p> <p>The number of participants varied between trials from 10 (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>) to 321 (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>). </p> <p>In total 10 trials were multicentre (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>) and seven trials were single centre (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>); it was unclear whether the remaining seven trials were multicentre or single centre. Seven trials were run in Australia (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). Six trials were run in Europe ‐ three trials were run in Germany (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>), two in the UK (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>) and one in Italy (<a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>). Two trials were run in Canada (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>) and three trials in the USA (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>); a further two trials were run in centres across both Canada and the USA (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). One trial was run in Brazil (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>), one in India (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>), and one trial did not clearly state where it was run (<a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>). </p> </section> <section id="CD001506-sec-0044"> <h5 class="title">Participants</h5> <p>The ages of participants ranged from one month (<a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>) to 56 years (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>), but details of age were not given in three studies (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>). Most studies only recruited participants over the age of five or six years, but three studies included only infants or preschool children, or a mix of both (<a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). Most of the studies recruited approximately equal numbers of males and females, although five studies included a disproportionate number of females (over 60% female) (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). One study included disproportionately fewer females overall and particularly in the intervention group (13.3%) (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). </p> <p>Fifteen trials stated the diagnostic criteria for CF in the participants, which confirmed CF on the basis of a positive sweat chloride test or the presence of two common genetic mutations (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). The remaining nine trials only stated that the participants had CF. </p> <section id="CD001506-sec-0045"> <h6 class="title">Selection by tolerance for hypertonic saline</h6> <p>Four trials stated they tested for tolerance to hypertonic saline (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). Two trials excluded those who were intolerant to their test dose of hypertonic saline (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>), and <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> excluded participants who demonstrated bronchial reactivity following hypertonic saline defined by a fall in FEV<sub>1</sub> of 15% following tolerability testing. Three trials excluded those that had known intolerance of hypertonic saline at the screening visit (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>). Four trials stated that prior use of hypertonic saline was an exclusion criterion (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). Additionally, two trials excluded participants who had previously used rhDNase (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). </p> </section> <section id="CD001506-sec-0046"> <h6 class="title">Baseline microbiology</h6> <p>Baseline sputum microbiology was stated in 13 trials (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a> mentioned bacterial growth, but no details were given. The <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> trial measured change in bacterial density for <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i>, but did not state baseline microbiology. </p> <section id="CD001506-sec-0047"> <p><b><i>P aeruginosa</i> </b></p> <p>The presence of <i>P aeruginosa</i> was described in 12 trials. In one trial, seven (37%) participants were described as colonised with <i>P aeruginosa</i> (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>), and 10 out of 12 participants in the later Robinson trial were colonised with <i>P aeruginosa</i> (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). In the later Amin trial, 17 out of 18 (94.4%) had a positive sputum culture for <i>P aeruginosa</i> (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>). In the <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a> trial, <i>P aeruginosa</i> was cultured in 17% of participants. In the <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> trial 60 participants (38%) and 69 participants (42.3%) were colonised with <i>P aeruginosa</i> in the hypertonic saline group and isotonic saline groups, respectively. <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> reported that three out of the 14 participants were chronically colonised with <i>P aeruginosa</i>. <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> reported the presence of <i>P aeruginosa</i> in 79 of the 83 participants in the hypertonic saline group and 78 of the 81 control participants. In each of two further trials, all 10 participants had <i>P aeruginosa</i> in their sputum (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>). In the <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> trial, 48% of participants had <i>P aeruginosa</i>. <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a> reported the presence of <i>P aeruginosa</i> in 23 (33%) participants. <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> reported median log colony forming units (CFU) (min to max) at baseline but found no difference between the groups. </p> </section> <section id="CD001506-sec-0048"> <p><b><i>S aureus</i> </b></p> <p>The presence of <i>S aureus</i> was described in six trials. <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a> reported that <i>S aureus</i> was cultured in 42% of participants. <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> reported that <i>S aureus</i> was present in 44 of the 83 participants in the hypertonic saline group and 47of the 81 control participants. Robinson reported that 5 out of 10 participants in the 1997 trial and 7 out of 12 in the 1999 trial had <i>S aureus</i> (including two who also had <i>P aeruginosa</i>) (<a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> reported that 39% of participants were colonised with <i>S aureus</i>. <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> reported median log CFU (min to max) at baseline, but found no difference between the groups. </p> </section> <section id="CD001506-sec-0049"> <p><b>Other pathogens</b></p> <p>Three studies excluded participants if they were colonised with <i>Burkholderia cepacia</i> complex (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a> further excluded any participant who had positive sputum cultures for non‐tuberculosis mycobacteria in the past year. Three trials reported that no participants in either group had <i>B cepacia</i> (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>). </p> <p>Robinson also reported in the 1999 trial that 4 out of 12 participants had <i>Aspergillus fumigatus</i> (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>), and <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> reported that 2% of participants were infected with <i>Stenotrophomonas maltophilia</i>. <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a> reported a wide range of pathogens. </p> </section> </section> <section id="CD001506-sec-0050"> <h6 class="title">Baseline clinical severity</h6> <p>Most trials recruited participants with stable disease; in one of the Robinson trials, it was clearly stated that people with CF who were clinically unstable (defined as an exacerbation in the previous four weeks) were excluded (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). Three further trials excluded participants who were experiencing or had recently experienced an acute respiratory exacerbation (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> also excluded any participant with a secondary chronic lung condition not related to their CF, or other major organ dysfunction. Three trials required participants to be clinically stable (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>). <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a> included only participants with a baseline FEV<sub>1</sub> of greater than 80% predicted and a room air oxyhaemoglobin saturation of greater than 90%. In the <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> trial, participants were required to have an FEV<sub>1</sub> greater than 20% predicted at baseline and to be on stable medications for the previous 14 days, and the participants in the later Amin trial were required to have an FEV1 of ≥ 40% predicted (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>). In the trial by <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>, the children had FEV<sub>1</sub> and FVC greater than 90% predicted. In two trials by Robinson, participants needed to be in a stable clinical condition without any change to their medications (<a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>); only the 1997 Robinson trial included a participant with an FEV<sub>1</sub> % predicted of less than 30% (<a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>). <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> required participants to have an FEV<sub>1</sub> less than 70% predicted (people with CF with at least moderate lung disease) and be clinically stable with no exacerbations or change in medications in the last 14 days (consequently, these participants have more severe lung disease at baseline, mean FEV<sub>1</sub> % predicted 48% (range 14 to 77%)). <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a> stated that all participants received routine treatment for five years. Others used mean FEV<sub>1</sub> as a % predicted value or FVC as a % predicted value to assess disease severity (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>). <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a> recruited participants with clinical symptoms of rhinosinusitis, but did not state the clinical severity of lung disease or whether they were stable clinically at the recruitment. </p> <p>Three trials recruited participants who were experiencing an acute exacerbation (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> enrolled participants with a confirmed diagnosis of CF within 24 hours of a hospital admission for management of a pulmonary exacerbation (defined as at least 4 out of 12 criteria described by <a href="./references#CD001506-bbs2-0067" title="FuchsHJ , BorowitzDS , ChristiansenDH , MorrisEM , NashML , RamseyBW , et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine1994;331(10):637-42.">Fuchs 1994</a>) for a minimum of seven days). The <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a> trial selected 10 consecutive adolescents admitted with an exacerbation of their lung disease who all had productive coughs. </p> </section> </section> <section id="CD001506-sec-0051"> <h5 class="title">Interventions</h5> <p>An ultrasonic nebuliser was used to deliver hypertonic saline in nine trials (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>); while eight trials used a high‐output jet nebuliser (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). One trial used a hybrid ulltrasonic / jet nebulier, Pari LC Sprint Sinus nebuliser (<a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>). One trial used an eFlow nebuliser (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>), and two used a PARI LC Sprint junior nebuliser (<a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). One trial stated only that the inhalation was aerosolised (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>), and two trials did not state the type of nebuliser used (<a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>). </p> <p>Different concentrations of hypertonic saline were used in the trials, ranging from 3.5% to 7%, and this is outlined in detail in the tables (<a href="./references#CD001506-sec-0230" title="">Characteristics of included studies</a>). </p> <p>In 17 trials, isotonic (0.9%) saline was used as a control (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). Four of these trials compared hypertonic saline 7% with isotonic saline 0.9% twice daily (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>) and two trials compared hypertonic saline 6% to isotonic saline twice daily (<a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>) and a further trial compared hypertonic saline 6% to isotonic saline three times a day (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>). Two trials added quinine sulphate (0.25 mg/mL) to both solutions to mask the taste (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). One trial administered 6% hypertonic saline or isotonic saline once per day, approximately 1 mL to each nostril (<a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>). Six trials used a single administration of nebulised hypertonic saline compared to isotonic saline (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>;). In the 1996 trial, Robinson compared a single administration of nebulised hypertonic saline (7%), amiloride (0.3% in 0.12% NaCl) and a combination of amiloride and hypertonic saline to isotonic saline (0.9%) (<a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>), while in the 1997 trial Robinson compared differing concentrations of nebulised hypertonic saline (3%, 7%, and 12%) with isotonic saline and voluntary cough (<a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>). In the 1999 trial, Robinson compared hypertonic saline 6% to 0.9% isotonic saline with matched voluntary cough, mannitol 300 mg, and placebo capsules with matched voluntary cough (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). In the <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a> trial, participants attended for two visits at least one week apart. They received either 5 mL 0.12% isotonic saline or 5 mL 7% hypertonic saline, with the order of treatment randomised. Two trials did not state the frequency of nebulisation (<a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>). </p> <p>One trial compared 7% hypertonic saline with 3% hypertonic saline twice a day (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). </p> <p>Three trials compared hypertonic saline to rhDNase (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). <a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a> used a regimen of hypertonic saline 6% (10 mL) compared to 2.5 mg rhDNase twice daily; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> compared nebulised 5.75% saline (10 mL) to 2.5 mg rhDNase twice daily; and <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> compared hypertonic saline 7% (5 mL) twice daily to rhDNase 2.5 mg daily or to rhDNase 2.5 mg alternate daily. </p> <p><a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a> compared hypertonic saline 7% (3 mL) to Mistabron® 20% (a mucolytic agent). </p> <p>Two trials compared hypertonic saline 7% with inhaled xylitol twice a day (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). </p> <p>Additional treatments were also used in association with the hypertonic saline. With the exception of three trials (<a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>), all trials pretreated participants with short‐acting beta‐agonists. In the <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> trial, the only pretreated participants were those who were already using bronchodilators or whose FEV<sub>1</sub> fell by more than 15% after the test dose of hypertonic saline. Pretreatment was not stated by <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>. </p> <p>In the <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> trial participants performed physiotherapy at home and received hypertonic saline or isotonic saline prior to their regular physiotherapy session. The place of chest physiotherapy is likely to be an important contributor to mucolytic therapy, but its role as a confounder was not addressed. </p> <p>Two trials used hypertonic saline or isotonic saline as an adjunct to physiotherapy and an exercise programme while hospitalised for a pulmonary exacerbation when all participants also received intravenous antibiotics (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). In one trial participants received hypertonic saline 7%, three times a day (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>), and in the second trial they received hypertonic saline 6% as a single treatment (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). </p> </section> <section id="CD001506-sec-0052"> <h5 class="title">Outcomes</h5> <p>Lung function was the most common outcome measured, but this was reported in a number of ways. Fifteen trials reported on FEV<sub>1</sub> (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>); eight trials reported on FVC (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>); and four reported on FEF<sub>25-75</sub> (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>). Four trials measured LCI (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). A number of trials reported on less common measures of lung function (see the tables for further details (<a href="./references#CD001506-sec-0230" title="">Characteristics of included studies</a>) and one trial simply reported on general lung function (<a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>). Mucociliary clearance was reported in six trials (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>) and two reported on sputum production (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). Pulmonary exacerbations were reported in eight trials (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>) and <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> additionally reported additional antibiotics for all causes. Four trials reported sputum cultures (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>) and three trials reported changes in quantitative microbiology (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). A further seven trials reported symptom scores (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>), and two reported on satisfaction or preference (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>). One trial reported on sinus and nasal symptoms (<a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>). Tolerability was only reported on by one trial (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>), and one trial reported on nebulisation time (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>). Linked to this, two trials reported adherence to treatment (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). Ten trials reported on QoL (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>), and eight trials on adverse events (<a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). Two trials reported data relating to cost in comparison to rhDNase (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). </p> </section> </section> <section id="CD001506-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded 29 trials from the review (<a href="./references#CD001506-bbs2-0025" title="ACTRN12619001681145. Effect of the MetaNeb® on measures of lung clearance index, other measures of lung function and patient reported outcomes in individuals admitted to hospital for an acute exacerbation of their Cystic Fibrosis: a randomised controlled trial. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619001681145 (first posted 18 September 2019). [CFGD REGISTER: PE354a] ">ACTRN12619001681145</a>; <a href="./references#CD001506-bbs2-0026" title="ACTRN12621000855820. Immediate effects of the MetaNeb® on regional lung perfusion, ventilation and other measures of lung function compared to those of huff and cough in adults with stable cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12621000855820 (first posted 12 July 2021). ">ACTRN12621000855820</a>; <a href="./references#CD001506-bbs2-0027" title="AquinoES , GotoDM , SantosAS , CoelhoCC , FuccioMB , SaldivaPHN , et al. Effects of hypertonic saline solution and continuous positive airway pressure on respiratory mucus contact angle and mucus transportability by cough in cystic fibrosis patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:Poster #G7. [CENTRAL: CN-00679594] [CFGD REGISTER: PE199b] AquinoES , ShimuraF , SantosAS , GotoDM , CoelhoCC , deFuccioMB , et al. CPAP has no effect on clearance, sputum properties, or expectorated volume in cystic fibrosis. Respiratory Care2012;57(11):1914-9. [CFGD REGISTER: PE199a] ">Aquino 2012</a>; <a href="./references#CD001506-bbs2-0028" title="BrivioA , CerutiC , GambazzaS , ColomboC . Randomized double-blind monocentric trial on tolerability, acceptability and efficacy of two formulations of inhaled 7% hypertonic saline with and without hyaluronic acid in reducing airways inflammation in patients with cystic fibrosis - preliminary results. Journal of Cystic Fibrosis2013;12 Suppl 1:S104. [ABSTRACT NO.: 217] [CENTRAL: 999881] [CFGD REGISTER: BD208a] BrivioA , ConeseM , GambazzaS , BiffiA , TirelliAS , RussoM , et al. Pilot Randomized Controlled Trial Evaluating the Effect of Hypertonic Saline With and Without Hyaluronic Acid in Reducing Inflammation in Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2016;29(6):482-9. [CENTRAL: 1155400] [CFGD REGISTER: BD208b] [PMID: 27149365]">Brivio 2016</a>; <a href="./references#CD001506-bbs2-0029" title="BrownAW , LaubeBL , ZemanK , LechtzinN , SharplessG , WuJ , et al. Durability of hypertonic saline for enhancing mucociliary clearance in cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:303. [ABSTRACT NO.: 237] [CFGD REGISTER: BD173] 5500100000010577 TrimbleAT , Whitney BrownA , LaubeBL , LechtzinN , ZemanKL , WuJ , et al. Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis. Journal of Cystic Fibrosis2018;17(5):650-6. [CENTRAL: CN-01645710] [CFGD REGISTER: BD173c] [EMBASE: 620273897]">Brown 2010</a>; <a href="./references#CD001506-bbs2-0030" title='BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Advances in Therapy2010;27(11):870-8. [CENTRAL: 781252] [CFGD REGISTER: BD156c] [EMBASE: 2010642492] [PMID: 20953746]BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Hyaluronic acid improves tolerability of hypertonic saline in CF patients. Journal of Cystic Fibrosis2010;9 Suppl 1:S63. [ABSTRACT NO.: 245] [CENTRAL: 775087] [CFGD REGISTER: BD156b] BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Inhaled hyaluronic acid improves pleasantness and tolerability of nebulised hypertonic saline in patients with cystic fibrosis. Pediatric Pulmonology2009;44 Suppl 32:243. [ABSTRACT NO.: 93] [CFGD REGISTER: BD156a] NCT01658449. Comparison of the tolerability of two formulations of hypertonic saline in cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT01658449 (first posted 7 August 2012). '>Buonpensiero 2010</a>; <a href="./references#CD001506-bbs2-0031" title="CorcoranTE , GodovchikJE , DonnKH , BusickDR , GoralskiJ , LockeLW , et al. Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis. Pediatric Pulmonology2017;52(9):1142-9. [CFGD REGISTER: BD207] [CTG: NCT02141191]NCT02141191. A study of lung clearance after hypertonic saline delivery using the tpad device [A randomized crossover mucociliary clearance study of aerosolized 7% NACL solution administered overnight by the tpad device to subjects with cystic fibrosis]. clinicaltrials.gov/show/nct02141191 (first posted 19 May 2014). [CENTRAL: CN-01596846] [CFGD REGISTER: BD207b] ">Corcoran 2017</a>; <a href="./references#CD001506-bbs2-0032" title="De ConoN , SchelstraeteP , HaerynckF , Van daeleS , SandersM , De BaetsF . Hypertonic saline: effect on mucus rheology and spirometry. Journal of Cystic Fibrosis2008;7(Suppl 2):S24. [ABSTRACT NO.: 93] [CFGD REGISTER: BD130] ">DeCono 2008</a>; <a href="./references#CD001506-bbs2-0033" title='ACTRN12611000673943. A randomised trial of the effect of timing of nebulised hypertonic saline in relation to airway clearance physiotherapy, in people with cystic fibrosis lung disease [Randomised trial of the effect of timing of nebulised hypertonic saline in relation to airway clearance physiotherapy, on subjective efficacy, tolerability and overall satisfaction, and lung function parameters in adults with cystic fibrosis lung disease]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000673943 (first registered 4 July 2011). [CFGD REGISTER: BD160e] DenticeR , ElkinsM , ByeP . Hypertonic saline before vs during vs after physiotherapy techniques for airway clearance in people with cystic fibrosis: A randomised trial. Physiotherapy2011;97:eS308-9. [ABSTRACT NO.: RR-PL-3136] [CENTRAL: 1089301] [CFGD REGISTER: BD160d] [EMBASE: 71882596]DenticeR , ElkinsMR , ByePT . A randomised trial of the effect of timing of hypertonic saline inhalation in relation to airway clearance physiotherapy in adults with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:384. [ABSTRACT NO.: 459] [CFGD REGISTER: BD160a] DenticeRL , ElkinsMR , ByeP . Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial. Journal of Physiotherapy2012;58(1):33-40. [CFGD REGISTER: BD160b] DenticeRL , ElkinsMR , ByePT . Online Supplementary Material - Table 3: Individual outcome data to "Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial" [online]. Journal of Physiotherapy2012;58(1):33-40 Online. [CFGD REGISTER: BD160c] '>Dentice 2012</a>; <a href="./references#CD001506-bbs2-0034" title="DonaldsonSH , BennettW , ZemanK , KnowlesMR , BoucherRC . Efficacy of amiloride and hypertonic saline in cystic fibrosis. Pediatric Pulmonology2003;Suppl 25:251. [CFGD REGISTER: BD110a] DonaldsonSH , BennettWD , ZemanKL , KnowlesMR , TarranR , BoucherRC . Mucus clearance and lung function in cystic fibrosis with hypertonic saline. New England Journal of Medicine2006;354(3):241-50. [CFGD REGISTER: BD110b] DonaldsonSH , BennettWD , ZemanKL , KnowlesMR , TarranR , BoucherRC . Online supplement to 'Mucus clearance and lung function in cystic fibrosis with hypertonic saline'. New England Journal of Medicine2006;354(3):241-50 Online. [CFGD REGISTER: BD110c] NCT00274391. Efficacy of amiloride and hypertonic saline in cystic fibrosis [Efficacy of amiloride and hypertonic saline in cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00274391 (first posted 10 January 2006). ">Donaldson 2006</a>; <a href="./references#CD001506-bbs2-0035" title="ACTRN12606000053527. Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with cystic fibrosis [Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with cystic fibrosis]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12606000053527 (first registered 7 February 2006). [CFGD REGISTER: BD124b] ElkinsMR , TingpejP , MoriartyCP , YozghatlianV , RoseBR , HarbourC , et al. Tolerability of hypertonic saline when delivered rapidly via the Eflow® rapid nebulizer in subjects with cystic fibrosis. Pediatric Pulmonlogy2006;41 (Suppl 29):292. [CFGD REGISTER: BD124a] ">Elkins 2006b</a>; <a href="./references#CD001506-bbs2-0036" title="EUCTR2007-002707-40-BE. The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in cystic fibrosis patients. www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002707-40 (first registered 28 June 2007). ">EUCTR2007‐002707‐40‐BE</a>; <a href="./references#CD001506-bbs2-0037" title="GenkovaN , BoshevaM , IvanchevaD . Inhaled hypertonic saline solution in cystic fibrosis. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998. ">Genkova 1998</a>; <a href="./references#CD001506-bbs2-0038" title="GrasemannH , TullisE , RatjenF . A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis. Journal of Cystic Fibrosis2013;12(5):468-74. [CFGD REGISTER: GN233b] GrasemannH , TullisE , RatjenF . A randomized placebo controlled study on the effects of L-arginine inhalation in patients with cystic fibrosis . Pediatric Pulmonology 2011;46 Suppl 34:293-4. [CFGD REGISTER: GN233c] GrasemannH , TullisE , RatjenF . Inhaled L-arginine in patients with cystic fibrosis - a randomized controlled trial. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO.: 81] [CFGD REGISTER: GN233a] NCT00405665. The short term safety and efficacy of inhaled L-arginine in patients with cystic fibrosis [Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis]. clinicaltrials.gov/ct2/show/NCT00405665 (first posted 30 November 2006). ">Grasemann 2013</a>; <a href="./references#CD001506-bbs2-0039" title="IRCT20180307038994N1. Comparison of the nebulized mannitol with nebulized hypertonic saline on pulmonary function in patients with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20180307038994N1 (first received 15 April 2018). ">IRCT20180307038994N1</a>; <a href="./references#CD001506-bbs2-0040" title="IRCT20191112045413N2. Study the Effectiveness of Outpatient treatment in Cystic Fibrosis Patients in Exacerbation Phase. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20191112045413N2 (first registered 14 February 2020). ">IRCT20191112045413N2</a>; <a href="./references#CD001506-bbs2-0041" title="IRCT20201017049055N1. Evaluation of the effectiveness of 7% plus hypertonic saline in comparison with 7% hypertonic saline in reducing the growth of Pseudomonas aeruginosa in lung of the patient with cystic fibrosis disease. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20201017049055N1 (first registered 23 April 2021). ">IRCT20201017049055N1</a>; <a href="./references#CD001506-bbs2-0042" title="KingM , DasguptaB , TomkiewiczRP , BrownNE . Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease. American Journal of Respiratory and Critical Care Medicine1997;156(1):173-7. ">King 1997</a>; <a href="./references#CD001506-bbs2-0043" title="KobylyanskyVI , GembitskayaTE . Study of the mucociliary and cough clearance in patients with mucoviscidosis and evaluation of hypertonic sodium chorlide solution influence on them. European Respiratory Journal2000;16(Suppl 31):121S. [CFGD REGISTER: BD111] 5500100000002413 ">Kobylyansky 2000</a>; <a href="./references#CD001506-bbs2-0044" title="NCT01094704. Durability of hypertonic saline for enhancing mucociliary clearance in cystic fibrosis. clinicaltrials.gov/show/NCT01094704 (first posted 29 March 2010). ">NCT01094704</a>; <a href="./references#CD001506-bbs2-0045" title="ISRCTN13412080. Effects of inhaled hypertonic saline in children with cystic fibrosis [Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: a crossover, randomized clinical trial]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13412080 (first registered 6 July 2016). NennaR , MidullaF , LambiaseC , De CastroG , ZicariAM , IndinnimeoL , et al. Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial. Italian Journal of Pediatrics2017;43(1):60. [CFGD REGISTER: BD238] [DOI: 10.1186/s13052-017-0376-6]">Nenna 2017</a>; <a href="./references#CD001506-bbs2-0046" title="NCT01753869. Timing of hypertonic saline inhalation relative to airways clearance in cystic fibrosis [Timing of hypertonic saline inhalation relative to airways clearance in cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01753869 (first posted 20 December 2012). [CFGD REGISTER: BD231c] O'NeillK , MoranF , TunneyMM , ElbornJS , BradburyI , DowneyDG , et al. Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study. BMJ Open Respiratory Research2017;4(1):e000168. [CFGD REGISTER: BD231b] [DOI: 10.1136/bmjresp-2016-000168]O’NeillK , MoranF , BradburyI , DowneyDG , RendallJ , TunneyMM , et al. Exploring the timing of hypertonic saline (HTS) and airways clearance techniques (ACT) in cystic fibrosis (CF): a cross over study. Thorax2016;71(Suppl 3):A134-5. [CFGD REGISTER: BD231a] ">O'Neill 2017</a>; <a href="./references#CD001506-bbs2-0047" title="RosM , CasciaroR , LuccaF , AlatriF , SaloniniE , FavilliF , et al. Tolerability and acceptability in patients with cystic fibrosis (CF) of two formulations of 7% hypertonic saline: a prospective multicenter clinical study. Pediatric Pulmonology2012;47(S35):364. [ABSTRACT NO.: 390] [CFGD REGISTER: BD181a] 5500100000011650 RosM , CasciaroR , LuccaF , TroianiP , SaloniniE , FavilliF , et al. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery2014;27(2):133-7. [CFGD REGISTER: BD181b] ">Ros 2012</a>; <a href="./references#CD001506-bbs2-0048" title="NCT01377792. Study of long-term treatment with hypertonic saline in patients with cystic fibrosis [Phase 4 study of the efficacy of long-term treatment with hypertonic saline on pulmonary exacerbations in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01377792 (first received 21 June 2011). [CFGD REGISTER: BD182b] Ruiz de Valbuena MaizM , LamasA , MaizL , GironR , BarrioM , delCampoR , et al. Study of the efficacy of long-term treatment with high volume compared to standard volume of hypertonic saline on pulmonary exacerbations in patients with cystic fibrosis. Pediatric Pulmonology2012;47 (S35):360. [ABSTRACT NO: 379: 379] [CFGD REGISTER: BD182a] ">Ruiz de Valbuena Maiz 2012</a>; <a href="./references#CD001506-bbs2-0049" title="Herrero CortinaB , San Miguel PagolaM , Cebria i RanzoMA , Gomez RomeroM , Diaz GutierrezF , ReychlerG . Short-term effects of hypertonic saline nebulization combined with oscillatory positive expiratory pressure in cystic fibrosis:randomised crossover trial. Journal of Cystic fibrosis2016;15 Suppl 1:S33. [ABSTRACT NO.: WS21.3] [CFGD REGISTER: BD229a] NCT02303808. Positive expiratory pressure during inhalation of hypertonic saline in patients with cystic fibrosis [Effect of introducing a positive expiratory pressure device during inhalation of hypertonic saline in patients with cystic fibrosis: a randomized crossover trial]. clinicaltrials.gov/ct2/show/NCT02303808 (first received 01 December 2014). San Miguel PagolaM , Herrero CortinaB , Cebria i IranzoMA , Gomez RomeroM , Diaz GutierrezF , ReychlerG . Hypertonic saline nebulization combined with oscillatory positive expiratory pressure accelerate sputum clearance in cystic fibrosis: A randomised crossover trial. European Respiratory Journal2016;48(Suppl 60):PA1369. [CFGD REGISTER: BD229b] San Miguel-PagolaM , ReychlerG , Cebria i IranzoMA , Gomez-RomeroM , Diaz-GutierrezF , Herrero-CortinaB . Impact of hypertonic saline nebulisation combined with oscillatory positive expiratory pressure on sputum expectoration and related symptoms in cystic fibrosis: a randomised crossover trial. Physiotherapy2020;107:243-51. [CFGD REGISTER: BD229d] ">San Miguel‐Pagola 2016</a>; <a href="./references#CD001506-bbs2-0050" title="ACTRN12615001067561. Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT) [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks on lung structure in patients with cystic fibrosis at 3-6 years of age, in parallel with the North American SHIP clinical trial, as measured by computed tomography (CT)]. apps.who.int/trialsearch/Trial3.aspx?trialid=ACTRN12615001067561 (first received 13 October 2015). EUCTR2015-004143-39-NL. Saline hypertonic in preschoolers and lung structure as measured by computed tomography [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-004143-39-NL (first received 21 December 2015). [CENTRAL: CN-01854740] [CFGD REGISTER: BD262c] ISRCTN13083896. Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT). trialsearch.who.int/Trial2.aspx?TrialID=NTR5502 (date first registered 29 September 2015). [CFGD REGISTER: BD262g] NCT02950883. Saline hypertonic in preschoolers + CT (SHIP-CT) [Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT)]. clinicaltrials.gov/ct2/show/NCT02950883 (first received 01 November 2016). NTR5502. Saline hypertonic in preschoolers and lung structure as measured by computed tomography [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study]. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR55022015. [CENTRAL: CN-01880673] [CFGD REGISTER: BD262d] TiddensH , ChenY , AndrinopoulouE , DavisS , RosenfeldM , StukovskyK , et al. Effect of inhaled hypertonic saline on structural lung disease in preschool children with cystic fibrosis. The SHIP-CT study. Journal of Cystic Fibrosis2021;20 Suppl 2:S255. [CFGD REGISTER: BD262e] TiddensHA , ChenY , AndrinopoulouER , DavisSD , RosenfeldM , RatjenF , et al. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. The Lancet. Respiratory Medicine 2022 March 11 [Epub ahead of print];S2213-2600(21):00546-4. [DOI: 10.1016/S2213-2600(21)00546-4] [FGD REGISTER: BD262f]TiddensHA , ChenY , DavisSD , RosenfeldM , RatjenF , Hinckley StukovskyKD , et al. The effect of hypertonic saline treatment in pre-schoolers with cystic fibrosis on lung structure as measured by chest computed tomography. SHIP-CT study. Journal of Cystic Fibrosis2021;20 Suppl 1:S56. [CFGD REGISTER: BD262h] ">Tiddens 2022</a>; <a href="./references#CD001506-bbs2-0051" title="Van GinderdeurenF , VerbanckS , Van CauwelaertK , VanlaethemS , SchuermansD , VinckenW , et al. Chest physiotherapy in cystic fibrosis: short-term effects of autogenic drainage preceded by wet inhalation of saline versus autogenic drainage preceded by intrapulmonary percussive ventilation with saline. Respiration2008;76(2):175-80. [CFGD REGISTER: BD178] ">Van Ginderdeuren 2008</a>; <a href="./references#CD001506-bbs2-0052" title="Van GinderdeurenF , VanlaethemS , EynsH , De SchutterI , DewachterE , MalfrootA . Influence of inhaled hypertonic saline (NaCl 6%) before or during autogenic drainage on sputum weight, oxygen saturation, heart frequency and dyspnea in cystic fibrosis patients. Journal of Cystic Fibrosis2011;10(Suppl 1):S62. [CFGD REGISTER: BD164] ">Van Ginderdeuren 2011</a>; <a href="./references#CD001506-bbs2-0053" title="VanlaethemS , Van GinderdeurenF , EynsH , MalfrootA . Influence of inhaled hypertonic saline combined with airway clearance on SpO2, heart rate, dyspnoea and wet sputum weight in hospitalised CF patients. Journal of Cystic Fibrosis2008;7(Suppl 2):S71. [CENTRAL: 643104] [CFGD REGISTER: BD129] ">Vanlaethem 2008</a>). </p> <p>Five trials were not randomised in design and were therefore excluded (<a href="./references#CD001506-bbs2-0032" title="De ConoN , SchelstraeteP , HaerynckF , Van daeleS , SandersM , De BaetsF . Hypertonic saline: effect on mucus rheology and spirometry. Journal of Cystic Fibrosis2008;7(Suppl 2):S24. [ABSTRACT NO.: 93] [CFGD REGISTER: BD130] ">DeCono 2008</a>; <a href="./references#CD001506-bbs2-0036" title="EUCTR2007-002707-40-BE. The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in cystic fibrosis patients. www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002707-40 (first registered 28 June 2007). ">EUCTR2007‐002707‐40‐BE</a>; <a href="./references#CD001506-bbs2-0039" title="IRCT20180307038994N1. Comparison of the nebulized mannitol with nebulized hypertonic saline on pulmonary function in patients with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20180307038994N1 (first received 15 April 2018). ">IRCT20180307038994N1</a>; <a href="./references#CD001506-bbs2-0041" title="IRCT20201017049055N1. Evaluation of the effectiveness of 7% plus hypertonic saline in comparison with 7% hypertonic saline in reducing the growth of Pseudomonas aeruginosa in lung of the patient with cystic fibrosis disease. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20201017049055N1 (first registered 23 April 2021). ">IRCT20201017049055N1</a>; <a href="./references#CD001506-bbs2-0044" title="NCT01094704. Durability of hypertonic saline for enhancing mucociliary clearance in cystic fibrosis. clinicaltrials.gov/show/NCT01094704 (first posted 29 March 2010). ">NCT01094704</a>) and three were excluded as there was no comparison group (<a href="./references#CD001506-bbs2-0033" title='ACTRN12611000673943. A randomised trial of the effect of timing of nebulised hypertonic saline in relation to airway clearance physiotherapy, in people with cystic fibrosis lung disease [Randomised trial of the effect of timing of nebulised hypertonic saline in relation to airway clearance physiotherapy, on subjective efficacy, tolerability and overall satisfaction, and lung function parameters in adults with cystic fibrosis lung disease]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000673943 (first registered 4 July 2011). [CFGD REGISTER: BD160e] DenticeR , ElkinsM , ByeP . Hypertonic saline before vs during vs after physiotherapy techniques for airway clearance in people with cystic fibrosis: A randomised trial. Physiotherapy2011;97:eS308-9. [ABSTRACT NO.: RR-PL-3136] [CENTRAL: 1089301] [CFGD REGISTER: BD160d] [EMBASE: 71882596]DenticeR , ElkinsMR , ByePT . A randomised trial of the effect of timing of hypertonic saline inhalation in relation to airway clearance physiotherapy in adults with cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:384. [ABSTRACT NO.: 459] [CFGD REGISTER: BD160a] DenticeRL , ElkinsMR , ByeP . Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial. Journal of Physiotherapy2012;58(1):33-40. [CFGD REGISTER: BD160b] DenticeRL , ElkinsMR , ByePT . Online Supplementary Material - Table 3: Individual outcome data to "Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial" [online]. Journal of Physiotherapy2012;58(1):33-40 Online. [CFGD REGISTER: BD160c] '>Dentice 2012</a>; <a href="./references#CD001506-bbs2-0037" title="GenkovaN , BoshevaM , IvanchevaD . Inhaled hypertonic saline solution in cystic fibrosis. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998. ">Genkova 1998</a>; <a href="./references#CD001506-bbs2-0040" title="IRCT20191112045413N2. Study the Effectiveness of Outpatient treatment in Cystic Fibrosis Patients in Exacerbation Phase. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20191112045413N2 (first registered 14 February 2020). ">IRCT20191112045413N2</a>). Two trials were cross‐over trials which had an insufficient washout period (<a href="./references#CD001506-bbs2-0027" title="AquinoES , GotoDM , SantosAS , CoelhoCC , FuccioMB , SaldivaPHN , et al. Effects of hypertonic saline solution and continuous positive airway pressure on respiratory mucus contact angle and mucus transportability by cough in cystic fibrosis patients. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:Poster #G7. [CENTRAL: CN-00679594] [CFGD REGISTER: PE199b] AquinoES , ShimuraF , SantosAS , GotoDM , CoelhoCC , deFuccioMB , et al. CPAP has no effect on clearance, sputum properties, or expectorated volume in cystic fibrosis. Respiratory Care2012;57(11):1914-9. [CFGD REGISTER: PE199a] ">Aquino 2012</a>; <a href="./references#CD001506-bbs2-0045" title="ISRCTN13412080. Effects of inhaled hypertonic saline in children with cystic fibrosis [Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: a crossover, randomized clinical trial]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN13412080 (first registered 6 July 2016). NennaR , MidullaF , LambiaseC , De CastroG , ZicariAM , IndinnimeoL , et al. Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial. Italian Journal of Pediatrics2017;43(1):60. [CFGD REGISTER: BD238] [DOI: 10.1186/s13052-017-0376-6]">Nenna 2017</a>). One trial was excluded as it was undertaken in a non‐CF population (<a href="./references#CD001506-bbs2-0043" title="KobylyanskyVI , GembitskayaTE . Study of the mucociliary and cough clearance in patients with mucoviscidosis and evaluation of hypertonic sodium chorlide solution influence on them. European Respiratory Journal2000;16(Suppl 31):121S. [CFGD REGISTER: BD111] 5500100000002413 ">Kobylyansky 2000</a>) and a further trial was performed in vitro (<a href="./references#CD001506-bbs2-0042" title="KingM , DasguptaB , TomkiewiczRP , BrownNE . Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease. American Journal of Respiratory and Critical Care Medicine1997;156(1):173-7. ">King 1997</a>). Three trials were excluded as they studied hypertonic saline in conjunction with other therapies, but did not include a comparator group without hypertonic saline (<a href="./references#CD001506-bbs2-0028" title="BrivioA , CerutiC , GambazzaS , ColomboC . Randomized double-blind monocentric trial on tolerability, acceptability and efficacy of two formulations of inhaled 7% hypertonic saline with and without hyaluronic acid in reducing airways inflammation in patients with cystic fibrosis - preliminary results. Journal of Cystic Fibrosis2013;12 Suppl 1:S104. [ABSTRACT NO.: 217] [CENTRAL: 999881] [CFGD REGISTER: BD208a] BrivioA , ConeseM , GambazzaS , BiffiA , TirelliAS , RussoM , et al. Pilot Randomized Controlled Trial Evaluating the Effect of Hypertonic Saline With and Without Hyaluronic Acid in Reducing Inflammation in Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2016;29(6):482-9. [CENTRAL: 1155400] [CFGD REGISTER: BD208b] [PMID: 27149365]">Brivio 2016</a>; <a href="./references#CD001506-bbs2-0030" title='BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Advances in Therapy2010;27(11):870-8. [CENTRAL: 781252] [CFGD REGISTER: BD156c] [EMBASE: 2010642492] [PMID: 20953746]BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Hyaluronic acid improves tolerability of hypertonic saline in CF patients. Journal of Cystic Fibrosis2010;9 Suppl 1:S63. [ABSTRACT NO.: 245] [CENTRAL: 775087] [CFGD REGISTER: BD156b] BuonpensieroP , De GregorioF , SepeA , Di PasquaA , FerriP , SianoM , et al. Inhaled hyaluronic acid improves pleasantness and tolerability of nebulised hypertonic saline in patients with cystic fibrosis. Pediatric Pulmonology2009;44 Suppl 32:243. [ABSTRACT NO.: 93] [CFGD REGISTER: BD156a] NCT01658449. Comparison of the tolerability of two formulations of hypertonic saline in cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT01658449 (first posted 7 August 2012). '>Buonpensiero 2010</a>; <a href="./references#CD001506-bbs2-0047" title="RosM , CasciaroR , LuccaF , AlatriF , SaloniniE , FavilliF , et al. Tolerability and acceptability in patients with cystic fibrosis (CF) of two formulations of 7% hypertonic saline: a prospective multicenter clinical study. Pediatric Pulmonology2012;47(S35):364. [ABSTRACT NO.: 390] [CFGD REGISTER: BD181a] 5500100000011650 RosM , CasciaroR , LuccaF , TroianiP , SaloniniE , FavilliF , et al. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery2014;27(2):133-7. [CFGD REGISTER: BD181b] ">Ros 2012</a>). One trial compared hypertonic saline with or without pretreatment with amiloride (<a href="./references#CD001506-bbs2-0034" title="DonaldsonSH , BennettW , ZemanK , KnowlesMR , BoucherRC . Efficacy of amiloride and hypertonic saline in cystic fibrosis. Pediatric Pulmonology2003;Suppl 25:251. [CFGD REGISTER: BD110a] DonaldsonSH , BennettWD , ZemanKL , KnowlesMR , TarranR , BoucherRC . Mucus clearance and lung function in cystic fibrosis with hypertonic saline. New England Journal of Medicine2006;354(3):241-50. [CFGD REGISTER: BD110b] DonaldsonSH , BennettWD , ZemanKL , KnowlesMR , TarranR , BoucherRC . Online supplement to 'Mucus clearance and lung function in cystic fibrosis with hypertonic saline'. New England Journal of Medicine2006;354(3):241-50 Online. [CFGD REGISTER: BD110c] NCT00274391. Efficacy of amiloride and hypertonic saline in cystic fibrosis [Efficacy of amiloride and hypertonic saline in cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00274391 (first posted 10 January 2006). ">Donaldson 2006</a>). Six trials did not compare hypertonic saline to control, instead they compared different airway clearance techniques used in conjunction with hypertonic saline (<a href="./references#CD001506-bbs2-0025" title="ACTRN12619001681145. Effect of the MetaNeb® on measures of lung clearance index, other measures of lung function and patient reported outcomes in individuals admitted to hospital for an acute exacerbation of their Cystic Fibrosis: a randomised controlled trial. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619001681145 (first posted 18 September 2019). [CFGD REGISTER: PE354a] ">ACTRN12619001681145</a>; <a href="./references#CD001506-bbs2-0026" title="ACTRN12621000855820. Immediate effects of the MetaNeb® on regional lung perfusion, ventilation and other measures of lung function compared to those of huff and cough in adults with stable cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12621000855820 (first posted 12 July 2021). ">ACTRN12621000855820</a>; <a href="./references#CD001506-bbs2-0049" title="Herrero CortinaB , San Miguel PagolaM , Cebria i RanzoMA , Gomez RomeroM , Diaz GutierrezF , ReychlerG . Short-term effects of hypertonic saline nebulization combined with oscillatory positive expiratory pressure in cystic fibrosis:randomised crossover trial. Journal of Cystic fibrosis2016;15 Suppl 1:S33. [ABSTRACT NO.: WS21.3] [CFGD REGISTER: BD229a] NCT02303808. Positive expiratory pressure during inhalation of hypertonic saline in patients with cystic fibrosis [Effect of introducing a positive expiratory pressure device during inhalation of hypertonic saline in patients with cystic fibrosis: a randomized crossover trial]. clinicaltrials.gov/ct2/show/NCT02303808 (first received 01 December 2014). San Miguel PagolaM , Herrero CortinaB , Cebria i IranzoMA , Gomez RomeroM , Diaz GutierrezF , ReychlerG . Hypertonic saline nebulization combined with oscillatory positive expiratory pressure accelerate sputum clearance in cystic fibrosis: A randomised crossover trial. European Respiratory Journal2016;48(Suppl 60):PA1369. [CFGD REGISTER: BD229b] San Miguel-PagolaM , ReychlerG , Cebria i IranzoMA , Gomez-RomeroM , Diaz-GutierrezF , Herrero-CortinaB . Impact of hypertonic saline nebulisation combined with oscillatory positive expiratory pressure on sputum expectoration and related symptoms in cystic fibrosis: a randomised crossover trial. Physiotherapy2020;107:243-51. [CFGD REGISTER: BD229d] ">San Miguel‐Pagola 2016</a>; <a href="./references#CD001506-bbs2-0051" title="Van GinderdeurenF , VerbanckS , Van CauwelaertK , VanlaethemS , SchuermansD , VinckenW , et al. Chest physiotherapy in cystic fibrosis: short-term effects of autogenic drainage preceded by wet inhalation of saline versus autogenic drainage preceded by intrapulmonary percussive ventilation with saline. Respiration2008;76(2):175-80. [CFGD REGISTER: BD178] ">Van Ginderdeuren 2008</a>; <a href="./references#CD001506-bbs2-0052" title="Van GinderdeurenF , VanlaethemS , EynsH , De SchutterI , DewachterE , MalfrootA . Influence of inhaled hypertonic saline (NaCl 6%) before or during autogenic drainage on sputum weight, oxygen saturation, heart frequency and dyspnea in cystic fibrosis patients. Journal of Cystic Fibrosis2011;10(Suppl 1):S62. [CFGD REGISTER: BD164] ">Van Ginderdeuren 2011</a>; <a href="./references#CD001506-bbs2-0053" title="VanlaethemS , Van GinderdeurenF , EynsH , MalfrootA . Influence of inhaled hypertonic saline combined with airway clearance on SpO2, heart rate, dyspnoea and wet sputum weight in hospitalised CF patients. Journal of Cystic Fibrosis2008;7(Suppl 2):S71. [CENTRAL: 643104] [CFGD REGISTER: BD129] ">Vanlaethem 2008</a>) and one did not use hypertonic saline but rather compared L‐arginine with isotonic saline (<a href="./references#CD001506-bbs2-0038" title="GrasemannH , TullisE , RatjenF . A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis. Journal of Cystic Fibrosis2013;12(5):468-74. [CFGD REGISTER: GN233b] GrasemannH , TullisE , RatjenF . A randomized placebo controlled study on the effects of L-arginine inhalation in patients with cystic fibrosis . Pediatric Pulmonology 2011;46 Suppl 34:293-4. [CFGD REGISTER: GN233c] GrasemannH , TullisE , RatjenF . Inhaled L-arginine in patients with cystic fibrosis - a randomized controlled trial. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO.: 81] [CFGD REGISTER: GN233a] NCT00405665. The short term safety and efficacy of inhaled L-arginine in patients with cystic fibrosis [Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis]. clinicaltrials.gov/ct2/show/NCT00405665 (first posted 30 November 2006). ">Grasemann 2013</a>). Four trials compared different formulations or timings of hypertonic saline, or both (<a href="./references#CD001506-bbs2-0029" title="BrownAW , LaubeBL , ZemanK , LechtzinN , SharplessG , WuJ , et al. Durability of hypertonic saline for enhancing mucociliary clearance in cystic fibrosis. Pediatric Pulmonology2010;45 Suppl 33:303. [ABSTRACT NO.: 237] [CFGD REGISTER: BD173] 5500100000010577 TrimbleAT , Whitney BrownA , LaubeBL , LechtzinN , ZemanKL , WuJ , et al. Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis. Journal of Cystic Fibrosis2018;17(5):650-6. [CENTRAL: CN-01645710] [CFGD REGISTER: BD173c] [EMBASE: 620273897]">Brown 2010</a>; <a href="./references#CD001506-bbs2-0035" title="ACTRN12606000053527. Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with cystic fibrosis [Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with cystic fibrosis]. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12606000053527 (first registered 7 February 2006). [CFGD REGISTER: BD124b] ElkinsMR , TingpejP , MoriartyCP , YozghatlianV , RoseBR , HarbourC , et al. Tolerability of hypertonic saline when delivered rapidly via the Eflow® rapid nebulizer in subjects with cystic fibrosis. Pediatric Pulmonlogy2006;41 (Suppl 29):292. [CFGD REGISTER: BD124a] ">Elkins 2006b</a>; <a href="./references#CD001506-bbs2-0046" title="NCT01753869. Timing of hypertonic saline inhalation relative to airways clearance in cystic fibrosis [Timing of hypertonic saline inhalation relative to airways clearance in cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01753869 (first posted 20 December 2012). [CFGD REGISTER: BD231c] O'NeillK , MoranF , TunneyMM , ElbornJS , BradburyI , DowneyDG , et al. Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study. BMJ Open Respiratory Research2017;4(1):e000168. [CFGD REGISTER: BD231b] [DOI: 10.1136/bmjresp-2016-000168]O’NeillK , MoranF , BradburyI , DowneyDG , RendallJ , TunneyMM , et al. Exploring the timing of hypertonic saline (HTS) and airways clearance techniques (ACT) in cystic fibrosis (CF): a cross over study. Thorax2016;71(Suppl 3):A134-5. [CFGD REGISTER: BD231a] ">O'Neill 2017</a>; <a href="./references#CD001506-bbs2-0048" title="NCT01377792. Study of long-term treatment with hypertonic saline in patients with cystic fibrosis [Phase 4 study of the efficacy of long-term treatment with hypertonic saline on pulmonary exacerbations in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01377792 (first received 21 June 2011). [CFGD REGISTER: BD182b] Ruiz de Valbuena MaizM , LamasA , MaizL , GironR , BarrioM , delCampoR , et al. Study of the efficacy of long-term treatment with high volume compared to standard volume of hypertonic saline on pulmonary exacerbations in patients with cystic fibrosis. Pediatric Pulmonology2012;47 (S35):360. [ABSTRACT NO: 379: 379] [CFGD REGISTER: BD182a] ">Ruiz de Valbuena Maiz 2012</a>) and one trial looked at the effect of hypertonic saline on structural lung disease via MRI (<a href="./references#CD001506-bbs2-0050" title="ACTRN12615001067561. Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT) [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks on lung structure in patients with cystic fibrosis at 3-6 years of age, in parallel with the North American SHIP clinical trial, as measured by computed tomography (CT)]. apps.who.int/trialsearch/Trial3.aspx?trialid=ACTRN12615001067561 (first received 13 October 2015). EUCTR2015-004143-39-NL. Saline hypertonic in preschoolers and lung structure as measured by computed tomography [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-004143-39-NL (first received 21 December 2015). [CENTRAL: CN-01854740] [CFGD REGISTER: BD262c] ISRCTN13083896. Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT). trialsearch.who.int/Trial2.aspx?TrialID=NTR5502 (date first registered 29 September 2015). [CFGD REGISTER: BD262g] NCT02950883. Saline hypertonic in preschoolers + CT (SHIP-CT) [Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT)]. clinicaltrials.gov/ct2/show/NCT02950883 (first received 01 November 2016). NTR5502. Saline hypertonic in preschoolers and lung structure as measured by computed tomography [A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial - Ship-CT study]. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR55022015. [CENTRAL: CN-01880673] [CFGD REGISTER: BD262d] TiddensH , ChenY , AndrinopoulouE , DavisS , RosenfeldM , StukovskyK , et al. Effect of inhaled hypertonic saline on structural lung disease in preschool children with cystic fibrosis. The SHIP-CT study. Journal of Cystic Fibrosis2021;20 Suppl 2:S255. [CFGD REGISTER: BD262e] TiddensHA , ChenY , AndrinopoulouER , DavisSD , RosenfeldM , RatjenF , et al. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. The Lancet. Respiratory Medicine 2022 March 11 [Epub ahead of print];S2213-2600(21):00546-4. [DOI: 10.1016/S2213-2600(21)00546-4] [FGD REGISTER: BD262f]TiddensHA , ChenY , DavisSD , RosenfeldM , RatjenF , Hinckley StukovskyKD , et al. The effect of hypertonic saline treatment in pre-schoolers with cystic fibrosis on lung structure as measured by chest computed tomography. SHIP-CT study. Journal of Cystic Fibrosis2021;20 Suppl 1:S56. [CFGD REGISTER: BD262h] ">Tiddens 2022</a>). We excluded the final trial because the hypertonic saline was given overnight via nasal cannulae rather than by facemask or nebuliser (<a href="./references#CD001506-bbs2-0031" title="CorcoranTE , GodovchikJE , DonnKH , BusickDR , GoralskiJ , LockeLW , et al. Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis. Pediatric Pulmonology2017;52(9):1142-9. [CFGD REGISTER: BD207] [CTG: NCT02141191]NCT02141191. A study of lung clearance after hypertonic saline delivery using the tpad device [A randomized crossover mucociliary clearance study of aerosolized 7% NACL solution administered overnight by the tpad device to subjects with cystic fibrosis]. clinicaltrials.gov/show/nct02141191 (first posted 19 May 2014). [CENTRAL: CN-01596846] [CFGD REGISTER: BD207b] ">Corcoran 2017</a>). </p> <section id="CD001506-sec-0054"> <h5 class="title">Studies awaiting classification</h5> <p>There are six trials currently listed as 'Awaiting classification' until more information is available to allow a judgement regarding eligibility (<a href="./references#CD001506-bbs2-0054" title="BalinottiJ , RodriguezV , ZaragozaS , LubovichS , KofmanC , Garcia BournissenF . Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with cystic fibrosis diagnosed by neonatal screening. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A3342. [CENTRAL: 1127230] [CFGD REGISTER: BD227b] TeperA , BalinottiJ , RodriguezV , Zaragoza S LubovichS , KofmanC , Garcia BournissenF . Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with cystic fibrosis (CF) diagnosed by neonatal screening. Journal of Cystic Fibrosis2015;14 Suppl 1:S49. [ABSTRACT NO.: ePS04.8] [CFGD REGISTER: BD227a] ">Balinotti 2015</a>; <a href="./references#CD001506-bbs2-0055" title="ACTRN12610000754044. Trial of different concentrations of nebulised saline for cystic fibrosis saline at lower tonicity in cystic fibrosis (SALTI-CF) trial [The effect of nebulised 0.9% vs 3% vs 6% saline on lung function and quality of life in people with cystic fibrosis]. apps.who.int/trialsearch/Trial3.aspx?trialid=ACTRN12610000754044 (first received 13 September 2010). DwyerT , ElkinsM , DenticeR , ForbesS , MacArthurM , CooperP , et al. Saline at a lower tonicity in cystic fibrosis (SALTI-CF) trial - a randomised controlled trial comparing 0.9% v 3% v 6% nebulised saline. Journal of Cystic Fibrosis2013;12 Suppl 1:S19. [ABSTRACT NO.: WS9.5] [CFGD REGISTER: BD186] ">Dwyer 2013</a>; <a href="./references#CD001506-bbs2-0056" title="HofmannT , SenierI , ZierschA , GeidelC , RegnisJ , LindemannH . Additive effects of amiloride and hypertonic saline on respiratory ion transport in cystic fibrosis [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:119. [CFGD REGISTER: BD75] ">Hofmann 1997</a>; <a href="./references#CD001506-bbs2-0057" title="LennoxA , BrownS , CorcoranTE , MyerburgMM , PilewskiJM . Pilot study of inhaled sodium bicarbonate: safety and ph changes after 1-2 doses. Pediatric Pulmonology2016;51 (Suppl 45):281. [ABSTRACT NO.: 236] [CFGD REGISTER: BD255a] NCT03391414. Effects of inhaled bicarbonate on airway pH in cystic fibrosis. clinicaltrials.gov/show/NCT03391414 (first posted 5 January 2018). [CFGD REGISTER: BD255b] ">Lennox 2016</a>; <a href="./references#CD001506-bbs2-0058" title="PalacioS , GiugnoH , Diaz CasauxA , LuceroB , SmithS , GiorgettiM , et al. Inhaled 7% hypertonic saline treatment in preschool children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S7, Abstract no: WS3.5. [CENTRAL: 1000053] [CFGD REGISTER: BD205] ">Palacio 2014</a>; <a href="./references#CD001506-bbs2-0059" title="Mayer-HamblettN , NicholsDP , Odem-DavisK , RiekertKA , SawickiGS , DonaldsonSH , et al. Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY Clinical Trial Study Design. Annals of the American Thorac Society2021;18(8):1397-405. [CFGD REGISTER: BD315b] [DOI: 10.1513/AnnalsATS.202010-1336SD]Mayer-HamblettN , RatjenF , RussellR , DonaldsonSH , RiekertKA , SawickiGS , et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respiratory Medicine 2022 Nov 4 [Epub ahead of print]:S2213-2600(22)00434-9. [CFGD REGISTER: BD315c] [DOI: 10.1016/S2213-2600(22)00434-9]NCT04378153. Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY). clinicaltrials.gov/ct2/show/NCT04378153 (first posted 7 May 2020). [CFGD REGISTER: BD315a] ">SIMPLIFY 2022</a>). </p> <p>One trial is a prospective, double‐blind randomised controlled trial (RCT) that recruited 19 participants (<a href="./references#CD001506-bbs2-0054" title="BalinottiJ , RodriguezV , ZaragozaS , LubovichS , KofmanC , Garcia BournissenF . Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with cystic fibrosis diagnosed by neonatal screening. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A3342. [CENTRAL: 1127230] [CFGD REGISTER: BD227b] TeperA , BalinottiJ , RodriguezV , Zaragoza S LubovichS , KofmanC , Garcia BournissenF . Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with cystic fibrosis (CF) diagnosed by neonatal screening. Journal of Cystic Fibrosis2015;14 Suppl 1:S49. [ABSTRACT NO.: ePS04.8] [CFGD REGISTER: BD227a] ">Balinotti 2015</a>). The intervention group received hypertonic saline 3% plus 0.25 mg/kg salbutamol twice daily compared to the control group, which received isotonic saline 0.9% plus 0.25 mg/kg salbutamol twice daily for a year. The stated outcomes are maximal flow at functional residual capacity (change from baseline), pulmonary exacerbations, respiratory rate, nutritional status and adverse events. This trial is only published as an abstract at present. </p> <p>The <a href="./references#CD001506-bbs2-0055" title="ACTRN12610000754044. Trial of different concentrations of nebulised saline for cystic fibrosis saline at lower tonicity in cystic fibrosis (SALTI-CF) trial [The effect of nebulised 0.9% vs 3% vs 6% saline on lung function and quality of life in people with cystic fibrosis]. apps.who.int/trialsearch/Trial3.aspx?trialid=ACTRN12610000754044 (first received 13 September 2010). DwyerT , ElkinsM , DenticeR , ForbesS , MacArthurM , CooperP , et al. Saline at a lower tonicity in cystic fibrosis (SALTI-CF) trial - a randomised controlled trial comparing 0.9% v 3% v 6% nebulised saline. Journal of Cystic Fibrosis2013;12 Suppl 1:S19. [ABSTRACT NO.: WS9.5] [CFGD REGISTER: BD186] ">Dwyer 2013</a> trial is a three‐armed RCT of parallel design with a duration of 16 weeks. Participants were randomised to either inhalation of 4 mL of nebulised 6% hypertonic saline plus 0.25 mg/mL quinine sulphate twice a day, inhalation of 4 mL of nebulised 3% hypertonic saline plus 0.25 mg/mL quinine sulphate twice a day or the control intervention of inhalation of 4 mL of nebulised 0.9% isotonic saline pus 0.25mg/mL quinine sulphate twice a day. The primary outcome was lung function measured by the change in FEV<sub>1</sub> % predicted, and secondary outcomes included other measures of lung function, QoL, exercise capacity, exacerbations, adverse events and sputum bacterial diversity. </p> <p>The <a href="./references#CD001506-bbs2-0056" title="HofmannT , SenierI , ZierschA , GeidelC , RegnisJ , LindemannH . Additive effects of amiloride and hypertonic saline on respiratory ion transport in cystic fibrosis [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:119. [CFGD REGISTER: BD75] ">Hofmann 1997</a> trial is an open‐label, single‐dose, RCT that included 20 participants. Participants were randomised to either amiloride in hypertonic saline 5.58% or amiloride in isotonic saline, and the primary outcome was change in ion flow by nasal potential difference. We have been unable to find any further information than an abstract. </p> <p>A further trial listed as awaiting classification is a trial registration document for a cross‐over RCT comparing inhaled solution of 8.4% hypertonic bicarbonate by nebuliser with inhaled solution of 7% hypertonic saline by nebuliser (<a href="./references#CD001506-bbs2-0057" title="LennoxA , BrownS , CorcoranTE , MyerburgMM , PilewskiJM . Pilot study of inhaled sodium bicarbonate: safety and ph changes after 1-2 doses. Pediatric Pulmonology2016;51 (Suppl 45):281. [ABSTRACT NO.: 236] [CFGD REGISTER: BD255a] NCT03391414. Effects of inhaled bicarbonate on airway pH in cystic fibrosis. clinicaltrials.gov/show/NCT03391414 (first posted 5 January 2018). [CFGD REGISTER: BD255b] ">Lennox 2016</a>). The primary outcome was the change in exhaled breath condensate pH, and secondary outcomes included change in expectorated sputum and change in spirometry. All outcomes were measured at four hours and after two inhalations on a single day. We have been unable to find any further information or publications relating to the trial . </p> <p>The fifth trial is an open‐label, parallel group, RCT of parallel design which ran for 24 weeks (<a href="./references#CD001506-bbs2-0058" title="PalacioS , GiugnoH , Diaz CasauxA , LuceroB , SmithS , GiorgettiM , et al. Inhaled 7% hypertonic saline treatment in preschool children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S7, Abstract no: WS3.5. [CENTRAL: 1000053] [CFGD REGISTER: BD205] ">Palacio 2014</a>). Investigators enrolled 27 children aged three to six years and randomised them to either hypertonic saline 7% nebulised twice a day or isotonic saline 0.9% nebulised twice a day. The primary outcome was lung function with secondary outcomes measuring respiratory symptoms, new isolation of <i>P aeruginosa,</i> rate of exacerbations, adverse events and adherence. </p> <p>The final trial listed as awaiting assessment is a multicentre stopping trial where participants are randomised to stopping treatment or continuing (<a href="./references#CD001506-bbs2-0059" title="Mayer-HamblettN , NicholsDP , Odem-DavisK , RiekertKA , SawickiGS , DonaldsonSH , et al. Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY Clinical Trial Study Design. Annals of the American Thorac Society2021;18(8):1397-405. [CFGD REGISTER: BD315b] [DOI: 10.1513/AnnalsATS.202010-1336SD]Mayer-HamblettN , RatjenF , RussellR , DonaldsonSH , RiekertKA , SawickiGS , et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respiratory Medicine 2022 Nov 4 [Epub ahead of print]:S2213-2600(22)00434-9. [CFGD REGISTER: BD315c] [DOI: 10.1016/S2213-2600(22)00434-9]NCT04378153. Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY). clinicaltrials.gov/ct2/show/NCT04378153 (first posted 7 May 2020). [CFGD REGISTER: BD315a] ">SIMPLIFY 2022</a>). Investigators randomised clinically stable children (aged 12 years or over) and adults, who have been taking triple therapy (Kaftrio™) (elexacaftor/tezacaftor/ivacaftor) for at least 90 days, to either discontinuing hypertonic saline therapy or continuing it over a period of six weeks. The primary outcome is absolute change in FEV<sub>1</sub> % predicted at week 6; secondary outcomes are adverse events and absolute change in respiratory symptoms. </p> </section> <section id="CD001506-sec-0055"> <h5 class="title">Ongoing studies</h5> <p>The review authors identified two ongoing trials from trials registries (<a href="./references#CD001506-bbs2-0060" title="ISRCTN14081521. A randomised open-label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies (the CF STORM trial). trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN14081521 (first posted 31 March 2021). ">ISRCTN14081521</a>; <a href="./references#CD001506-bbs2-0061" title="NCT02343445. Clearing lungs with ENAC inhibition in cystic fibrosis (CLEAN-CF) [A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of P-1037 solution for inhalation in patients with cystic fibrosis (CF)]. clinicaltrials.gov/ct2/show/NCT02343445 (first posted 22 January 2015). ">NCT02343445</a>). Both were described as randomised controlled trials of parallel design.  </p> <p>One three‐arm trial is comparing P‐1037 solution for inhalation in either hypertonic saline 4.2% or in 0.17% isotonic saline to placebo (0.17% saline). The trial is recruiting children aged 12 or over who have been clinically stable for at least two weeks before enrolment. All treatments are inhaled twice daily over a period of 15 days. The primary outcomes are adverse events and FEV<sub>1</sub> change from pre‐dosing to one hour post‐dosing. Secondary outcomes measure FEV<sub>1</sub> (absolute change from baseline to Day 15); FVC (absolute change from baseline to Day 15); Cystic Fibrosis Questionnaire ‐ Revised (CFQ‐R) (<a href="./references#CD001506-bbs2-0073" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>); and forced expiratory flow at 25% to <i>75</i>% of FVC (FEF<sub>25%-75%</sub>) (absolute change from baseline to Day 15) (<a href="./references#CD001506-bbs2-0061" title="NCT02343445. Clearing lungs with ENAC inhibition in cystic fibrosis (CLEAN-CF) [A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of P-1037 solution for inhalation in patients with cystic fibrosis (CF)]. clinicaltrials.gov/ct2/show/NCT02343445 (first posted 22 January 2015). ">NCT02343445</a>). </p> <p>The second ongoing trial is a stopping trial similar to the <a href="./references#CD001506-bbs2-0059" title="Mayer-HamblettN , NicholsDP , Odem-DavisK , RiekertKA , SawickiGS , DonaldsonSH , et al. Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY Clinical Trial Study Design. Annals of the American Thorac Society2021;18(8):1397-405. [CFGD REGISTER: BD315b] [DOI: 10.1513/AnnalsATS.202010-1336SD]Mayer-HamblettN , RatjenF , RussellR , DonaldsonSH , RiekertKA , SawickiGS , et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respiratory Medicine 2022 Nov 4 [Epub ahead of print]:S2213-2600(22)00434-9. [CFGD REGISTER: BD315c] [DOI: 10.1016/S2213-2600(22)00434-9]NCT04378153. Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY). clinicaltrials.gov/ct2/show/NCT04378153 (first posted 7 May 2020). [CFGD REGISTER: BD315a] ">SIMPLIFY 2022</a> trial above and known as CF STORM (<a href="./references#CD001506-bbs2-0060" title="ISRCTN14081521. A randomised open-label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies (the CF STORM trial). trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN14081521 (first posted 31 March 2021). ">ISRCTN14081521</a>). The CF STORM trial includes adults and children aged 12 or over with CF who are established on triple therapy (Kaftrio™) for more than three months. Participants are randomised to either continue muco‐active therapy (includes rhDNase and hypertonic saline) or discontinuing it for 52 weeks. When we are able to include this trial we will need to obtain IPD to look at the effects of stopping hypertonic saline versus continuing as opposed to those who stopped rhDNase. The primary outcome is change in FEV<sub>1</sub> % predicted at 52 weeks, whilst secondary outcomes report change in FEF<sub>25-75</sub> % predicted at 52 weeks; need for extra antibiotic treatment (number of courses and number of days of extra oral, IV, or nebulised antibiotics) at 52 weeks; need for extra chronic medications; number and proportion of positive respiratory cultures for significant pathogens; hospital admission; change in nutritional status; number of pulmonary exacerbations; change in QoL using CFQ‐R; adverse events; and costs to the UK National Health Service (<a href="./references#CD001506-bbs2-0060" title="ISRCTN14081521. A randomised open-label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies (the CF STORM trial). trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN14081521 (first posted 31 March 2021). ">ISRCTN14081521</a>). </p> </section> </section> </section> <section id="CD001506-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>Please refer to the risk of bias figures (<a href="#CD001506-fig-0002">Figure 2</a>; <a href="#CD001506-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD001506-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001506-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD001506-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary table: review authors' judgements for each risk of bias item for each study" data-id="CD001506-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary table: review authors' judgements for each risk of bias item for each study </p> </div> </div> </div> <section id="CD001506-sec-0057"> <h4 class="title">Allocation</h4> <section id="CD001506-sec-0058"> <h5 class="title">Generation of the randomisation sequence</h5> <p>No details of the randomisation process were provided by 10 trials (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). For nine of these we judged the risk of bias to be unclear; however, additional data received from Dr Adde confirmed that a random numbers table was used to generate the randomisation sequence (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>), as such we judged this trial to have a low risk of bias. </p> <p>We also judged a further 13 trials to have a low risk of bias (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). Computer‐generated randomisation lists were used in seven trials (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>), two trials used random permuted‐block allocation (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>), and one reported that participants drew lots to decide treatment (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>). <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> stated the use of random number tables. <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a> used a coin toss to randomise participants. <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> used telephone randomisation to an independent trials co‐ordinating unit, stratified by hospital and balanced after each group of 12 children. </p> <p>We judged there to be a high risk of bias in the <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> trial as participants were enrolled sequentially upon admission to hospital. </p> </section> <section id="CD001506-sec-0059"> <h5 class="title">Allocation concealment</h5> <p>In 11 trials, investigators did not report any details regarding methods of allocation concealment (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). We judged 10 of these to have an unclear risk of bias. Additional data received from Dr Adde confirmed that the sequence of treatment was put into numbered envelopes which were kept in the hospital pharmacy and not opened until after participants were recruited (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>); thus we judged this trial to have a low risk of bias. </p> <p>We judged a further 12 trials to have a low risk of bias (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). Ten trials concealed the allocation sequence either by using investigators off‐site, investigators not otherwise involved in the trial or a secure website (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). Randomisation was coded such that investigators were blinded to the identity of the intervention at the time of analysis in one trial (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>), and in another each participant was assigned to order of treatment by a coin toss (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). </p> <p>One trial used sequential alternate allocation, and thus we did not judge the allocation to be adequately concealed (high risk of bias) (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). </p> </section> </section> <section id="CD001506-sec-0060"> <h4 class="title">Blinding</h4> <p>Five trials  were described as "blinded" and we judged them to be at a low risk of bias (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>); two of these trials reported adding quinine sulphate to the solutions to mask the taste  (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). </p> <p>We judged four trials to have an unclear risk of bias (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a> did not provide any detail to allow us to make a decision as to whether the participants were blinded, whilst the remaining three trials were described as blinded, but admitted that participants may have been able to discern which group they were in due to the taste and duration of nebulisation for the different interventions (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). </p> <p>We judged the remaining 15 trials to have a high risk of bias due to the discernible taste of hypertonic saline (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). The <a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a> trial attempted to blind participants by adding quinine sulphate to the solutions to mask the taste, but additional information stated that participants were well aware of their allocation as the taste of hypertonic saline could not be masked. <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a> described their trial as single‐blind and did not address the issue of the taste of hypertonic saline, and one trial was open‐label (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>). </p> <p>Regarding the blinding of the investigators, 11 trials reported that researchers were blinded and so had a low risk of bias (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). A lack of information led us to judge 12 trials as having an unclear risk of bias (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a> and <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a> were described as single‐blind and stated that participants could discern the taste of hypertonic saline, thus implying that the researchers were blinded, and <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a> was described as double‐blind, although the participants could discern the taste, but there were no definite statements on the blinding of trial investigators. We judged one trial to be at high risk of bias with regard to blinding of investigators as the trial was open‐label (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>). </p> </section> <section id="CD001506-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>We judged six trials to have an unclear risk of bias due to incomplete outcome data (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> provided no information about whether an ITT analysis was used; three trials did not state as whether an ITT approach had been used and did not describe any withdrawals (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). The <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a> trial had no description of dropouts. <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> provided details of withdrawals with reasons and used an ITT analysis, but an additional report of airway inflammatory changes following treatment stated that only 28 of the 48 participants were able to perform induced sputum and be included for these outcomes. </p> <p>We judged 17 trials to be at low risk (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). Three trials stated there were no withdrawals (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>). The remaining trials gave details of withdrawals and the reasons for these. <a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a> did not report withdrawals; additional data provided by the trial investigators stated that one participant (not included in the analysis) had to stop treatment with hypertonic saline due to severe dyspnoea during its nebulisation. <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a> described details of missing data for three participants; two due to uninterpretable LCI results and one due to an inability to adhere to the trial protocol. <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a> trial excluded three participants but analysed the remaining 18 participants on an ITT basis. Similarly, <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a> lost three of the 23 randomised participants, but full reasons were given. In the <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> trial, two participants (one from each group) withdrew voluntarily after randomisation and before the first dose; a clear description of withdrawals after randomisation was given by group and with reasons, with a total of 82 participants in the hypertonic saline group and 80 in control group included in an ITT analysis. <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a> reported that only one participant in the 3% hypertonic saline group was lost to follow‐up. <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a> described two dropouts following randomisation and accounted for this by replacing them. <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a> detailed six dropouts due to non‐adherence. Only two participants withdrew from the <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a> trial, one in each group, with full reasons given. <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> gave details (with reasons) of withdrawals, which were in roughly equal numbers across groups, and reported an ITT analysis of 158 participants in the hypertonic saline group and 163 in the control group. In the <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a> trial, 10 out of 150 participants did not complete the trial; this was less than 15% and investigators supplied full reasons. Only one participant dropped out of the <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> trial, the remaining 59 participants completed the trial and were included in the analysis. Two trials gave details of withdrawals, but did not state whether an ITT analysis had been performed (<a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). In the <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> trial, six participants withdrew in total (three from each group) with reasons given. In the <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a> trial there was a clear description of dropouts and withdrawals. </p> <p><a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a> stated that no adverse events were reported with hypertonic saline, but did not give any information for the placebo group. We judged this trial to be at high risk of bias for this domain. </p> </section> <section id="CD001506-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Three trials were reported only in abstract form, thus limiting the availability of data concerning the outcomes which were planned to have been reported; and we judged these to have an unclear risk of bias (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>). A further two trials did not report all the outcomes listed in the methods, and we also deemed these to be at an unclear risk of bias (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>). In the remaining 19 trials, the outcomes stated in the 'Methods' section were reported in the 'Results' section (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). </p> </section> <section id="CD001506-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>We found descriptions of sample size calculations in 13 trials (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>); however, the remaining 11 trials did not undertake such calculations (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). </p> <p>In total 14 trials used a cross‐over design, but six of these either did not use or did not state a washout period between treatment arms (<a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>), and we judged the risk of bias to be unclear. Eight trials did report the washout period; the stated washout periods were one week (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>), two weeks (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>), three weeks (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>), four weeks (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>) and eight weeks (<a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). We judged these eight trials to be at low risk of bias. </p> </section> </section> <section id="CD001506-sec-0064"> <h3 class="title" id="CD001506-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD001506-tbl-0001"><b>Summary of findings 1</b> Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (stable lung disease)</a>; <a href="./full#CD001506-tbl-0002"><b>Summary of findings 2</b> Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (during acute exacerbations of lung disease)</a>; <a href="./full#CD001506-tbl-0003"><b>Summary of findings 3</b> Hypertonic saline compared with rhDNase with for cystic fibrosis</a>; <a href="./full#CD001506-tbl-0004"><b>Summary of findings 4</b> Hypertonic saline compared with amiloride for cystic fibrosis</a>; <a href="./full#CD001506-tbl-0005"><b>Summary of findings 5</b> Hypertonic saline compared with sodium‐2‐mercaptoethane sulphonate (Mistabron®) for cystic fibrosis</a>; <a href="./full#CD001506-tbl-0006"><b>Summary of findings 6</b> Hypertonic saline compared with mannitol for cystic fibrosis</a>; <a href="./full#CD001506-tbl-0007"><b>Summary of findings 7</b> Hypertonic saline 7% versus xylitol for cystic fibrosis</a>; <a href="./full#CD001506-tbl-0008"><b>Summary of findings 8</b> Hypertonic saline 7% versus hypertonic saline 3% for cystic fibrosis</a> </p> <p>We graded the certainty of the evidence for those outcomes included in the summary of findings tables. For the definitions of these gradings, please refer to the summary of findings tables (<a href="./full#CD001506-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD001506-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001506-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001506-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD001506-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD001506-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD001506-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD001506-tbl-0008">summary of findings Table 8</a>). </p> <section id="CD001506-sec-0065"> <h4 class="title">Hypertonic saline 3% to 7% versus isotonic saline in stable lung disease</h4> <p>This comparison included 15 trials (n = 931) (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). A summary of the results and our judgements with regard to the certainty of the evidence can be found in the table (<a href="./full#CD001506-tbl-0001">summary of findings Table 1</a>). </p> <p>In the analysis, due to data limitations, we have entered and analysed data from cross‐over trials as if they were from parallel trials. One trial assessed children with stable lung disease and chronic sinuitis and looked at the effect of the intervention on sinus symptoms (<a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>).  </p> <p>We report results from one trial narratively; this trial has been published as an abstract only, and we have been unable to ascertain the duration of the trial or intervention (<a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>). </p> <section id="CD001506-sec-0066"> <h5 class="title">Primary outcomes</h5> <section id="CD001506-sec-0067"> <h6 class="title">1. Lung function</h6> <section id="CD001506-sec-0068"> <p><b>a. FEV<sub>1</sub> </b></p> <p>Four trials (246 participants) examined the effect of hypertonic saline 3% to 7% compared to isotonic saline on the change in FEV<sub>1</sub> % predicted after two to four weeks treatment (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>). We are uncertain if there was an improvement in FEV<sub>1</sub> % predicted in the hypertonic saline group compared to isotonic saline (MD 3.30%, 95% CI 0.71 to 5.89; 4 trials, 246 participants; very low‐certainty evidence; <a href="./references#CD001506-fig-0005" title="">Analysis 1.1</a>). </p> <p><a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a> selected 20 children aged 6 to 18 years old with essentially normal lung function as measured by spirometry with an FEV<sub>1</sub> greater than 80% predicted and found no difference compared to isotonic saline (MD ‐0.42%, 95% CI ‐7.45 to 6.61; <a href="./references#CD001506-fig-0005" title="">Analysis 1.1</a>). </p> <p>The two earlier trials recruited participants with greater impairment in lung function (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>). When the data from these two trials were pooled and analysed, there was an improvement in FEV<sub>1</sub> % predicted at four weeks compared to control (MD 4.15%, 95% CI 1.14 to 7.16; 2 trials, 205 participants; <a href="./references#CD001506-fig-0005" title="">Analysis 1.1</a>). The I² value at this time point for all participants is 51% (according to our definition this may just represent substantial heterogeneity); however, if the <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> trial is removed from the meta‐analysis I² reverts to zero. The participants in the <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> trial had a lower FEV<sub>1</sub> % predicted at baseline than in the other trials, which may account for this difference. Similarly, for the analysis of data for participants aged over 14 years, which combines data for just two trials (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>), the lower baseline lung function values of the participants in the <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> trial could account for this heterogeneity. </p> <p>Only <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> examined the mean % change in FEV<sub>1</sub> % predicted at time points after four weeks (4, 12, 24, 36 and 48 weeks). Trial results failed to demonstrate a benefit over isotonic saline at any time‐point, other than at 24 weeks (MD 5.37%, 95% CI 1.03 to 9.71; 1 trial, 140 participants; low‐certainty evidence). </p> <p><a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a> stated that the trial measured lung function, but did not report any results other than to state there was no difference in lung function results. </p> <p><a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a> also measured FEV<sub>1</sub>% predicted at day 1 and day 29, with no differences seen between the groups. However, as hypertonic saline was not delivered to the airways, these outcomes are not included in our analysis (<a href="./references#CD001506-fig-0005" title="">Analysis 1.1</a>). </p> <p>One trial was a single‐dose trial which measured FEV<sub>1</sub> % predicted 24 hours after the single dose and found no difference between treatments (MD 0.30, 95% CI ‐3.48 to 4.08; 1 trial, 18 participants; <a href="./references#CD001506-fig-0005" title="">Analysis 1.1</a>) (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>). </p> </section> <section id="CD001506-sec-0069"> <p><b>b. FVC</b></p> <p>We analysed data from three trials for the mean change in FVC % predicted at four weeks (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>). When the data were pooled they did not demonstrate a difference in FVC (MD 1.07%, 95% CI ‐1.63 to 3.78; 3 trials, 225 participants; <a href="./references#CD001506-fig-0006" title="">Analysis 1.2</a>). </p> <p>Again, only <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> measured the change in FVC % predicted at 48 weeks (134 participants). There was no difference between groups, although the control group showed no improvement over this period of time (<a href="./references#CD001506-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD001506-sec-0070"> <p><b>c. Lung volumes</b></p> <p>These were not reported as outcomes in any of the included trials.</p> </section> <section id="CD001506-sec-0071"> <p><b>d. Change in FEV<sub>0.5</sub> and FEV<sub>0.75</sub> </b></p> <p><a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> assessed infant lung function in a subset of participants (73 out of 158), which included FEV<sub>0.5</sub>, and found a small difference (but with wide CIs) following treatment with hypertonic saline compared to isotonic saline at 48 weeks (MD 41.00 mL, 95% CI 0.96 to 81.04; <a href="./references#CD001506-fig-0007" title="">Analysis 1.3</a>). </p> <p>A further trial (150 participants) using infant lung function measured change in FEV<sub>0.75</sub> L/min (<a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>); investigators found no difference at 12 weeks, 24 weeks, 36 weeks or 48 weeks (<a href="./references#CD001506-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD001506-sec-0072"> <p><b>e. LCI</b></p> <p>Four trials used LCI as their primary outcome (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). In the <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a> trial, the original trial investigators' analysis found hypertonic saline improved LCI compared to isotonic saline at four weeks, although in our analysis we are uncertain whether there was a difference between groups (MD ‐1.03, 95% CI ‐2.76 to 0.70; 1 trial, 19 participants; very low‐certainty evidence; <a href="./references#CD001506-fig-0009" title="">Analysis 1.5</a>). </p> <p>The <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a> trial was a single‐dose study which reported change from baseline in LCI and found a treatment effect of ‐0.60 (standard error (SE) 0.32) between groups. </p> <p>The <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a> and <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a> trials both reported change in LCI in a preschool population at 12 months. Our analysis shows a small improvement in LCI favouring the hypertonic saline group where a fall in LCI indicates better lung function (MD ‐0.60, 95% CI ‐1.00 to ‐0.19; 2 trials, 190 participants; <a href="./references#CD001506-fig-0010" title="">Analysis 1.6</a>).  </p> </section> </section> <section id="CD001506-sec-0073"> <h6 class="title">2. Mortality</h6> <p>Only one trial (23 participants) reported all cause mortality as an outcome, and there were no deaths in either group (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>). </p> </section> </section> <section id="CD001506-sec-0074"> <h5 class="title">Secondary outcomes</h5> <section id="CD001506-sec-0075"> <h6 class="title">1. Measures of sputum clearance</h6> <p>Four trials used radio‐labelled aerosol clearance to assess mucociliary clearance (<a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>), and we judged the certainty of the evidence to be very low. In this method the participant was given the radio‐labelled aerosol from an ultrasonic nebuliser and serial lung scans were performed. Two of the Robinson trials showed that hypertonic saline increased radioisotope clearance compared to isotonic saline controls, P &lt; 0.05 (<a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>) and P &lt; 0.01 (<a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>). The <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a> trial showed that increasing concentrations of hypertonic saline also had an effect, with a difference between hypertonic saline 3% and hypertonic saline 12% favouring the higher concentration; but no difference between hypertonic saline 7% and hypertonic saline 12% was reported (<a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>). A comparison was made between three trials for per cent isotope clearance at 60 to 120 minutes (<a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>); we are uncertain whether treatment with hypertonic saline improved isotope clearance (MD 6.14%, 95% CI 2.56 to 9.72; 3 trials, 68 participants; very low‐certainty evidence; <a href="./references#CD001506-fig-0011" title="">Analysis 1.7</a>). </p> <p>Two of the Robinson trials reported measuring mucociliary clearance as 'area under the curve' (AUC), where the lower the value of AUC is, the faster the clearance, (<a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>) and showed that hypertonic saline 7% and hypertonic saline 12% improved mucociliary clearance compared to isotonic saline. In the <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a> trial, the results for AUC showed hypertonic saline and hypertonic saline with amiloride were significantly different from cough, isotonic saline and amiloride alone. Combined analysis of the two trials favoured treatment (MD ‐212.06, 95% CI ‐271.64 to ‐152.48; 2 cross‐over trials, 22 participants; <a href="./references#CD001506-fig-0012" title="">Analysis 1.8</a>). </p> <p>The participants in the Robinson trials had moderate to severe airflow obstruction; those in the <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a> trial had a mean FEV<sub>1</sub> % predicted of 60.8% (range 27% to 112%); those in the <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a> trial had a mean FEV<sub>1</sub> % predicted of 52% (range 31% to 84%); and in the <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a> trial, the mean FEV<sub>1</sub> was 60% (range 27% to 112%). This differed from the <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a> trial, who only included participants with normal lung function (greater than 90% predicted FEV<sub>1</sub> and FVC). In this trial there was no difference in mucociliary clearance measured at 20, 60, 90 minutes and 24 hours. </p> <p>One trial used gamma scintigraphy to measure the mucociliary clearance rate (% clearance) after treatment at 28 days (MD 5.12%, 95% CI 1.07 to 9.17; 1 trial, 20 participants; <a href="./references#CD001506-fig-0013" title="">Analysis 1.9</a>) (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>). </p> </section> <section id="CD001506-sec-0076"> <h6 class="title">2. Measures of exercise capacity</h6> <p><a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> demonstrated an improvement in exercise tolerance; the paper used a visual analogue scale (VAS) and during week 1 reported a mean (SD) improvement with hypertonic saline of 2.05 (1.3) and with isotonic saline of 1.7 (1.25) (P = 0.015); during week 2 the mean (SD) rise with hypertonic saline was 2.76 (1.45) and with isotonic saline 1.75 (1.6) (P = 0.02) (<a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>). When analysed, these data favour hypertonic saline both at week 1 (MD 0.88, 95% CI 0.19 to 1.57; 1 trial, 53 participants; <a href="./references#CD001506-fig-0014" title="">Analysis 1.10</a>) and at week 2 (MD 1.01, 95% CI 0.18 to 1.84; 1 trial, 53 participants; <a href="./references#CD001506-fig-0014" title="">Analysis 1.10</a>).  </p> </section> <section id="CD001506-sec-0077"> <h6 class="title">3. Measures of QoL and symptom scores</h6> <p>Five trials (678 participants) assessed health‐related QoL (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). One trial assessed the CFQ‐R for both parent and participant (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>), and two trials used the CFQ‐R for parents only (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a> used the standard CFQ‐R respiratory domain at four weeks, and the <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> trial measured QoL using the SF‐36 questionnaire and the Cystic Fibrosis Questionnaire (CFQ) for adults and for parents. </p> <p>The CFQ‐R domain for parents or participants was assessed in three trials (365 participants) (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>), and demonstrated no difference between groups (<a href="./references#CD001506-fig-0015" title="">Analysis 1.11</a>). There is moderate heterogeneity for CFQ Parent data (three trials) according to our definition above; the I² value is 47%. This value reverts to zero if the data from the <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> trial are removed. This trial recruited young children under the age of five years in contrast to the other two trials, which may account for the heterogeneity (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>). The <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a> trial also used the parent‐reported CFQ‐R respiratory domain and found no difference between groups at 48 weeks (adjusted treatment difference 0.1 (95% CI ‐5.7 to 5.8), taken directly from the trial paper). </p> <p><a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> reported a significantly higher (better) score in the mental health domain of the SF‐36 in participants over 14 years (MD 7.77, 95% CI 1.86 to 13.68; 1 trial, 91 participants; <a href="./references#CD001506-fig-0015" title="">Analysis 1.11</a>); however, the overall score for the CFQ and SF‐36 was no different in those under 14 years of age (MD 2.84, 95% CI ‐7.90 to 13.58; 1 trial, 91 participants; <a href="./references#CD001506-fig-0015" title="">Analysis 1.11</a>) (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). There were better results in the domains of role (P = 0.04), emotion (P = 0.03) and health (P = 0.01) in the CFQ Adult compared to the control group. In participants under the age of 14, the digestion domain was better (P = 0.02) in the control group compared to the hypertonic saline group using the CFQ for parents. This trial also measured absenteeism from work and school; and participants in the hypertonic saline group experienced fewer days off work, school or days they were unable to participate in usual activity; seven days in the hypertonic saline group as compared to 24 days in the control group (P &lt; 0.001) (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). </p> <p><a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a> reported CFQ‐R respiratory domain at four weeks, and again found no difference between groups (<a href="./references#CD001506-fig-0015" title="">Analysis 1.11</a>). </p> <p>Two trials assessed symptoms using a VAS with 10 cm scales ranging from ‐5 cm to +5 cm (<a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). One trial found improvements in symptoms for quality of sleep and feeling of cleared chest measured after one and two weeks of treatment with hypertonic saline 6% (<a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>). The Riedler trial looked at a similar VAS for feeling of cleared chest alone, which was measured four days after treatment and demonstrated a difference in their first block of 10 participants favouring hypertonic saline 6% compared to isotonic saline (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). The results of the two trials were pooled and demonstrated a result favouring treatment (MD 0.97, 95% CI 0.35 to 1.60; 2 trials, 72 participants; <a href="./references#CD001506-fig-0016" title="">Analysis 1.12</a>). </p> <p>One trial compared hypertonic saline versus isotonic saline delivered via a pulsating nebuliser (designed to enhance aerosol deposition into the nose and sinus cavities) for improving nasal and sinus symptoms, assessed using the validated Sino‐Nasal Outcome Test‐20 (SNOT‐20) symptom score (<a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>). This tool is a disease‐specific, health‐related, 20‐item QoL measure for people with rhinosinusitis focusing on rhinogenous as well as on general discomforts. Scores range between 0 and 5 for each item, with higher scores indicating a greater health burden. On the first day of treatment, the hypertonic saline group described worsened symptom scores, mean (SD) 23.0 (10.4) compared to 24.8 (11.0) in the isotonic saline group (P &lt; 0.005). By day 29 however, there was no difference between the groups; hypertonic saline 20.7 (10.1) and isotonic saline 19.4 (9.6) (<a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>). </p> </section> <section id="CD001506-sec-0078"> <h6 class="title">4. Pulmonary exacerbations</h6> <section id="CD001506-sec-0079"> <p><b>a. frequency</b></p> <p>Four trials (607 participants) reported on this outcome but, although the definition of exacerbations was comparable, we elected not to pool the data as the age difference between the participants in the trials was so great (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). We judged the certainty of the evidence to be very low. </p> <p><a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> reported pulmonary exacerbations as a secondary outcome. The trial found there were fewer exacerbations per year requiring intravenous antibiotic therapy in the hypertonic saline group than in the control group (MD ‐0.46, 95% CI ‐0.82 to ‐0.10; <a href="./references#CD001506-fig-0017" title="">Analysis 1.13</a>) (<a href="#CD001506-fig-0004">Figure 4</a>). It was also reported that the mean number of days on which participants met this definition of an exacerbation was 17 days in the control group and six days in the hypertonic saline group (difference 11 days, 95% CI 3 to 19; P = 0.02). The interval during which participants remained free of exacerbations was also significantly longer in the hypertonic saline group than in the control group (P = 0.03). The <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> trial also found that there was no difference in the mean number of visits not requiring antibiotics (MD ‐0.25, 95% ‐0.84 to 0.34; <a href="./references#CD001506-fig-0017" title="">Analysis 1.13</a>) (<a href="#CD001506-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD001506-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Hypertonic saline 3% to 7% versus isotonic saline, outcome: 1.13 Average number of exacerbations" data-id="CD001506-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypertonic saline 3% to 7% versus isotonic saline, outcome: 1.13 Average number of exacerbations </p> </div> </div> </div> <p><a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> stated in the original trial report that exacerbations, defined according to signs and symptoms alone, regardless of treatment, were also less frequent in the hypertonic saline group compared to control: 1.32 per participant and 2.74 per participant respectively (difference 1.42, 95% CI 0.86 to 1.99; P &lt; 0.001). The mean number of days during which participants met criteria for a symptom‐defined exacerbation was 69 days in the control group and 22 days in the hypertonic saline group (difference 47 days, 95% CI 30 to 63; P &lt; 0.001). The time participants remained free of exacerbations was significantly longer in the hypertonic saline group (P &lt; 0.001), with a 48‐week exacerbation‐free survival rate of 41% in the hypertonic saline group and 16% in the control group. </p> <p><a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> used protocol‐defined exacerbations as their primary outcome. They found no difference in the mean (SD) number of exacerbations; those with hypertonic saline experienced 2.3 (1.69) events per year, compared to isotonic saline 2.3 (1.15) events per year (<a href="./references#CD001506-fig-0017" title="">Analysis 1.13</a>). </p> <p>The <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a> and <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a> trials both reported the rate of pulmonary exacerbations and also time to first exacerbation in preschool children and infants. <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a> reported the exacerbation rate in each group and found no difference (hypertonic saline group 1.1 (95% CI 0.0 to 2.1); isotonic saline group 1.2 (95% CI 0.4 to 1.9); P = 0.86). The probability of remaining free of pulmonary exacerbations in the hypertonic saline group compared to the isotonic saline group was 0.78, i.e. no difference. </p> <p>The <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a> trial reported time to first pulmonary exacerbation as a hazard ratio (HR) at 48 weeks and again found no difference (HR 0.94, 95% CI 0.65 to 1.36; P = 0.63). </p> </section> <section id="CD001506-sec-0080"> <p><b>b. admission to hospital</b></p> <p><a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> stated that there was no difference reported in hospitalisation rates between the hypertonic saline group and the controls (<a href="./references#CD001506-fig-0018" title="">Analysis 1.14</a>). </p> </section> <section id="CD001506-sec-0081"> <p><b>c. duration of hospital stay (post hoc change)</b></p> <p>No trial reported the duration of hospitalisation due to pulmonary exacerbations.</p> </section> <section id="CD001506-sec-0082"> <p><b>d. outpatient treatments (hospital in the home, unscheduled visits to the doctor)</b></p> <p>No trial reported details of outpatient treatments due to pulmonary exacerbations.</p> </section> </section> <section id="CD001506-sec-0083"> <h6 class="title">5. Medication delivery time</h6> <p>No trials reported on this as an outcome.</p> </section> <section id="CD001506-sec-0084"> <h6 class="title">6. Cost</h6> <p>No trials reported on this as an outcome.</p> </section> <section id="CD001506-sec-0085"> <h6 class="title">7. Adherence</h6> <p>Four trials (655 participants) judged treatment adherence by the number of returned ampoules or vials (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>).  </p> <p>We were only able to analyse data from one trial; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a> reported the mean adherence rate in each group and found no difference between groups (MD ‐0.03, 95% CI ‐0.07 to 0.01; 1 trial, 150 participants; <a href="./references#CD001506-fig-0019" title="">Analysis 1.15</a>). </p> <p>We report the results from three trials narratively. In the cross‐over trial by <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>, adherence was 95.3% for the hypertonic saline period and 84.5% for the isotonic saline period; this was not statistically significant (P = 0.26). <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> reported adherence as 63% in the control group compared to 64% in the hypertonic saline group. <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> reported no difference in adherence between those receiving hypertonic saline and isotonic saline, with an overall mean adherence of 75.2% (95% CI 72.2% to 78.2%).  </p> </section> <section id="CD001506-sec-0086"> <h6 class="title">8. Bacteriology</h6> <p>Four trials (607 participants) reported on bacteriology; we were able to analyse data from two trials (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>) and report narrative results from two trials (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). </p> <p><a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> measured the bacterial load of sputum; but when analysed, there was no difference between groups in the concentration of <i>P aeruginosa</i> or <i>S aureus</i> from baseline to 48 weeks (<a href="./references#CD001506-fig-0020" title="">Analysis 1.16</a>). The <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a> trial reported on time (years) to first isolation of a CF pathogen and found no difference for either <i>S aureus,H influenzae</i> or <i>P aeruginosa</i> (<a href="./references#CD001506-fig-0021" title="">Analysis 1.17</a>). </p> <p><a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> found no new bacterial pathogens, and the pathogens that were identified did not differ between the groups. The <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a> trial reported that changes in microbiology during the study did not differ significantly between the two groups. </p> </section> <section id="CD001506-sec-0087"> <h6 class="title">9. Adverse events</h6> <p>Adverse events were reported in ten trials (825 participants) (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). Where appropriate data are available, we have presented these in the analyses (<a href="./references#CD001506-fig-0022" title="">Analysis 1.18</a>; <a href="./references#CD001506-fig-0023" title="">Analysis 1.19</a>; <a href="./references#CD001506-fig-0024" title="">Analysis 1.20</a>). We deemed the certainty of the evidence to be low. </p> <p>We report adverse events below split by time frame, but we have been unable to ascertain the time frame for one trial (<a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>). This trial demonstrated that participants with an FEV<sub>1</sub> % predicted of 40% to 70% at baseline experienced a significant fall in FEV<sub>1</sub> following isotonic saline, while none of the participants fell significantly with hypertonic saline (<a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>).  </p> <section id="CD001506-sec-0088"> <p><b>Single‐dose trials</b></p> <p>Two single‐dose trials (n = 32) reported adverse events (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). </p> <p><a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a> (20 participants) reported three adverse events. In one participant FEV<sub>1</sub> dropped by more than 20% after inhaling hypertonic saline and the participant discontinued with the trial. Two participants reported shortness of breath and chest tightness related to inhalation of hypertonic saline; both were given salbutamol and continued on the trial. </p> <p>In the <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a> trial, despite participants being pretreated with terbutaline, there was a tendency for those who received hypertonic saline to have a larger fall in FEV<sub>1</sub> % predicted within five minutes of receiving hypertonic saline, although the difference was not statistically significant (<a href="./references#CD001506-fig-0022" title="">Analysis 1.18</a>). Participants who received hypertonic saline described higher scores for throat irritation on a VAS compared to isotonic saline control, though the number describing throat irritation was not stated. Frequency of cough in those treated with hypertonic saline could not be directly compared to the days when they received the isotonic saline control as to they were encouraged to cough on the control days to match the active day's cough so as not to confound the results of the mucociliary clearance data (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). </p> </section> <section id="CD001506-sec-0089"> <p><b>Two to four weeks</b></p> <p>Three trials (n = 101) of two to four weeks' duration reported adverse events (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>). </p> <p><a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a> reported the overall number of adverse events and adverse events related to the trial drugs, rather than the number of participants experiencing an adverse event. There were no significant differences in cough, hoarseness or chest pain (P = 0.17); however, there were significantly more overall adverse events in the hypertonic saline group for the symptoms of increased sputum production, fever, rhinorrhoea, malaise and ear infections (P = 0.0035). <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a> further reported a mean (SD) drop in FEV<sub>1</sub> % predicted after the first inhalation of hypertonic saline 116 (140) mL and after isotonic saline 41 (88) mL; when analysed, the data showed no difference between groups (<a href="./references#CD001506-fig-0022" title="">Analysis 1.18</a>). </p> <p>We were able to combine data for two trials (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>). No differences were found between groups for any adverse event, cough, pharyngitis, chest tightness, haemoptysis, wheezing, nasal congestion or increased sputum production (<a href="./references#CD001506-fig-0023" title="">Analysis 1.19</a>). </p> </section> <section id="CD001506-sec-0090"> <p><b>48 to 52 weeks</b></p> <p>Four trials (n = 677) reported adverse events at 48 to 52 weeks (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). </p> <p>The <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> trial reported the number of adverse events (not participants experiencing adverse events) as pulmonary exacerbations (see above), chest pain, gastro‐intestinal symptoms, headache, joint pain, pharyngitis and tonsillitis; these were significantly fewer in the hypertonic saline group. Adverse drug reactions were also reported, events that in the opinion of the investigator were related directly to the trial medication. These were significantly higher in the hypertonic saline group (n = 14) than the control group (n = 1), P = 0.01, and included cough, chest tightness, pharyngitis, haemoptysis, sinusitis, sneezing, tonsillitis and vomiting (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). </p> <p>We were able to combine data for the remaining three trials (<a href="./references#CD001506-fig-0024" title="">Analysis 1.20</a>). </p> <p>There was no difference between groups with regard to any adverse events, serious adverse events, cough, chest tightness, vomiting, wheezing, nasal congestion, ear infection, abdominal distension, or diarrhoea (<a href="./references#CD001506-fig-0024" title="">Analysis 1.20</a>). We graded the certainty of evidence as low. </p> <p>Fever was slightly more common in the isotonic saline group (RR 0.73, 95% CI 0.53 to 1.00; 3 trials, 513 participants; low‐certainty evidence; <a href="./references#CD001506-fig-0024" title="">Analysis 1.20</a>), whilst rhinorrhoea was more common in the hypertonic saline groups (RR 1.70, 95% CI 1.04 to 2.79; 1 trials, 42 participants; low‐certainty evidence; <a href="./references#CD001506-fig-0024" title="">Analysis 1.20</a>). </p> </section> </section> </section> </section> <section id="CD001506-sec-0091"> <h4 class="title">Hypertonic saline 3% to 7% versus isotonic saline during acute exacerbations of lung disease </h4> <p>Two trials (n = 142) assessed the effect of hypertonic saline during an acute exacerbation of lung disease (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). One was of parallel design, and we were able to enter data into the analysis (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). The second trial used a cross‐over design and, due to data limitations, we have reported the results narratively (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). A summary of the results and our judgements in regard to the certainty of the evidence can be found in <a href="./full#CD001506-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD001506-sec-0092"> <h5 class="title">Primary outcomes</h5> <section id="CD001506-sec-0093"> <h6 class="title">1. Lung function</h6> <section id="CD001506-sec-0094"> <p><b>a. FEV<sub>1</sub> </b></p> <p>Only the <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> trial assessed the change in lung function, and this was as a secondary outcome. Spirometry was performed daily, and the investigators reported that FEV<sub>1</sub> was higher in the hypertonic saline arm using a mixed‐effects model in the first 10 days of treatment. We were able to assess the change from baseline in FEV<sub>1</sub> % predicted after the authors supplied the raw data. Hypertonic saline may make little or no difference to the change in FEV1 % predicted compared to isotonic saline at treatment day 7, the 99 participants reporting data at treatment day 10, or the 130 participants at time of discharge (low‐certainty evidence) (<a href="./references#CD001506-fig-0025" title="">Analysis 2.1</a>).  Dentice also showed that participants treated with hypertonic saline were more likely to return to their pre‐exacerbation FEV<sub>1</sub> than those treated with isotonic saline, 75% versus 57% (number needed to treat for an additional beneficial outcome (NNTB) was 6 (95% CI 3 to 65)) (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). </p> </section> <section id="CD001506-sec-0095"> <p><b>b. FVC</b></p> <p>Only <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> measured the change in FVC, as a secondary outcome and in a similar manner to FEV<sub>1</sub>. We were able to assess the change from baseline in FVC % predicted after the authors supplied the raw data. Again, there was no evidence of any difference between groups when assessed at treatment day 7 (130 participants), at day 10 (99 participants) or at discharge (130 participants), although significance was nearly reached at this time point, MD 6.1% (95% CI ‐0.68 to 12.88) (<a href="./references#CD001506-fig-0026" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD001506-sec-0096"> <h6 class="title">2. Mortality</h6> <p>There were no deaths reported in either short‐term trial (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>) (low‐certainty evidence). </p> </section> </section> <section id="CD001506-sec-0097"> <h5 class="title">Secondary outcomes</h5> <section id="CD001506-sec-0098"> <h6 class="title">1. Measures of sputum clearance</h6> <p>This outcome was not reported in either trial (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). </p> </section> <section id="CD001506-sec-0099"> <h6 class="title">2. Exercise tolerance</h6> <p><a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> assessed exercise tolerance using the shuttle walk test, comparing the groups at day 7; the results just failed to demonstrate a difference between groups (MD 46.00 m, 95% CI ‐14.81 to 106.81; 1 trial, 132 participants; <a href="./references#CD001506-fig-0027" title="">Analysis 2.3</a>). </p> </section> <section id="CD001506-sec-0100"> <h6 class="title">3. Measures of QoL and symptom score</h6> <p><a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a> used a VAS to report a feeling of cleared chest in a short‐term cross‐over trial. The paper reported median (interquartile range) scores, which we were unable to analyse and so report narratively. The score was significantly higher after hypertonic saline, median (range) 2.0 (0.0 to 3.0) compared to after isotonic saline 0.5 (‐2.0 to 2.3) (P = 0.04), but this was not the case after participants had crossed over to the alternate arm, when the median (range) score was 2.0 (1.0 to 3.0) for hypertonic saline and 1.0 (0.0 to 3.0) for isotonic saline (P = 0.463) (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). </p> <p><a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> also used a VAS (100 mm scale) to measure changes in chest congestion, sleep disturbance and dyspnoea (both daily and at the time of discharge) and analysed the data using a mixed‐effect model. At discharge, the hypertonic saline group had significantly less severe sleep disturbance by 15 mm (95% CI 6 to 23), chest congestion by 9 mm (95% CI 4 to 14) and dyspnoea by 6 mm (95% CI 1 to 12). <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> also measured QoL using the SF‐36 and the CFQ at day 7 and at discharge, but reported no differences between the groups. </p> </section> <section id="CD001506-sec-0101"> <h6 class="title">4. Pulmonary exacerbations</h6> <p><a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> assessed the length of time until the next pulmonary exacerbation requiring hospitalisation and duration of hospitalisation. </p> <section id="CD001506-sec-0102"> <p><b>b. admission to hospital</b></p> <p>We are uncertain whether there is any difference between treatment groups in the length of time until the next pulmonary exacerbation requiring hospitalisation, HR 0.86 (95% CI 0.57 to 1.30). We assessed this evidence as low certainty (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). </p> </section> <section id="CD001506-sec-0103"> <p><b>c. duration of hospital stay</b></p> <p>This was the primary outcome in the <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> trial. The length of stay was 12 days in the hypertonic saline group and 13 days in the isotonic saline group. The paper reported this with an MD of one day (95% CI 0 to 2 days), P = 0.07. The mean estimate of one day was below the two‐day difference nominated in the sample size calculation. </p> </section> </section> <section id="CD001506-sec-0104"> <h6 class="title">5. Medication delivery time</h6> <p>This outcome was not assessed by either trial (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). </p> </section> <section id="CD001506-sec-0105"> <h6 class="title">6. Cost of treatment</h6> <p>This outcome was not assessed by either trial (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). </p> </section> <section id="CD001506-sec-0106"> <h6 class="title">7. Adherence</h6> <p>In <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>, both treatment arms demonstrated very good adherence; only 6% of the hypertonic saline group and 14% of the control group were less than 75% adherent to the allocated intervention. <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a> did not report adherence. </p> </section> <section id="CD001506-sec-0107"> <h6 class="title">8. Bacteriology</h6> <p><a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> found no evidence of any difference between the groups in terms of bacterial density when comparing bacterial cultures taken on admission with cultures taken at day 7. There was no evidence of any difference between the groups for participants who were positive for <i>P aeruginosa</i> on admission and who were negative on day 7 (10% in the hypertonic saline group and 6% in the isotonic saline group). Clearance of <i>S aureus</i> was higher in both groups, but still did not show any evidence of a difference between groups: 25% in the hypertonic group and 24% in the control group. This outcome was not reported by <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>. </p> </section> <section id="CD001506-sec-0108"> <h6 class="title">9. Adverse events</h6> <p>Both trials reported on adverse events, but we judged the certainty of the evidence to be very low.  </p> <p><a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> reported that no participants had an acute fall greater than 15% in FEV<sub>1</sub> or oxygen desaturation after their first dose of hypertonic saline (with salbutamol before treatment). There were reports of mild cough and wheeze that resolved in 15 minutes; but there were no serious adverse events reported in either group. </p> <p><a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a> reported that most participants coughed "substantially more" when inhaling hypertonic saline compared to isotonic saline, especially during the first few minutes of inhalation, but this usually resolved before the end of the inhalation period. </p> </section> </section> </section> <section id="CD001506-sec-0109"> <h4 class="title">Hypertonic saline versus mucus mobilising treatments</h4> <section id="CD001506-sec-0110"> <h5 class="title">Hypertonic saline versus rhDNase</h5> <p>Three trials were eligible for inclusion in this comparison (n = 80) (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). All three were cross‐over trials; due to data limitations we analysed two of these as if they were parallel trials (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>), but we were able to analyse the <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> data using the generic inverse variance method. A summary of the main results and judgements on the certainty of the evidence are presented in <a href="./full#CD001506-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD001506-sec-0111"> <h6 class="title">Primary outcomes</h6> <section id="CD001506-sec-0112"> <p><b>1. Lung function</b></p> <p>a. FEV<sub>1</sub> </p> <p>All three trials reported on this outcome (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> measured the mean increase in FEV<sub>1</sub> % predicted from baseline comparing hypertonic saline 3% 5 mL (3% increase) to daily rhDNase (16% increase) and alternate‐daily rhDNase (14% increase). We present comparisons between daily hypertonic saline and daily rhDNase in this review; these were reported by <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> and <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>. The results have not been pooled because the duration of the interventions in the two trials was very different; three weeks for the <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> trial and three months for the <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> trial. </p> <p>After three weeks, we are uncertain if there is a difference between hypertonic saline and rhDNase (very low‐certainty evidence; 1 trial; <a href="./references#CD001506-fig-0028" title="">Analysis 3.1</a>) (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>). After three months, there was a lower change in FEV<sub>1</sub> % predicted after hypertonic saline compared to rhDNase, but we are uncertain of this result as the certainty of evidence is very low (MD 8.00%, 95% CI 2.00 to 14.00; 1 trial, 47 participants; very low‐certainty evidence; <a href="./references#CD001506-fig-0028" title="">Analysis 3.1</a>) (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). Both <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> and <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> compared the number of participants who improved their FEV<sub>1</sub> by 10% or more from baseline after treatment. At three weeks, <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> reported in the paper that those treated with hypertonic saline were less likely to increase their FEV<sub>1</sub> by 10%, but our analysis does not show a statistical difference between treatments; this was also true for the <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> trial at three months (<a href="./references#CD001506-fig-0029" title="">Analysis 3.2</a>). </p> <p><a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a> reported the change in FEV<sub>1</sub> % predicted and found no difference between treatments. The results have not been presented in a meta‐analysis as they did not report an MD and standard error. </p> <p>b. FVC</p> <p><a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> reported that there was no difference between daily rhDNase and hypertonic saline (<a href="./references#CD001506-fig-0030" title="">Analysis 3.3</a>).  </p> </section> <section id="CD001506-sec-0113"> <p><b>2. Mortality</b></p> <p>None of the trials reported on this outcome.</p> </section> </section> <section id="CD001506-sec-0114"> <h6 class="title">Secondary outcomes</h6> <section id="CD001506-sec-0115"> <p><b>1. Measures of sputum clearance</b></p> <p>None of the trials reported on this outcome.</p> </section> <section id="CD001506-sec-0116"> <p><b>2. Measures of exercise capacity</b></p> <p>Suri measured exercise tolerance using a three‐minute step test at the end of each treatment period. As part of the step test, the changes in the saturation of haemoglobin with oxygen in arterial blood (SaO2), the VAS score and the 'fifteen count breathlessness score' (FCS) were recorded (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). They reported no differences between the groups for either oxygen saturation, VAS for breathlessness, or FCS (<a href="./references#CD001506-fig-0031" title="">Analysis 3.4</a>; <a href="./references#CD001506-fig-0032" title="">Analysis 3.5</a>; <a href="./references#CD001506-fig-0033" title="">Analysis 3.6</a>).  </p> </section> <section id="CD001506-sec-0117"> <p><b>3. Measures of QoL and symptom scores</b></p> <p>Two trials reported on this outcome; however, the results have not been pooled as the outcome measures were not standardised (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> assessed symptoms using the quality of well‐being self‐administered form 1.04. They reported there was no difference in scores between the groups (<a href="./references#CD001506-fig-0034" title="">Analysis 3.7</a>). <a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a> assessed symptom scores using a five‐point Likert scale and also reported no difference between groups. </p> </section> <section id="CD001506-sec-0118"> <p><b>4. Pulmonary exacerbations</b></p> <p><a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> described pulmonary exacerbations during the trial, with 15 episodes occurring during treatment with hypertonic saline and 18 with daily rhDNase. We are uncertain if there is any difference between treatments (very low‐certainty evidence).  </p> </section> <section id="CD001506-sec-0119"> <p><b>5. Medication delivery time</b></p> <p><a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> compared delivery time in minutes between hypertonic saline 5.85% 10 mL twice‐daily and rhDNase 2.5 mg twice‐daily and found that hypertonic saline took longer to nebulise (MD ‐31.00 minutes, 95% CI ‐37.56 to ‐24.44; 1 trial, 14 participants (cross‐over design with 14 participants in each arm); <a href="./references#CD001506-fig-0035" title="">Analysis 3.8</a>). The large difference in nebulisation time relates to the difference in volumes nebulised using the same Pari master or Pari LL nebuliser (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>).  </p> </section> <section id="CD001506-sec-0120"> <p><b>6. Cost</b></p> <p>Two trials compared the cost of treatment between rhDNase and hypertonic saline (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>).  </p> <p><a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> compared one month of hypertonic saline treatment with rhDNase (Deutschmark (DM) 2427) to hypertonic saline (DM 86).  </p> <p><a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> compared total healthcare cost for the treatments incorporating not just drug cost but also admission, outpatient review, cost of investigations and the cost of utilising community resources. <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> investigated the mean cost difference between daily rhDNase and hypertonic saline and alternate‐day rhDNase at 12 weeks. As reported in the original paper, the drug cost per day was reported to be GBP 0.38 for hypertonic saline, GBP 20.39 for once‐daily rhDNase and GBP 10.20 for alternate‐day rhDNase (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). The average total cost of an occupied bed per day ranged from GBP 280 to GBP 397 (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). The mean annual drug cost of daily rhDNase was GBP 1755 compared with GBP 37 for hypertonic saline and the MD in the total health service cost between daily rhDNase and hypertonic saline was GBP 1409.00 (95% CI GBP 440.00 to GBP 2318.00). The MD in total cost between daily rhDNase and alternate‐day rhDNase was GBP 513.00 (95% CI GBP ‐546.00 to GBP 1510.00) (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>).  </p> </section> <section id="CD001506-sec-0121"> <p><b>7. Adherence</b></p> <p>Only <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> assessed adherence and reported the number of returned treatment packs. Those on rhDNase had compliance rates of 84%, with those on hypertonic saline having 93% compliance. </p> </section> <section id="CD001506-sec-0122"> <p><b>8. Bacteriology</b></p> <p><a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> assessed sputum microbiology throughout the trial and did not identify any new pathogens acquired during the course of the trial amongst individuals. </p> <p><a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a> compared <i>P aeruginosa</i> growth and found no difference in bacterial load using hypertonic saline compared to rhDNase. </p> </section> <section id="CD001506-sec-0123"> <p><b>9. Adverse events</b></p> <p>Based on data from one trial we are uncertain if there is any difference in adverse events between groups as we judged the certainty of the evidence to be very low. Three participants had to withdraw because of a fall of 15% or greater in FEV<sub>1</sub> after receiving hypertonic saline despite pretreatment with bronchodilators. Increased cough was very common with all treatments and reported in 13 participants using hypertonic saline, 17 on daily rhDNase and 23 on alternate day rhDNase (very low‐certainty evidence) (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). </p> </section> </section> </section> <section id="CD001506-sec-0124"> <h5 class="title">Hypertonic saline versus amiloride</h5> <p>One trial was eligible for inclusion in this comparison (n = 12) (<a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>). The main results and the certainty of the evidence are presented in <a href="./full#CD001506-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD001506-sec-0125"> <h6 class="title">Primary outcomes</h6> <section id="CD001506-sec-0126"> <p><b>1. Lung function</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0127"> <p><b>2. Mortality</b></p> <p>The included trial did not report on this as an outcome.</p> </section> </section> <section id="CD001506-sec-0128"> <h6 class="title">Secondary outcomes</h6> <section id="CD001506-sec-0129"> <p><b>1. Measures of sputum clearance</b></p> <p>The included trial looked at the effect of amiloride with hypertonic saline and amiloride alone compared to isotonic saline (<a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>). We are uncertain whether there is any difference with amiloride plus hypertonic saline or amiloride alone compared to isotonic saline (very low‐certainty evidence). </p> </section> <section id="CD001506-sec-0130"> <p><b>2. Measures of exercise capacity</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0131"> <p><b>3. Measures of QoL and symptom scores</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0132"> <p><b>4. Pulmonary exacerbations</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0133"> <p><b>5. Medication delivery time</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0134"> <p><b>6. Cost</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0135"> <p><b>7. Adherence</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0136"> <p><b>8. Bacteriology</b></p> <p>The included trial did not report on this as an outcome.</p> </section> <section id="CD001506-sec-0137"> <p><b>9. Adverse events</b></p> <p>The included trial did not report on this as an outcome.</p> </section> </section> </section> <section id="CD001506-sec-0138"> <h5 class="title">Hypertonic saline versus sodium‐2‐mercaptoethane sulphonate (Mistabron®)</h5> <p>One trial was eligible for inclusion in this comparison (n = 29) (<a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). Only 3 mL of 7% hypertonic saline was used in the <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a> trial. We were unable to enter data into the graphs, because SDs were not reported in the paper. The main results and the judgements on the certainty of the evidence are presented in <a href="./full#CD001506-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD001506-sec-0139"> <h6 class="title">Primary outcomes</h6> <section id="CD001506-sec-0140"> <p><b>1. Lung function</b></p> <p><a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a> compared sodium‐2‐mercaptoethane sulphonate 20% 3 mL twice‐daily to hypertonic saline 7% 3 mL twice‐daily. Participants were divided into sputum producers and non‐sputum producers. The sputum producers who were given sodium‐2‐mercaptoethane sulphonate increased peak expiratory flow (PEF) (change from baseline of 7 L/min) compared to hypertonic saline (change from baseline of ‐2 L/min, P &lt; 0.02). There was no significant difference in PEF in the non‐sputum producers. Furthermore, FVC was not significantly different in either group. The V<sub>max</sub> 50% vital capacity (VC) increased in the sputum producers with sodium‐2‐mercaptoethane sulphonate (+10) compared to hypertonic saline (0; P &lt; 0.005). In the non‐sputum producers, hypertonic saline improved V<sub>max</sub> 50% VC (+14) compared to sodium‐2‐mercaptoethane sulphonate (‐5), but this was not significant. In the sputum producers group residual volume (RV) and total lung capacity (TLC) improved with hypertonic saline (+1) compared to sodium‐2‐mercaptoethane sulphonate (‐5; P &lt; 0.05). In the non‐sputum producers group, sodium‐2‐mercaptoethane sulphonate had no effect (0) on RV or TLC, whilst hypertonic saline had some effect (‐6), again this did not reach statistical significance.  </p> </section> <section id="CD001506-sec-0141"> <p><b>2. Mortality</b></p> <p>The included trial did not report on this as an outcome.</p> </section> </section> <section id="CD001506-sec-0142"> <h6 class="title">Secondary outcomes</h6> <section id="CD001506-sec-0143"> <p><b>1. Measures of sputum clearance</b></p> <p>We are uncertain whether there is any difference in sputum volume, colour or cough frequency between the groups (very low‐certainty evidence) (<a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>).  </p> </section> <section id="CD001506-sec-0144"> <p><b>2. Measures of exercise capacity</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0145"> <p><b>3. Measures of QoL and symptom scores</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0146"> <p><b>4. Pulmonary exacerbations</b></p> <p>There was no change in sputum bacteriology or the number of courses of antibiotics prescribed (<a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>) (very low‐certainty evidence).  </p> </section> <section id="CD001506-sec-0147"> <p><b>5. Delivery time</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0148"> <p><b>6. Cost</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0149"> <p><b>7. Adherence</b></p> <p>The included trial did not report on this as an outcome.</p> </section> <section id="CD001506-sec-0150"> <p><b>8. Bacteriology</b></p> <p>The included trial did not report on this as an outcome.</p> </section> <section id="CD001506-sec-0151"> <p><b>9. Adverse events</b></p> <p>In the <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a> trial, the group given sodium‐2‐ mercaptoethane sulphonate and hypertonic saline described coughing at the beginning of their inhalations; no other serious adverse events occurred (very low‐certainty evidence). </p> </section> </section> </section> <section id="CD001506-sec-0152"> <h5 class="title">Hypertonic saline versus mannitol</h5> <p>One trial was eligible for inclusion in this comparison (n = 12) (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). In the analysis, due to data limitations, data from this cross‐over trial have been entered and analysed as if they were from a parallel trial. The main results and the certainty judgements on the evidence are presented in <a href="./full#CD001506-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD001506-sec-0153"> <h6 class="title">Primary outcomes</h6> <section id="CD001506-sec-0154"> <p><b>1. Lung function</b></p> <p>The change from the pre‐intervention FEV<sub>1</sub> was reported at five minutes after inhalation and again 95 minutes later (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). The paper reported the mean (standard error (SE)) value for each intervention and their respective controls at each time‐point, but only reported the level of significance compared to control. At five minutes post inhalation the mean (SE) change in FEV<sub>1</sub> for hypertonic saline was ‐5.8 (1.2) and for mannitol ‐7.3 (2.5); at the later time point the mean (SE) difference was ‐2.0 (0.7) for hypertonic saline and ‐1.8 (2.7) for mannitol (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>) (very low‐certainty evidence).  </p> </section> <section id="CD001506-sec-0155"> <p><b>2. Mortality</b></p> <p>The included trial did not report on this as an outcome. </p> </section> </section> <section id="CD001506-sec-0156"> <h6 class="title">Secondary outcomes</h6> <section id="CD001506-sec-0157"> <p><b>1. Measures of sputum clearance</b></p> <p>In the included trial, we are uncertain whether there was any difference between mannitol at 300 mg and hypertonic saline for matched voluntary cough (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>) (very low‐certainty evidence).  </p> </section> <section id="CD001506-sec-0158"> <p><b>2. Measures of exercise capacity</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0159"> <p><b>3. Measures of QoL and symptom scores</b></p> <p>In the 1999 trial, Robinson used a VAS to assess the need to cough and reported that there was no difference between hypertonic saline 6% and mannitol 300 mg (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). </p> </section> <section id="CD001506-sec-0160"> <p><b>4. Pulmonary exacerbations</b></p> <p>The included trial did not report on this as an outcome. </p> </section> <section id="CD001506-sec-0161"> <p><b>5. Medication delivery time</b></p> <p>Robinson compared the time taken to nebulise hypertonic saline 6% (4.4 mL) to mannitol 300 mg and found hypertonic saline took less time (MD ‐6.10 min, 95% CI ‐7.32 to ‐4.88; 1 trial, 12 participants; <a href="./references#CD001506-fig-0036" title="">Analysis 4.1</a>) (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>).  </p> </section> <section id="CD001506-sec-0162"> <p><b>6. Cost</b></p> <p>The included trial did not report on this as an outcome.</p> </section> <section id="CD001506-sec-0163"> <p><b>7. Adherence</b></p> <p>The included trial did not report on this as an outcome.</p> </section> <section id="CD001506-sec-0164"> <p><b>8. Bacteriology</b></p> <p>The included trial did not report on this as an outcome.</p> </section> <section id="CD001506-sec-0165"> <p><b>9. Adverse events</b></p> <p>In the 1999 Robinson trial, mannitol was regarded as more irritating than the control on VAS. While FEV<sub>1</sub> fell significantly five minutes after treatment with both mannitol and hypertonic saline 6% compared to control (P = 0.004), by 95 minutes we are uncertain whether there is any difference between the groups (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>) (very low‐certainty evidence). </p> </section> </section> </section> </section> <section id="CD001506-sec-0166"> <h4 class="title">Hypertonic saline 7% versus aerosolised xylitol</h4> <p>Two trials (89 participants) are included in this comparison (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). A summary of the results and our judgements with regard to the certainty of the evidence can be found in the <a href="./full#CD001506-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD001506-sec-0167"> <h5 class="title">Primary outcomes</h5> <section id="CD001506-sec-0168"> <h6 class="title">1. Lung function</h6> <section id="CD001506-sec-0169"> <p><b>a. FEV<sub>1</sub> </b></p> <p>Both of the included trials reported change in FEV<sub>1</sub> % predicted at 14 days and we are uncertain whether there is any difference between groups MD (very low‐certainty evidence; <a href="./references#CD001506-fig-0037" title="">Analysis 5.1</a>) (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). </p> </section> <section id="CD001506-sec-0170"> <p><b>b. FVC</b></p> <p>Only <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> reported on FVC and again found no difference between groups (<a href="./references#CD001506-fig-0038" title="">Analysis 5.2</a>). </p> </section> </section> <section id="CD001506-sec-0171"> <h6 class="title">2. Mortality</h6> <p>No deaths were reported in either group in either trial (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>; <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). </p> </section> </section> <section id="CD001506-sec-0172"> <h5 class="title">Secondary outcomes</h5> <section id="CD001506-sec-0173"> <h6 class="title">1. Measures of sputum clearance</h6> <p>Neither of the trials reported on this outcome.</p> </section> <section id="CD001506-sec-0174"> <h6 class="title">2. Exercise tolerance</h6> <p>Neither of the trials reported on this outcome.</p> </section> <section id="CD001506-sec-0175"> <h6 class="title">3. Measures of QoL and symptom score</h6> <p>The <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> trial reported change in CFQ‐R score but did not provide sufficient data for the analysis; the authors reported that there were no differences in any domain between the two groups (<a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). </p> </section> <section id="CD001506-sec-0176"> <h6 class="title">4. Pulmonary exacerbations</h6> <p>The <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> trial reported median time to next pulmonary exacerbation and stated that there was no difference between groups after participants were followed up for six months (low‐certainty evidence). </p> </section> <section id="CD001506-sec-0177"> <h6 class="title">5. Medication delivery time</h6> <p>Neither of the trials reported this outcome.</p> </section> <section id="CD001506-sec-0178"> <h6 class="title">6. Cost of treatment</h6> <p>Neither of the trials reported this outcome.</p> </section> <section id="CD001506-sec-0179"> <h6 class="title">7. Adherence</h6> <p>The <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> trial reported on the mean number of doses taken and found no difference between the hypertonic saline group or the xylitol group (<a href="./references#CD001506-fig-0039" title="">Analysis 5.3</a>). </p> </section> <section id="CD001506-sec-0180"> <h6 class="title">8. Bacteriology</h6> <p>Both trials reported on bacteriology outcomes, but only in participants who were able to produce sputum. The <a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a> trial found a slight reduction in the sputum density of <i>P aeruginosa</i> in the xylitol group compared to the hypertonic saline (MD 2.91 log CFU/mL, 95% CI 0.26 to 5.56; 1 cross‐over trial, 27 participants; <a href="./references#CD001506-fig-0040" title="">Analysis 5.4</a>) but when the results were combined with data from the <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> trial, there was no difference between groups. This outcome was only measured in participants who were able to produce sputum. </p> <p>The <a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a> trial also reported on <i>P aeruginosa</i> mucoid and <i>S aureus</i>. Investigators found that there was a greater reduction in sputum density in the hypertonic saline group compared to the xylitol group (MD ‐1.80 log CFU/mL, 95% CI ‐3.48 to ‐0.12; 1 trial, 40 participants; <a href="./references#CD001506-fig-0040" title="">Analysis 5.4</a>), conversely there was no difference between groups in the change in sputum density of <i>S aureus</i> (<a href="./references#CD001506-fig-0040" title="">Analysis 5.4</a>) (<a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). </p> </section> <section id="CD001506-sec-0181"> <h6 class="title">9. Adverse events</h6> <p>Both trials reported the number of participants experiencing adverse events during the trial period. No participants in the xylitol group from either trial reported serious adverse events compared to three out of 69 participants in the hypertonic saline groups (one participant had pneumonia (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>) and two participants were diagnosed with distal intestinal obstruction syndrome, but this was deemed to be unrelated to the study (<a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>)). When we entered the data into our analysis, we found no differences between groups for any adverse event, serious adverse events, gastrointestinal disorders, hepatobiliary disorders, bronchospasm, haemoptysis, or vascular disorders (very low‐certainty evidence; <a href="./references#CD001506-fig-0041" title="">Analysis 5.5</a>). </p> </section> </section> </section> <section id="CD001506-sec-0182"> <h4 class="title">Hypertonic saline 7% versus hypertonic saline 3%</h4> <p>One trial (30 children) are included in this comparison (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). A summary of the results and our judgements in regard to the certainty of the evidence can be found in the tables (<a href="./full#CD001506-tbl-0008">summary of findings Table 8</a>). </p> <section id="CD001506-sec-0183"> <h5 class="title">Primary outcomes</h5> <section id="CD001506-sec-0184"> <h6 class="title">1. Lung function</h6> <section id="CD001506-sec-0185"> <p><b>a. FEV<sub>1</sub> </b></p> <p>There was no evidence of a difference in FEV<sub>1</sub> % predicted endpoint values between groups at 14 days and 28 days; only data for 28 days are entered in the analysis (<a href="./references#CD001506-fig-0042" title="">Analysis 6.1</a>). The mean percentage change from baseline in FEV<sub>1</sub> % predicted was greater in the 3% hypertonic saline group compared to the 7% hypertonic saline group although the CIs were wide (MD ‐13.00% predicted, 95% CI ‐25.27 to ‐0.73; 1 trial, 30 participants; very low‐certainty evidence; <a href="./references#CD001506-fig-0043" title="">Analysis 6.2</a>) (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). </p> </section> <section id="CD001506-sec-0186"> <p><b>b. FVC</b></p> <p>Similarly, there was no evidence of a difference in FVC % predicted endpoint values at either 14 or 28 days; again, only data for 28 days were entered in the analysis (<a href="./references#CD001506-fig-0044" title="">Analysis 6.3</a>). There was a greater improvement in mean change from baseline in the 3% hypertonic saline group at 28 days, but again, CIs were wide (MD ‐15.22% predicted, 95% CI ‐29.36 to ‐1.08; 1 trial, 30 participants; <a href="./references#CD001506-fig-0045" title="">Analysis 6.4</a>) (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). </p> </section> </section> <section id="CD001506-sec-0187"> <h6 class="title">2. Mortality</h6> <p>Mortality was not reported in this trial.</p> </section> </section> <section id="CD001506-sec-0188"> <h5 class="title">Secondary outcomes</h5> <section id="CD001506-sec-0189"> <h6 class="title">1. Measures of sputum clearance</h6> <p>The trial did not report on this outcome.</p> </section> <section id="CD001506-sec-0190"> <h6 class="title">2. Exercise tolerance</h6> <p>Exercise capacity was measured via peak expiratory flow rate (PEFR), % oxygen level in arterial blood (SaO<sub>2</sub>) and heart rate during a three‐minute step test (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). No differences were seen between groups for any of the outcomes; PEFR, % SaO<sub>2</sub> or heart rate (beats per minute (BPM)) (<a href="./references#CD001506-fig-0046" title="">Analysis 6.5</a>; <a href="./references#CD001506-fig-0047" title="">Analysis 6.6</a>; <a href="./references#CD001506-fig-0048" title="">Analysis 6.7</a>) . </p> </section> <section id="CD001506-sec-0191"> <h6 class="title">3. Measures of QoL and symptom score</h6> <p>This trial did not report on QoL, but did report symptoms of breathlessness (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). Participants were asked to rate perception of breathlessness during a three‐minute step test using a VAS where 0 was no breathlessness and 10 was severe breathlessness. Data showed no difference between groups (<a href="./references#CD001506-fig-0049" title="">Analysis 6.8</a>). </p> <p>Investigators also measured breathlessness using a 15‐count scale, where the children were asked to take a deep breath and then count out loud from one to 15. The number of breaths taken during the exercise was recorded. Mean ranks of the two groups were comparable, and no differences were seen (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). </p> </section> <section id="CD001506-sec-0192"> <h6 class="title">4. Pulmonary exacerbations</h6> <p>This outcome was not reported.</p> </section> <section id="CD001506-sec-0193"> <h6 class="title">5. Medication delivery time</h6> <p>This outcome was not reported.</p> </section> <section id="CD001506-sec-0194"> <h6 class="title">6. Cost of treatment</h6> <p>The authors of the trial noted that both of the treatments are cost‐effective, but the 3% strength is easily commercially available (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). </p> </section> <section id="CD001506-sec-0195"> <h6 class="title">7. Adherence</h6> <p>Participants were asked to return all unused containers and to keep a diary to assess adherence, but results were not reported (<a href="./references#CD001506-bbs2-0011" title="CTRI/2010/091/001279. A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis [Comparison of effects of 3% and 7% hypertonic saline nebulisation on lung function in children with cystic fibrosis: a randomized controlled trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001279 (first registered 16 September 2010). [CENTRAL: CN-01848671] [CFGD REGISTER: BD184b] GuptaS , AhmedF , LodhaR , GuptaYK , KabraSK . Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial. Journal of Tropical Pediatrics2012;58(5):375-81. ">Gupta 2012</a>). </p> </section> <section id="CD001506-sec-0196"> <h6 class="title">8. Bacteriology</h6> <p>This outcome was not reported</p> </section> <section id="CD001506-sec-0197"> <h6 class="title">9. Adverse events</h6> <p>The trial did not report adverse events.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001506-sec-0198" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001506-sec-0198"></div> <section id="CD001506-sec-0199"> <h3 class="title" id="CD001506-sec-0199">Summary of main results</h3> <section id="CD001506-sec-0200"> <h4 class="title">Hypertonic saline versus control (stable disease)</h4> <p>We included 15 trials comparing hypertonic saline to control in participants with stable lung disease (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0005" title="CardinaleF , MancaA , MappaL , TesseR , CavalloneR , LoffredoMS , et al. Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis. European Respiratory Journal2003;22(Suppl 45):231s. [CFGD REGISTER: BD115] ">Cardinale 2003</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0013" title="MainzJG , SchaedlichK , HentschelJ , SchumacherU , KoitschevC , KoitschevA , et al. Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S95. [ABSTRACT NO.: 146] [CENTRAL: 1081480] [CFGD REGISTER: CO59] MainzJG , SchumacherU , SchadlichK , HentschelJ , KoitschevC , KoitschevA , et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. Journal of Cystic Fibrosis 2016;15(6)(6):e57-e66. [CENTRAL: 1155399] [CFGD REGISTER: CO59b] [DOI: 10.1016/j.jcf.2016.05.003] [PMID: 27267518]NCT01086839. Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis [Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial]. clinicaltrials.gov/show/nct01086839 (first posted 15 March 2010). [CENTRAL: CN-01012975] [CFGD REGISTER: CO59c] ">Mainz 2015</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). We are uncertain whether the regular use of nebulised hypertonic saline by adults and children over the age of 12 years with CF and stable lung disease leads to an improvement in lung function (FEV<sub>1</sub> % predicted) after four weeks of treatment (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>), or whether there is any difference in lung function after 48 weeks of treatment (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). There were mixed results for other measures of lung function. Four trials in preschool children used LCI as their primary outcome and measure of lung function (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). Our analysis of one paediatric trial showed no difference in LCI at four weeks, although the original investigators reported a difference in favour of hypertonic saline (very low‐certainty evidence) (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>). In preschool children, treatment for 48 weeks with hypertonic saline did show a small improvement in LCI favouring the hypertonic saline group (MD ‐0.60, 95% CI ‐1.00 to ‐0.19; 2 trials, 190 participants; <a href="./references#CD001506-fig-0010" title="">Analysis 1.6</a>) (<a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). No trial reported on mortality. </p> <p>We are uncertain whether hypertonic saline improved mucociliary clearance compared to control (very low‐certainty evidence) (<a href="./references#CD001506-bbs2-0012" title="LaubeBL , SharplessG , CarsonKA , KellyA , MogayzelPJ . Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine2011;11:45. [CENTRAL: 806034] [CFGD REGISTER: BD157b] [PMID: 21896198]LaubeBL , SharplessGJ , KellyAE , MogayelPJ . Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis . Pediatric Pulmonology2009;44(Suppl 32):Abstract 77. [CFGD REGISTER: BD157a] NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). ">Laube 2009</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). Two trials assessed symptom improvement after short‐term treatment using simple VAS and found an improvement in feelings of better chest clearance, exercise tolerance and quality of sleep (<a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). In the long‐term trials (48 weeks), <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> showed treatment may improve some aspects of QoL in adults but not in children, while <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> showed no improvement in parent‐reported QoL scores. <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> also reported decreased absenteeism from work or school. When delivered by a Pari Sinus nebuliser, hypertonic saline did not improve nasal and sinus symptoms in one trial (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>). </p> <p>Hypertonic saline may make little or no difference to pulmonary exacerbations compared to isotonic saline. One multicentre trial (164 adults) showed that nebulised hypertonic saline reduced the frequency of pulmonary exacerbations (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). However, in a paediatric multicentre trial (321 children under six years of age with stable lung disease) hypertonic saline did not reduce the frequency of pulmonary exacerbations when compared to placebo (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>). Our analysis of the adult trial demonstrated a reduction in exacerbations requiring antibiotics, though no difference was seen in hospitalisations (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>). This finding has been felt to be important enough to result in an increasing uptake in treatment with hypertonic saline and led Rosenfeld to determine if early intervention in young children (under six years of age) would be beneficial. The <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a> trial was powered to assess an impact on well‐defined pulmonary exacerbations, but no benefit was seen after 48 weeks of treatment. Two trials in preschool children found that there may be no difference in rate of exacerbations between groups (<a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). </p> <p>No trial assessed medication delivery time or the cost of treatment. Limited reporting from three trials indicated no difference between hypertonic saline or control for adherence (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>)<i>.</i> </p> <p>Nine trials reported details of adverse events (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>; <a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0006" title="ChadwickSL , MossSJ , BottJ , GeddesDM , AltonEWFW . Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients. Thorax1997;52(Suppl 6):A43. [CFGD REGISTER: BD94] 5500100000001189 ">Chadwick 1997</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>).  </p> <p>Two single‐dose trials reported no difference between groups in fall in FEV<sub>1</sub> after inhalation of hypertonic saline but did report throat irritation, shortness of breath and chest tightness related to inhalation of hypertonic saline (<a href="./references#CD001506-bbs2-0003" title="AminR , StanojevicS , KaneM , WebsterH , RatjenF . A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine2016;112:59-64. [CFGD REGISTER: BD228] [PMID: 26856191]NCT02276898. A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index [A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index as a short-term pharmacodynamic biomarker in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02276898 (first posted 28 October 2014). ">Amin 2016</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). </p> <p>Three trials reported at two to four weeks, two of which found no differences between groups for cough, hoarseness, chest pain, pharyngitis, haemoptysis, wheezing, or nasal congestion (<a href="./references#CD001506-bbs2-0008" title="DonaldsonSH , Danielle SamulskiT , LaFaveC , ZemanK , WuJ , TrimbleA , et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. Journal of Cystic Fibrosis2020;19(6):942-8. [CFGD REGISTER: BD206c] DonaldsonSH , SamulskiD , LaFaveC , WuJ , ZemanK , SalazarC , et al. Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease. Pediatric Pulmonology2013;48 Suppl 36:280. [ABSTRACT NO.: 210] [CENTRAL: 999885] [CFGD REGISTER: BD206] DonaldsonSH , SamulskiTD , LaFaveC , ZemanK , CeppeA , DavisSD , et al. A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms. Pediatric Pulmonology2019;54 Suppl 2:354. [CFGD REGISTER: BD206b] NCT01031706. Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis [Sustained impact of hypertonic saline on mucociliary clearance in young children with cystic fibrosis]. clinicaltrials.gov/ct2/show/study/NCT01031706 (first posted 15 December 2009). ">Donaldson 2020</a>; <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a>). One trial reported more adverse events in the hypertonic saline group for fever, rhinorrhoea, malaise and ear infections (P = 0.003) (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>). </p> <p>Four trials reported at 48 weeks and found no differences between treatment groups for most adverse events including cough, chest tightness, pharyngitis, haemoptysis, sinusitis, sneezing, tonsillitis and vomiting. Fever was slightly more common in the isotonic saline group whilst rhinorrhoea was more common in the hypertonic saline group (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>; <a href="./references#CD001506-bbs2-0015" title="NCT01619657. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). clinicaltrials.gov/ct2/show/NCT01619657 (first posted 14 June 2012). StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria2018;44(2):60-1. [CFGD REGISTER: BD249c] StahlM , GraeberSY , SommerburgO , RicklefsI , DiekmannG , DopferC , et al. Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis). Pediatric Pulmonology2017;52(Suppl 47):302. [CENTRAL: CN-01430895] [CFGD REGISTER: BD249b] [EMBASE: 619069144]StahlM , RicklefsI , DopferC , BarthS , SchlegtendalA , GraeberSY , et al. Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS). Journal of Cystic Fibrosis2018;17(Suppl 3):S25-6. [CFGD REGISTER: BD249a] StahlM , RicklefsI , DopferC , BarthS , SommerburgO , DiekmannG , et al. Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF. Pediatric Pulmonology2019;54 Suppl 2:363. [CFGD REGISTER: BD249f] StahlM , WielputzMO , RicklefsI , DopferC , BarthS , SchlegtendalA , et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. American Journal of Respiratory and Critical Care Medicine2019;199(10):1238-48. [CENTRAL: CN-01655305] [CFGD REGISTER: BD249d] [PMID: 30409023]">PRESIS 2019</a>; <a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>; <a href="./references#CD001506-bbs2-0021" title="NCT02378467. Saline hypertonic in preschoolers (SHIP) [Saline hypertonic in preschoolers]. clinicaltrials.gov/ct2/show/NCT02378467 (first posted 4 March 2015). [CFGD REGISTER: BD258b] RatjenF , DavisSD , StanojevicS , KronmalRA , Hinckley StukovskyKD , JorgensenN , et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine2019;7(9):802-9. [CENTRAL: CN-01951461] [CFGD REGISTER: BD258c] [PMID: 31178421]RosenfeldM , DavisSD , Hinckley StukovskyK , JorgensenN , EnrightE , StanojevicS , et al. Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study. Pediatric Pulmonology2018;53(S2):323. [CENTRAL: CN-01648968] [CFGD REGISTER: BD258a] ">SHIP 2019</a>). </p> </section> <section id="CD001506-sec-0201"> <h4 class="title">Hypertonic saline versus control (acute exacerbation)</h4> <p>Two trials assessed hypertonic saline in participants hospitalised with an acute exacerbation (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). Hypertonic saline remains the only reported mucus clearing therapy that has been used in the context of acute exacerbations (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>). In adults admitted to hospital with an acute exacerbation of CF lung disease, hypertonic saline did not lead to a greater improvement in lung function as measured by FEV<sub>1</sub> % predicted (MD 5.10%, 95% CI ‐14.67 to 24.87; 1 trial, 130 participants; low‐certainty evidence) and FVC % predicted, although a greater proportion of those treated with hypertonic saline regained their pre‐exacerbation FEV<sub>1</sub> (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). No deaths were reported in either trial (low‐certainty evidence). Neither trial assessed measures of sputum clearance. Hypertonic saline did lead to improvements in symptoms and QoL as well as a modest reduction in length of hospital stay, although it did not lengthen the time until the next exacerbation (low‐certainty evidence). Neither trial assessed medication delivery time nor the cost of treatment. Only one trial reported on adherence and assessed this as very good in both treatment arms (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). The same trial reported no difference in any measures of bacteriology<i>.</i> Even though these trials treated participants with acute exacerbations of lung disease, <a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a> reported there were no serious adverse events and the intervention was well‐tolerated; <a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a> reported that initially most participants coughed "substantially more" when inhaling hypertonic saline compared to isotonic saline, but this usually resolved before the end of the inhalation period (very low‐certainty evidence). </p> </section> <section id="CD001506-sec-0202"> <h4 class="title">Hypertonic saline versus rhDNase</h4> <p>Three trials compared hypertonic saline to rhDNase (<a href="./references#CD001506-bbs2-0001" title="AddeFV , BorgesKT , HatanakaAC , NakaieCM , CardieriJM , OliveiraRC , et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients. Journal of Cystic Fibrosis2004;3(Suppl 1):S66. [CFGD REGISTER: BD113] ">Adde 2004</a>; <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>; <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). In comparison with rhDNase, there was no difference between treatments at three weeks (very low‐certainty evidence) (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>), but at three months hypertonic saline was less likely to result in an improvement in lung function in those with stable lung disease (very low‐certainty evidence) (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). Neither trial assessed LCI, mortality or measures of sputum clearance. One trial reported at 12 weeks on the change in exercise tolerance, dyspnoea, oxygen saturation during exercise and symptom score and found no differences between those treated with rhDNase and hypertonic saline (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>). In the same trial, all treatment arms experienced a high frequency of pulmonary exacerbations, but this may be a reflection of the severity of the groups' underlying lung disease (very low‐certainty evidence). In terms of cost, both <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> and <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> found hypertonic saline to be less expensive compared to rhDNase. One trial found that hypertonic saline took significantly longer than rhDNase to administer (<a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a>); this may have implications for adherence to treatment. <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> specifically examined adherence, which appeared high and comparable to rhDNase in the three‐month trial. Only one trial assessed adverse events and found similar rates of events between groups (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>) (very low‐certainty evidence). Acute bronchospasm remains a concern with hypertonic saline. Despite pretreatment of participants with bronchodilators, three were excluded from the <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> trial due to a fall in FEV<sub>1</sub> greater than 15%. </p> </section> <section id="CD001506-sec-0203"> <h4 class="title">Hypertonic saline versus amiloride</h4> <p>One small trial evaluated this comparison, but did not report on many of our outcomes (<a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>). The trial did report that there was no difference between hypertonic saline and amiloride in terms of sputum clearance (very low‐certainty evidence). </p> </section> <section id="CD001506-sec-0204"> <h4 class="title">Hypertonic saline compared with sodium‐2‐mercaptoethane sulphonate (Mistabron®)</h4> <p>One small trial evaluated this comparison, but did not provide data which we were able to analyse (<a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). The trial did not report FEV<sub>1</sub>, but reported mixed results for other lung function measurements. There was no difference between groups in measures of sputum clearance, sputum bacteriology or the number of courses of antibiotics prescribed (very low‐certainty evidence). All participants described coughing at the beginning of their inhalations; no other serious adverse events occurred (very low‐certainty evidence) (<a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>). </p> </section> <section id="CD001506-sec-0205"> <h4 class="title">Hypertonic saline versus mannitol</h4> <p>One cross‐over trial compared hypertonic saline to mannitol (<a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). Investigators assessed FEV<sub>1</sub> at up to 95 minutes, which is not of clinical relevance to this review (very low‐certainty evidence), and reported within‐group changes from baseline but no data for between‐group comparisons. There was no difference in sputum clearance between groups (very low‐certainty evidence). The trial also reported no difference between groups in symptoms (the need to cough) and that hypertonic saline took less time to nebulise than mannitol. However, mannitol was considered to be more irritating than hypertonic saline (very low‐certainty evidence). No other outcomes from this review were reported. </p> </section> <section id="CD001506-sec-0206"> <h4 class="title">Hypertonic saline versus xylitol</h4> <p>Two trials (89 participants) compared hypertonic saline to aerosolised xylitol, one of which was a cross‐over trial (<a href="./references#CD001506-bbs2-0014" title="NCT01355796. Inhaled xylitol versus saline in stable subjects with cystic fibrosis [Randomized cross over study of inhaled hypertonic xylitol versus hypertonic saline in stable subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01355796 (first posted 18 May 2011). ">NCT01355796</a>) and the other a parallel trial (<a href="./references#CD001506-bbs2-0022" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects [Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with exacerbation of cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00928135 (first posted 25 June 2009). [CFGD REGISTER: BD264a] SinghS , HornickD , FedlerJ , LaunspachJL , TeresiME , SantacroceTR , et al. Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis. Journal of Cystic Fibrosis2020;19(1):108-13. [CENTRAL: CN-01964766] [CFGD REGISTER: BD264b] [DOI: 10.1016/j.jcf.2019.06.016] [EMBASE: 2002325871] [PMID: 31327670]">Singh 2020</a>). There was no difference between groups in FEV<sub>1</sub> % predicted at 14 days (very low‐certainty evidence) or median time to exacerbation at six months (very low‐certainty evidence). </p> <p>We also found very low‐certainty evidence for no difference in adverse events between groups. </p> </section> <section id="CD001506-sec-0207"> <h4 class="title">Hypertonic saline 7% versus hypertonic saline 3%</h4> <p>One trial (30 participants) compared 7% hypertonic saline with 3% hypertonic saline and found that mean percentage change from baseline in FEV<sub>1</sub> % predicted was greater in the 3% group compared to the 7% group (very low‐certainty evidence). No other outcomes were reported. </p> </section> </section> <section id="CD001506-sec-0208"> <h3 class="title" id="CD001506-sec-0208">Overall completeness and applicability of evidence</h3> <p>The rationale behind the use of hypertonic saline is the inherent defect in the CFTR that results in abnormal airway mucus and reduced mucus clearance. This in turn is likely to predispose to recurring infection, which continues to have the greatest impact on mortality and morbidity in CF. Treatment to improve mucociliary clearance has been proposed to at least retard this progressive destructive process, to provide an adjunct to physical therapies and to reduce the reliance on antimicrobial use. </p> <p>A series of small proof‐of‐concept trials included in this review initially showed that hypertonic saline resulted in an improvement in measures of mucociliary clearance over isotonic saline and cough alone (<a href="./references#CD001506-bbs2-0016" title="ButtonBM , RiedlerJ , EngP , RoberstonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD69a] RiedlerJ , ReadeT , ButtonB , RobertsonCF . A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis. European Respiratory Journal1994;7(Suppl 18):430s. [CFGD REGISTER: BD69c] RiedlerJ , ReadeT , ButtonB , RobertsonCF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatric Child Health1996;32(1):48-50. [CFGD REGISTER: BD69b] ">Riedler 1996</a>; <a href="./references#CD001506-bbs2-0017" title="RobinsonM , RegnisJA , BaileyDL , KingM , BautovichGJ , ByePT . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(5):1503-9. [CFGD REGISTER: BD83] 5500100000001109 ">Robinson 1996</a>; <a href="./references#CD001506-bbs2-0018" title="RobinsonM , HemmingA , RegnisJ , WongA , BaileyD , BautotvichG , et al. Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis. Thorax1997;52(10):900-3. [CFGD REGISTER: BD45b] RobinsonM , HemmingAL , BaileyDL , MellisCM , BautovichGJ , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;153(Suppl):A70. [CFGD REGISTER: BD45a] 5500100000001559 RobinsonM , ParsonsS , HemmingA , BautovichG , MellisCM , ByePTP . Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Australian and New Zealand Journal of Medicine1997;27:258. [CFGD REGISTER: BD45c] 5500100000008140 ">Robinson 1997</a>; <a href="./references#CD001506-bbs2-0019" title="RobinsonM , DaviskasE , EberlS , BakerJ , AndersonSD , ByePT . Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonolgy1998;Suppl 17:280. [CFGD REGISTER: BD84a] RobinsonM , DaviskasE , EberlS , BakerJ , ChanH , Anderson, S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal1999;14(3):678-85. [CFGD REGISTER: BD84b] RobinsonM , DaviskasE , EberlS , BakerJ , ChanHK , AndersonSD , ByePT . The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology2000;29(6):484. [CFGD REGISTER: BD84c] ">Robinson 1999</a>). They showed that a dose of 7% hypertonic saline was more effective than 3%, but there was no significant advantage gained by increasing the dose to 12% or by adding amiloride. While they investigated the dose‐response effect of varying concentrations of saline, they did not look at the impact of the volume nebulised. </p> <p>The evidence available for hypertonic saline in stable CF lung disease has increased since this review was first published in 1999. However, the conclusions remain limited to a few relatively large multicentre trials that have examined the issue in heterogenous patient populations; and unfortunately there are no data on the effects of hypertonic saline in combination with rhDNase. The <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> trial, while not demonstrating a sustained improvement in lung function, remains promising by demonstrating a reduction in exacerbation frequency and a small improvement in QoL. This effect was not seen in children without airflow limitation as measured by spirometry (FEV<sub>1</sub> over 80% predicted) (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>). It did improve mucociliary clearance and ventilation inhomogeneity as measured by the LCI in those with mild lung disease, though the long‐term implications of this finding are unclear. When delivered following a bronchodilator it is an inexpensive additional therapy for people with CF, which does not appear to be associated significant adverse effects (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>). In younger children hypertonic saline did not improve measures of infant lung function or reduce pulmonary exacerbations (<a href="./references#CD001506-bbs2-0020" title='AlpernAN , BrumbackLC , RatjenF , RosenfeldM , DavisSD , QuittnerAL . Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis2015;14(3):403-11. [CENTRAL: 1130846] [CFGD REGISTER: BD175i] [PMID: 25443473]BrumbackLC , BainesA , RatjenF , DavisSD , DanielSL , QuittnerAL , et al. Pulmonary exacerbations and parent-reported outcomes in children &lt;6 years with cystic fibrosis. Pediatric Pulmonology2015;50:236-43. [CENTRAL: 1046755] [GR:: U01 HL092931/HL/NHLBI NIH HHS/United States] [JID:: 8510590] [PMCID:: PMC4213320] [PMID: 24777957] [U01: HL092932/HL/NHLBI NIH HHS/United States]DavisSD , RatjenF , BrumbackLC , JohnsonRC , FilbrunAG , KerbyGS , et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis2016;15(3):386-91. [CFGD REGISTER: BD175l] [PMID: 26547590]DavisSD , RosenfeldM , BrumbackL , DonaldsonS , JohnsonR , RowbothamR , et al. Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial. Pediatric Pulmonology2012;47(S35):302. [ABSTRACT NO.: 225] [CFGD REGISTER: BD175d] 5500100000011648 NCT01293084. Hypertonic saline and mucociliary clearance in children [Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT01293084 (first posted 10 February 2011). RatjenF , RosenfeldM , BrumbackL , DanielS , RowbothamR , KronmalR , et al. Efficacy of hypertonic saline in infants and young children: the ISIS study. Journal of Cystic Fibrosis2012;11 (Suppl 1):S50. [CFGD REGISTER: BD175a] RatjenF , SalazarJ , JensenR , AminR , GustafssonP , StanojevicS , et al. Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. European Respiratory Journal2012;40 Suppl:Abstract no: 1261. [CENTRAL: 1100495] [CFGD REGISTER: BD175j] [EMBASE: 71925430]RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA2012;307(21):2269-77. [CFGD REGISTER: BD175b] RosenfeldM , RatjenF , BrumbackL , DanielS , RowbothamR , McNamaraS , et al. Online supplement to "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial" [online]. JAMA2012;307(21):2269-77. [CENTRAL: 1155401] [CFGD REGISTER: BD175k] RosenfeldM , RatjenF , BrumbackL , KronmalR , DavisSD . Hypertonic saline in children with CF &lt;6 years of age: Results of the ISIS trial. Pediatric Pulmonology2012;47:172. [CENTRAL: 1030608] [CFGD REGISTER: BD175h] [EMBASE: 70891711]RosenfeldM . Hypertonic saline should be the first drug used in CF [summary]. Pediatric Pulmonology2013;48 Suppl 36:157, Summary: S12.3. [CENTRAL: 921667] SubbaraoP , StanojevicS , BrownM , JensenR , RosenfeldM , DavisS , et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. American Journal of Respiratory and Critical Care Medicine2013;188(4):456-60. [GR:: Canadian Institutes of Health Research/Canada] [JID:: 9421642] [OID: [Other ID]: NLM: PMC3778738] [PMCID:: PMC3778738] [PMID: 23742699] [SI:: ClinicalTrials.gov/NCT00709280]SubbararoP , StanojevicS , BrownM , JensenR , McDonaldN , GentK , et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study. Pediatric Pulmonology2012;47(S35):301. [CFGD REGISTER: BD175c] '>Rosenfeld 2012</a>). </p> <p>We chose lung function as our primary outcome because of its relationship in the long term with mortality in CF and by inference to see if hypertonic saline would alter this decline (<a href="./references#CD001506-bbs2-0063" title="CourtneyJM , BradleyJ , McCaughanJ , O'ConnorTM , ShorttC , BredinCP , et al. Predictors of mortality in adults with cystic fibrosis. Pediatric Pulmonolgy2007;42(6):525-32.">Courtney 2007</a>). <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> performed the largest trial in adults and children over six years of age, to address whether hypertonic saline (7%) compared to isotonic saline (0.9%) would improve FEV<sub>1</sub> after 48 weeks of treatment. The trial failed to demonstrate a significant improvement in lung function over 48 weeks, although our pooled analysis of both the smaller trial by <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> together with the <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a> trial did demonstrate a small improvement in FEV<sub>1</sub> after four weeks of treatment. </p> <p>One limitation of using lung function markers such FEV<sub>1</sub> is that, despite their association with long‐term outcomes, they may be relatively insensitive to small changes in CF, especially over time given the progressive nature of the disease. Also, those with intact lung function who may benefit most in the long term from hypertonic saline would be less likely to demonstrate an improvement. With this in mind, <a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a> used the LCI, which is a novel measure of ventilation inhomogeneity using an inert gas multiple‐breath washout technique and which has been validated in CF and shown to be more sensitive in detecting early airway disease (<a href="./references#CD001506-bbs2-0068" title="GustafssonPM , DeJongPA , TiddensHA . Multiple-breath inert gas washout and spirometry versus structural structural lung disease in cystic fibrosis. Thorax2008;63(2):129-34.">Gustafsson 2008</a>). Amin proposed that in those with only mild airflow limitation this would be more sensitive to change with hypertonic saline, and demonstrated this after four weeks of treatment, although there was no improvement seen with FEV<sub>1</sub> or even improvement in symptom scores (<a href="./references#CD001506-bbs2-0002" title="AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax2010;65(5):379-83. [CFGD REGISTER: BD158b] AminR , SubbaraoP , JabarA , BalkovecS , JensenR , KerriganS , et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology2009;44 Suppl 32:289, Abstract no: 223. [CFGD REGISTER: BD158a] NCT00635141. The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT00635141 (first posted 13 March 2008). ">Amin 2010</a>). It remains to be determined if this change will result in significant long‐term improvement in health for individuals with CF or how this may relate to the progression of CF lung disease. </p> <p>It is important to realise that before participants started the trials, they were pretreated with salbutamol and lung function was measured to determine whether they could tolerate hypertonic saline; only those who did tolerate it were allowed to carry on. This means that the results of the trials only apply to those people with CF who can tolerate hypertonic saline. </p> <p><a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> compared hypertonic saline 5.75% 10 mL twice‐daily to nebulised rhDNase 2.5 mg and found that, in both groups, FEV<sub>1</sub> improved to a similar degree in three weeks. In the <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> trial, twice‐daily 5 mL hypertonic saline 7% was compared to daily and alternate‐day rhDNase 2.5 mg. When treated with either rhDNase regimen, participants had a significant improvement in lung function from baseline, but when treated with hypertonic saline there was an increase of only 3% from baseline, less than seen in the <a href="./references#CD001506-bbs2-0004" title="BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. In: Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin. 1998:80. [CFGD REGISTER: BD70a] BallmannM , von derHardtH . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1(1):35-7. [CFGD REGISTER: BD70b] ">Ballmann 1998</a> and <a href="./references#CD001506-bbs2-0010" title="ButtonBM , RiedlerJ , EngP , RobertsonCF . Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology1996;Suppl 13:306. [CFGD REGISTER: BD71d] EngP , MortonJ , DouglasJ , RiedlerJ , WilsonJ , RobertsonCF . Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. European Respiratory Journal1995;8(Suppl 19):510s. [CFGD REGISTER: BD71c] EngPA , MortonJ , DouglassJ , RiedlerJ , WIlsonJ , RobertsonC . Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis. Australian &amp; New Zealand Journal of Medicine1995;25:440. [CFGD REGISTER: BD71b] EngPA , MortonJ , DouglassJA , RiedlerJ , WilsonJ , RobertsonCF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology1996;21(2):77-83. [CFGD REGISTER: BD71a] ">Eng 1996</a> trials. Both of these trials used 10 mL of hypertonic saline, compared to 5 mL as used by <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> and <a href="./references#CD001506-bbs2-0024" title="WellerP , IngramD , PreeceM , MatthewD . A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. In: Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58. [CFGD REGISTER: BD26b] WellerP , IngramD , PreeceM , MatthewD . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax1980;35(1):42-6. [CFGD REGISTER: BD26a] ">Weller 1980</a>. This raises the possibility that the effectiveness of treatment may also depend on the total volume of saline nebulised and this may account for the lower effect size seen by <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>. In addition, <a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a> found a wide variation in response to treatment with both rhDNase and hypertonic saline, with over 50% of participants demonstrating a more than 10% increase in FEV<sub>1</sub> with rhDNase and 35% of participants with hypertonic saline. Thus, despite the overall reduced effect seen with hypertonic saline on lung function in individuals, both rhDNase and hypertonic saline have the potential to substantially improve lung function in the medium term. The wide variation seen in response to both hypertonic saline and rhDNase raises the possibility that there may be subgroups of people with CF who are more likely to respond to efforts to improve mucociliary clearance. It also suggests that some individuals may respond better to one treatment compared to the other, and physicians may wish to consider this particularly in individuals who fail to respond to rhDNase. </p> </section> <section id="CD001506-sec-0209"> <h3 class="title" id="CD001506-sec-0209">Quality of the evidence</h3> <p>Using GRADE, we judged the certainty of the evidence from this review to be of very low to low certainty, depending on the outcome measured (<a href="./full#CD001506-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD001506-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001506-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001506-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD001506-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD001506-tbl-0006">summary of findings Table 6</a>). </p> <p>We do not think that the way the trials were designed affected the results, with even the cross‐over trials allowing for adequate washout at least in terms of lung function change. We judged that all participants had equal chances of being in either of the treatment groups. However, in all but two trials (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>; <a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>), the taste was not masked and participants would be able to identify the hypertonic saline. The participants who dropped out of the trials appear to have been accounted for and were unlikely to influence the results. </p> </section> <section id="CD001506-sec-0210"> <h3 class="title" id="CD001506-sec-0210">Potential biases in the review process</h3> <p>Two review authors independently extracted data using predefined data extraction sheets, and then a consensus was reached in regard to inclusion or exclusion. However, two authors (PW and VM) were involved in one trial (<a href="./references#CD001506-bbs2-0009" title="ByeP , ElkinsM , RobinsonM , MoriartyC , RoseB , HarbourC , et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2004;38(Suppl 27):329. [CFGD REGISTER: BD114a] ElkinsM , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC , et al. Three methods of monitoring adherence in a long-term trial in cystic fibrosis. Journal of Cystic Fibrosis2006;5 Suppl:S111. [CFGD REGISTER: BD114d] ElkinsMR , RobinsonM , MoriartyC , SercombeJ , RoseB , HarbourC . Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology2005;40(Suppl 28):268. [CFGD REGISTER: BD114c] ElkinsMR , RobinsonM , RoseBR , HarbourC , MoriartyC , MarksGB , et al. A controlled trial of long-term hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine2006;354(3):229-40. [CFGD REGISTER: BD114b] NCT00271310. The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis [The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT00271310 (first posted 30 December 2005). RatjenF . Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics2006;149(1):142. [CENTRAL: 1253122] [CFGD REGISTER: BD114e] [PMID: 17243308]">Elkins 2006a</a>) and one author (PW) was involved in a further trial (<a href="./references#CD001506-bbs2-0007" title="DenticeR , ElkinsM , ByeP . A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF). Physiotherapy 2015;101:eS356. [CENTRAL: 1126510] [CFGD REGISTER: BD185c] [EMBASE: 72114064]DenticeR , ElkinsM , ByeP . A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis. Pediatric Pulmonology2012;47 Suppl:257-8. [ABSTRACT NO.: 102] [CENTRAL: 1030604] [CFGD REGISTER: BD185b] [EMBASE: 70891850]DenticeR , ElkinsM , MiddletonP , BishopJ , WarkP , DorahyD , et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S38. [ABSTRACT NO.: WS19.4] [CFGD REGISTER: BD185a] DenticeRL , ElkinsMR , MiddletonPG , BishopJR , WarkPAB , DorahyDJ , et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax2016;71(2):141-7. [CENTRAL: 1138352] [CFGD REGISTER: BD185d] [EMBASE: 20160158105]">Dentice 2016</a>). Where one or more author(s) of this Cochrane Review was a co‐author on an included trial, a third party performed the data extraction and assessment of quality for that trial. </p> </section> <section id="CD001506-sec-0211"> <h3 class="title" id="CD001506-sec-0211">Agreements and disagreements with other studies or reviews</h3> <p>The first therapy used to enhance mucus clearance was rhDNase; it is effective in improving lung function in CF and has been adopted in most countries (<a href="./references#CD001506-bbs2-0074" title="RamseyBW , DorkinHL , for the Consensus Committee. Consensus conference: practical applications of Pulmozyme. September 22, 1993. Pediatric Pulmonology1993;17(6):404-8.">Ramsey 1994</a>). A separate systematic review found that, when compared with placebo, rhDNase improved lung function in people with CF in trials lasting from one month to two years (<a href="./references#CD001506-bbs2-0076" title="YangC , MontgomeryM . Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD001127. [DOI: 10.1002/14651858.CD001127.pub5]">Yang 2021</a>). There was a decrease in pulmonary exacerbations in trials of six months or longer. Voice alteration and rash were the only adverse events reported with increased frequency in randomised controlled trials. However, investigators also concluded that there was not enough evidence to firmly conclude if rhDNase is superior to hyperosmolar agents such as hypertonic saline in improving lung function. Nebulised rhDNase is a relatively expensive treatment, and in many countries its use is restricted to those who have degrees of impairment of lung function and who demonstrate an improvement in pulmonary function tests during a trial period (<a href="./references#CD001506-bbs2-0074" title="RamseyBW , DorkinHL , for the Consensus Committee. Consensus conference: practical applications of Pulmozyme. September 22, 1993. Pediatric Pulmonology1993;17(6):404-8.">Ramsey 1994</a>). </p> <p>Similar to the authors of the Cochrane Review of rhDNase (<a href="./references#CD001506-bbs2-0076" title="YangC , MontgomeryM . Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD001127. [DOI: 10.1002/14651858.CD001127.pub5]">Yang 2021</a>), we do not believe there is sufficient evidence to conclusively show superiority of rhDNase over hypertonic saline; however, the effect size does appear to be greater for the former. </p> <p>The other hyperosmolar agent that has been adapted for use as a treatment in CF is inhaled mannitol. This treatment is the subject of a Cochrane Review which found that, at least for up to six months, mannitol led to an improvement in lung function (<a href="./references#CD001506-bbs2-0072" title="NevittSJ , ThorntonJ , MurrayCS , DwyerT . Inhaled mannitol for cystic fibrosis. Cochrane Database of Systematic Reviews2020, Issue 5. Art. No: CD008649. [DOI: 10.1002/14651858.CD008649.pub4]">Nevitt 2020</a>). The review did not find that it improved QoL, but it did reduce exacerbation frequency. While mannitol was assessed against control, against rhDNase and in combination with rhDNase, it was not assessed against hypertonic saline. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001506-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow chart" data-id="CD001506-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow chart</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001506-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary table: review authors' judgements for each risk of bias item for each study" data-id="CD001506-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary table: review authors' judgements for each risk of bias item for each study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Hypertonic saline 3% to 7% versus isotonic saline, outcome: 1.13 Average number of exacerbations" data-id="CD001506-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypertonic saline 3% to 7% versus isotonic saline, outcome: 1.13 Average number of exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 1: Change in FEV1 (% predicted)" data-id="CD001506-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 1: Change in FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 2: Change in FVC (% predicted)" data-id="CD001506-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 2: Change in FVC (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 3: Mean change in FEV0.5 (mL)" data-id="CD001506-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 3: Mean change in FEV<sub>0.5</sub> (mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 4: Mean change in FEV0.75 (L)" data-id="CD001506-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 4: Mean change in FEV<sub>0.75</sub> (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 5: LCI" data-id="CD001506-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 5: LCI</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 6: LCI change from baseline" data-id="CD001506-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 6: LCI change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 7: Radiolabelled isotope clearance (%)" data-id="CD001506-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 7: Radiolabelled isotope clearance (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 8: Mucociliary clearance measured as area under the curve" data-id="CD001506-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 8: Mucociliary clearance measured as area under the curve </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 9: Change in mucocilliary clearance rate (% clearance)" data-id="CD001506-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 9: Change in mucocilliary clearance rate (% clearance) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 10: Exercise capacity (using a subjective visual analogue score)" data-id="CD001506-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 10: Exercise capacity (using a subjective visual analogue score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 11: Quality of life (change from baseline)" data-id="CD001506-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 11: Quality of life (change from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 12: Feeling of cleared chest (using a subjective visual analogue scale)" data-id="CD001506-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 12: Feeling of cleared chest (using a subjective visual analogue scale) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 13: Average number of pulmonary exacerbations" data-id="CD001506-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 13: Average number of pulmonary exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 14: Average number of hospital admissions per participant" data-id="CD001506-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 14: Average number of hospital admissions per participant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 15: Mean adherence rate" data-id="CD001506-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 15: Mean adherence rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 16: Change in log10 colony forming units (CFU)/g from baseline at final visit" data-id="CD001506-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 16: Change in log10 colony forming units (CFU)/g from baseline at final visit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 17: Mean time (years) to first detection of CF pathogens" data-id="CD001506-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 17: Mean time (years) to first detection of CF pathogens </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 18: Adverse events: acute fall in lung function" data-id="CD001506-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 18: Adverse events: acute fall in lung function </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 19: Adverse events 2 to 4 weeks" data-id="CD001506-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 19: Adverse events 2 to 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 20: Adverse events 48 to 52 weeks" data-id="CD001506-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Hypertonic saline 3% to 7% versus isotonic saline, Outcome 20: Adverse events 48 to 52 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hypertonic saline 3% to 7% versus isotonic saline in acute lung disease, Outcome 1: Change in FEV1 from baseline (% predicted)" data-id="CD001506-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Hypertonic saline 3% to 7% versus isotonic saline in acute lung disease, Outcome 1: Change in FEV<sub>1</sub> from baseline (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hypertonic saline 3% to 7% versus isotonic saline in acute lung disease, Outcome 2: Change in FVC from baseline (% predicted)" data-id="CD001506-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Hypertonic saline 3% to 7% versus isotonic saline in acute lung disease, Outcome 2: Change in FVC from baseline (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hypertonic saline 3% to 7% versus isotonic saline in acute lung disease, Outcome 3: Shuttle walk test" data-id="CD001506-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Hypertonic saline 3% to 7% versus isotonic saline in acute lung disease, Outcome 3: Shuttle walk test </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypertonic saline versus rhDNase, Outcome 1: Change in FEV1 (% predicted)" data-id="CD001506-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Hypertonic saline versus rhDNase, Outcome 1: Change in FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypertonic saline versus rhDNase, Outcome 2: Improvement in FEV1 &gt;10%" data-id="CD001506-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Hypertonic saline versus rhDNase, Outcome 2: Improvement in FEV<sub>1</sub> &gt;10% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypertonic saline versus rhDNase, Outcome 3: Change in FVC (% predicted)" data-id="CD001506-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Hypertonic saline versus rhDNase, Outcome 3: Change in FVC (% predicted)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypertonic saline versus rhDNase, Outcome 4: Exercise tolerance ‐ oxygen saturation" data-id="CD001506-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Hypertonic saline versus rhDNase, Outcome 4: Exercise tolerance ‐ oxygen saturation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypertonic saline versus rhDNase, Outcome 5: Exercise tolerance ‐ VAS for breathlessness" data-id="CD001506-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Hypertonic saline versus rhDNase, Outcome 5: Exercise tolerance ‐ VAS for breathlessness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypertonic saline versus rhDNase, Outcome 6: Exercise tolerance ‐ FCS" data-id="CD001506-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Hypertonic saline versus rhDNase, Outcome 6: Exercise tolerance ‐ FCS</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypertonic saline versus rhDNase, Outcome 7: Mean percentage change in quality of life score" data-id="CD001506-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Hypertonic saline versus rhDNase, Outcome 7: Mean percentage change in quality of life score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypertonic saline versus rhDNase, Outcome 8: Delivery time (minutes)" data-id="CD001506-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Hypertonic saline versus rhDNase, Outcome 8: Delivery time (minutes)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Hypertonic saline versus mannitol, Outcome 1: Delivery time (mins)" data-id="CD001506-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Hypertonic saline versus mannitol, Outcome 1: Delivery time (mins)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 1: FEV1 % predicted mean change from baseline" data-id="CD001506-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 1: FEV<sub>1</sub> % predicted mean change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 2: FVC % predicted mean change from baseline" data-id="CD001506-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 2: FVC % predicted mean change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 3: Adherence to treatment ‐ mean number of doses taken" data-id="CD001506-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 3: Adherence to treatment ‐ mean number of doses taken </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 4: Density of colonisation of pathogens ‐ change from baseline log CFU/mL" data-id="CD001506-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 4: Density of colonisation of pathogens ‐ change from baseline log CFU/mL </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 5: Adverse events" data-id="CD001506-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Hypertonic saline 7% versus xylitol, Outcome 5: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 1: FEV1 % predicted (absolute value)" data-id="CD001506-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 1: FEV<sub>1</sub> % predicted (absolute value) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 2: FEV1 % predicted mean percentage change from baseline" data-id="CD001506-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 2: FEV<sub>1</sub> % predicted mean percentage change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 3: FVC % predicted (absolute value)" data-id="CD001506-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 3: FVC % predicted (absolute value) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 4: FVC % predicted mean percentage change from baseline" data-id="CD001506-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 4: FVC % predicted mean percentage change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 5: Exercise capacity ‐ PEFR (L/min) via a 3‐minute step test" data-id="CD001506-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 5: Exercise capacity ‐ PEFR (L/min) via a 3‐minute step test </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 6: Exercise capacity ‐ SaO2 via a 3‐minute step test" data-id="CD001506-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 6: Exercise capacity ‐ SaO<sub>2</sub> via a 3‐minute step test </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 7: Exercise capacity ‐ heart rate (bpm) via a 3‐minute step test" data-id="CD001506-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 7: Exercise capacity ‐ heart rate (bpm) via a 3‐minute step test </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001506-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/urn:x-wiley:14651858:media:CD001506:CD001506-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 8: Breathlessness via a 3‐minute step test" data-id="CD001506-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_t/tCD001506-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Hypertonic saline 7% versus hypertonic saline 3%, Outcome 8: Breathlessness via a 3‐minute step test </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/media/CDSR/CD001506/image_n/nCD001506-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001506-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (stable lung disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (stable lung disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis (stable lung disease) </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline 3% to 7% </p> <p><b>Comparison:</b> isotonic saline </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Isotonic saline</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 3% to 7%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (% predicted) ranged from ‐1.42 to 2.8 in the isotonic saline groups. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (% predicted) was 3.30 higher (0.71 higher to 5.89 higher) in the hypertonic saline group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246</p> <p>(4 trials)<b><sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c,d,e</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> <p> </p> <p>Follow‐up: 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (% predicted) was 2.44 in the isotonic saline group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (% predicted) was 2.31 higher (2.72 lower to 7.34 higher) in the hypertonic saline group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,e</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The included trial also measured change in FEV<sub>1</sub> (% predicted) at: </p> <p>12 weeks, MD 4.10 (95% CI ‐0.08 to 8.28); 24 weeks, MD 5.37 (95% CI 1.03 to 9.71); and 36 weeks, MD 3.63 (95% CI ‐1.56 to 8.82). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> <p> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean LCI was 8.89 in the isotonic saline group.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean LCI was 1.03 lower (2.76 lower to 0.70 higher) in the hypertonic saline group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>f,g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design.</p> <p>2 trials reported change from baseline in LCI at 12 months in preschool children and found a slight difference between groups favouring hypertonic saline MD ‐0.60 (95% CI ‐1.00 to ‐0.19). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: up to 24 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The trials used radio‐labelled aerosol clearance and an 'area under the curve' measure to assess mucociliary clearance. </p> <p>Both measures significantly favoured treatment with hypertonic saline.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,e,f</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All trials had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: up to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 trial showed that there were fewer exacerbations per year requiring intravenous antibiotic therapy in the hypertonic saline group than in the isotonic saline group and that the interval during which participants remained free of exacerbations was also significantly longer in the hypertonic saline group. </p> <p> </p> <p>The second trial found no difference in the mean number of exacerbations per year or hospitalisation rates between the hypertonic saline group and the controls. </p> <p> </p> <p>2 further trials reported the rate of exacerbations in preschool children and found no difference between groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>607</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>very low<sup>e,h,i</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: up to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no differences between treatment groups in most adverse events including cough,chest tightness, pharyngitis, haemoptysis, sinusitis, sneezing, tonsillitis and vomiting. </p> <p>Fever was slightly more common in the isotonic saline group whilst rhinorrhoea was more common in the hypertonic saline group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further trial reported adverse events at this time point, but reported number of events rather than number of participants experiencing adverse events and we have not included these data in the analysis. </p> <p>Adverse events were also reported in shorter‐term trials.</p> <p>Single‐dose trials: there was little difference in the drop in FEV<sub>1</sub> within 5 minutes of receiving hypertonic saline (MD 5.20%, 95% CI ‐0.59 to 10.99; 1 trial, 12 participants) but participants reported throat irritation, shortness of breath and chest tightness related to inhalation of hypertonic saline. </p> <p>Medium‐term trials: 3 trials reported at 2 to 4 weeks and no differences were reported for cough, hoarseness, chest pain, pharyngitis, haemoptysis, wheezing, or nasal congestion. 1 trial reported more adverse events in the hypertonic saline group for fever, rhinorrhoea, malaise and ear infections (P = 0.003). The same trial reported increased sputum production in the hypertonic saline group whilst the remaining 2 trials did not report this adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second;<b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA:</b> not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>1 trial (n = 19) was of a cross‐over design.<br/><sup>b</sup>Downgraded once due to risk of bias arising from participants being able to discern the taste of the intervention and limited information about trial methods.<br/><sup>c</sup>Downgraded once due to imprecision caused by wide CIs.<br/><sup>d</sup>Downgraded once due to inconsistency as there was substantial heterogeneity (I<sup>2</sup> = 51%) which may have originated from different age groups recruited in the trials or different baseline levels of lung function.<br/><sup>e</sup>Downgraded once due to indirectness as the results only apply to those who can tolerate hypertonic saline.<br/><sup>f</sup>Downgraded twice due to imprecision: cross‐over trial analysed as a parallel trial (due to available data) which is likely to over‐estimate the within‐trial variability and increase imprecision, and small number of participants.<br/><sup>g</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline and the trial only included children aged 6 to 18 years, so results may not apply to adults.<br/><sup>h</sup>Downgraded once due to risk of bias: 1 trial was at high risk of detection bias as participants could discern the taste of the intervention.<br/><sup>i</sup>Downgraded once for inconsistency as there was heterogeneity in the results of the trials. Three out of the four trials reported no difference whilst one trial found a slight difference in favour of hypertonic saline. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (stable lung disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001506-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (during acute exacerbations of lung disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (during acute exacerbations of lung disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis (during acute exacerbations of lung disease) </p> <p><b>Settings:</b> hospitalised patients and outpatients </p> <p><b>Intervention:</b> hypertonic saline 3% to 7% </p> <p><b>Comparison:</b> isotonic saline </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Isotonic saline</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 3% to 7%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: approximately 14 days (at time of hospital discharge)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % change in FEV<sub>1</sub> (% predicted) was 32.3% in the isotonic saline group. </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % change in FEV<sub>1</sub> (% predicted) was 5.10% higher (14.67% lower to 24.87% higher) in the hypertonic saline 3% to 7% group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths were reported in either trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no significant difference between the groups in time until the next pulmonary exacerbation requiring hospitalisation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.86 (95% CI 0.57 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Adverse events reported were cough and wheeze.</p> <p>No serious adverse events were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>HR</b> : hazard ratio;<b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias: high risk of selection bias due to sequential allocation.<br/><sup>b</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline, and the trial included only adults so results may not apply to children.<br/><sup>c</sup>Downgraded once due to risk of bias: first trial was at high risk of detection bias as participants could discern the taste of the intervention, second trial was at high risk of selection bias due to sequential allocation.<br/><sup>d</sup>Downgraded once due to imprecision: no numerical data provided and small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline for cystic fibrosis (during acute exacerbations of lung disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001506-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hypertonic saline compared with rhDNase with for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with rhDNase with for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline (daily) </p> <p><b>Comparison:</b> rhDNase (daily)<sup>a</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>rhDNase</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: 3 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change from baseline in FEV<sub>1</sub> (% predicted) was 1.6% higher (7.96% lower to 11.16% higher) in the hypertonic saline group compared to the daily rhDNase group.<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>c,d,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design.</p> <p> </p> <p>No significant difference in the primary outcome (lung function) at this time‐point, with improvements only in secondary outcomes. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> <p> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change from baseline in FEV<sub>1</sub> (% predicted) was 8% higher (2% higher to 14% higher) in the hypertonic saline group compared to the daily rhDNase group.<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,f,g</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design.</p> <p>An additional cross‐over trial of 18 participants found no difference between treatments in FEV<sub>1</sub> after 10 weeks (no data presented). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of sputum clearance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>15 episodes occurred during treatment with hypertonic saline and 18 with daily rhDNase. There was no statistical difference between treatments (see comment). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,f,g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design.</p> <p>Number of episodes reported rather than the number of participants with exacerbations (leading to a unit of analysis issue) so data not entered into the analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Increased cough was reported in 13 participants using hypertonic saline and 17 on daily rhDNase. There were similar rates of other adverse events between treatment arms (see comment). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,f,g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had a cross‐over design, so data not entered into analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>An alternate day rhDNase group was also included in 1 trial (<a href="./references#CD001506-bbs2-0023" title="GrieveR , ThompsonS , NormandC , SuriR , BushA , WallisC . A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care2003;19(1):71-9. [CFGD REGISTER: BD96h] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2001;56(Suppl 3):iii84. [CFGD REGISTER: BD96f] SuriR , GrieveR , NormandC , MetcalfeC , ThompsonS , WallisC , et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax2002;57(10):841-6. [CFGD REGISTER: BD96e] SuriR , MarshallLJ , WallisC , MetcalfeC , BushA , ShuteJK . Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2002;166(3):352-5. [CFGD REGISTER: BD96d] SuriR , MetcalfeC , LeesB , FlatherM , NormandC , ThompsonS , et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis. Thorax2000;55:A75. [CFGD REGISTER: BD96g] SuriR , MetcalfeC , LeesB , GrieveR , FlatherM , NormandC , et al. Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet2001;358(9290):1316-21. [CFGD REGISTER: BD96b] SuriR , MetcalfeC , WallisC , BushA . Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine2007;101(2):254-60. [CFGD REGISTER: BD96k] SuriR , MetcalfeC , WallisC , BushA . Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis. Pediatric Pulmonology2004;37(4):305-10. [CFGD REGISTER: BD96i] SuriR , WallisC , BushA , ThompsonS , NormandC , FlatherM , et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment2002;6(34):iii, 1-60. [CFGD REGISTER: BD96j] SuriR , WallisC , BushA . In vivo use of hypertonic saline in cystic fibrosis. Pediatric Pulmonology2000;Suppl 20:125-6. [CFGD REGISTER: BD96a] SuriR , WallisC , MetcalfeC , ThompsonS , BushA , ShuteJ . Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2001;Suppl 22:281. [CFGD REGISTER: BD96c] ">Suri 2001</a>), but to allow a comparison across the trials, only results from the rhDNase daily group are presented in the tables.<br/><sup>b</sup>Data analysed as MD between treatment groups via generic inverse variance due to cross‐over design of the trial; therefore, an estimate of the assumed risk is not available.<br/><sup>c</sup>Downgraded once due to risk of bias: high risk of detection bias as participants could discern the taste of the intervention and limited information was provided about the methodological design of the trial.<br/><sup>d</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline.<br/><sup>e</sup>Downgraded once due to imprecision: cross‐over trial analysed as a parallel trial due to available data, this approach is likely to over‐estimate the within study variability and increase imprecision; also small sample size.<br/><sup>f</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline, and the trial included only participants under the age of 18 so results may not apply to adults.<br/><sup>g</sup>Downgraded once due to imprecision: small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hypertonic saline compared with rhDNase with for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001506-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hypertonic saline compared with amiloride for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with amiloride for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline </p> <p><b>Comparison:</b> amiloride </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Amiloride</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: change from baseline, short‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: change from baseline, long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: 60 minutes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no significant difference between treatment groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>LCI</b> : lung clearance index; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias: high risk of detection bias as participants could discern the taste of the intervention and limited information was provided about the trial methods (including whether a washout period was used).<br/><sup>b</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline, and the trial included only adults so results may not apply to children.<br/><sup>c</sup>Downgraded once due to imprecision: no numerical data provided and small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hypertonic saline compared with amiloride for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001506-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Hypertonic saline compared with sodium‐2‐mercaptoethane sulphonate (Mistabron®) for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with sodium‐2‐mercaptoethane sulphonate (Mistabron®) for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline </p> <p><b>Comparison:</b> sodium‐2‐mercaptoethane sulphonate </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sodium‐2‐mercaptoethane sulphonate</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: short‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant difference in sputum volume, colour or cough frequency between the groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> <p>The only information provided relevant to this outcome was that there was no change in the number of courses of antibiotics prescribed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> <p>Participants in both treatment groups described coughing at the beginning of their inhalations. </p> <p>No serious adverse events occurred during the trial.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>LCI</b> : lung clearance index; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias: high risk of detection bias as participants could discern the taste of the intervention and limited information was provided about the trial design.<br/><sup>b</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline and the trial included only children aged 6 to 15 years so results may not apply to other age groups.<br/><sup>c</sup>Downgraded once due to imprecision: no numerical data provided and small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Hypertonic saline compared with sodium‐2‐mercaptoethane sulphonate (Mistabron®) for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001506-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Hypertonic saline compared with mannitol for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with mannitol for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline </p> <p><b>Comparison:</b> mannitol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mannitol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: short‐term </p> <p> </p> <p>Follow‐up: up to 95 minutes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> <p>FEV<sub>1</sub> was assessed in the included trial at 5 minutes and 95 minutes postintervention. These very short‐term time‐points are not of clinical relevance to this review. </p> <p>Change from baseline within‐groups was reported but no between‐group data.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of sputum clearance</b> </p> <p> </p> <p>Follow‐up: up to 95 minutes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no significant difference between treatment groups for matched voluntary cough. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow‐up: up to 95 minutes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial had cross‐over design.</p> <p>Mannitol was considered to be a more 'irritating' treatment than other treatments (4‐armed trial); no specific data given. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>LCI</b> : lung clearance index; <b>NA</b>: not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias: high risk of detection bias as participants could discern the taste of the intervention and no washout period was used.<br/><sup>b</sup>Downgraded once due to applicability: results apply only to those who can tolerate hypertonic saline, and the trial included only participants over the age of 16 so results may not apply to younger children.<br/><sup>c</sup>Downgraded once due to applicability: the outcome measured only at very short‐term time points (minutes after intervention), which are not of clinical relevance to this review.<br/><sup>d</sup>Downgraded once due to imprecision: no numerical data provided and small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Hypertonic saline compared with mannitol for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001506-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Hypertonic saline 7% versus xylitol for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline 7% versus xylitol for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline 7% </p> <p><b>Comparison:</b> aerosolised xylitol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Xylitol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 7%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub> % predicted ranged from ‐0.1 to 8.8. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub> % predicted was 1.89% higher in the hypertonic saline </p> <p>(0.8% lower to 4.58% higher).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial had a cross‐over design.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths were reported in either trial.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of sputum clearance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference in median time to exacerbation between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were presented as a graph and we have reported narratively</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> serious adverse events </p> <p> </p> <p>Follow‐up: 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference between groups in relation to serious adverse events, RR 4.07 (95% CI 0.47 to 35.34). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no differences between treatment groups in specific adverse events including gastro‐intestinal disorders, hepato‐biliary disorders, bronchospasm, haemoptysis or vascular disorders. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second;<b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA:</b> not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias due to trial methods being unclear in one trial and the risk of participants being able to discern the taste of the interventions due to their sweet and salty taste.<br/><sup>b</sup>Downgraded once due to imprecision caused by small participant numbers.<br/><sup>c</sup>Downgraded once due to indirectness as the trials were only carried out in adults and the results may not be applicable to children.<br/><sup>d</sup>Downgraded once due to imprecision caused by low participant numbers, low event rates and wide CIs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Hypertonic saline 7% versus xylitol for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001506-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Hypertonic saline 7% versus hypertonic saline 3% for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline 7% versus hypertonic saline 3% for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> hypertonic saline 7% </p> <p><b>Comparison:</b> hypertonic saline 3% </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 3%</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hypertonic saline 7%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, short‐term </p> <p> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in FEV<sub>1</sub> % predicted was 12.53% (20.04). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV1 % predicted was 13.00% lower in the hypertonic saline 7% group</p> <p>(25.20% lower to 0.73% lower).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a, b, c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial was seriously underpowered and was carried out as a pilot study (sample size calculation stated that 394 participants were needed and the pilot trial included 30). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> change from baseline, long‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LCI</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of sputum clearance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second;<b>LCI</b> : lung clearance index; <b>MD</b> : mean difference; <b>NA:</b> not applicable; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of bias due to the trial being seriously underpowered.<br/><sup>b</sup>Downgraded once due to imprecision caused by small participant numbers.<br/><sup>c</sup>Downgraded once due to indirectness as the trials were only carried out in children and the results may not be applicable to adults. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Hypertonic saline 7% versus hypertonic saline 3% for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/full#CD001506-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001506-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 At 2 to 4 weeks (all participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [0.71, 5.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 At 2 to 4 weeks (participants aged 14 years and over)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [1.14, 7.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 At 2 to 4 weeks (children FEV1 &gt; 80% predicted)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐7.45, 6.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 At 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [‐0.08, 8.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.37 [1.03, 9.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.6 At 36 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [‐1.56, 8.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.7 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [‐2.72, 7.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.8 24 hours after single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐3.48, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change in FVC (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 At 2 to 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [‐1.63, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 At 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [0.79, 8.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.64 [0.17, 7.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 At 36 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [‐0.82, 7.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [‐1.09, 6.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mean change in FEV<sub>0.5</sub> (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Mean change in FEV<sub>0.75</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.03, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 36 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.01, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 LCI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 At 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 LCI change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.00, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.00, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Radiolabelled isotope clearance (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 At 60 mins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.14 [2.56, 9.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Mucociliary clearance measured as area under the curve <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐212.06 [‐271.64, ‐152.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Change in mucocilliary clearance rate (% clearance) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 At 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Exercise capacity (using a subjective visual analogue score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 At Week 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.19, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 At Week 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.18, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Quality of life (change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 CFQ parent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [‐1.69, 4.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 CFQ 14+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.77 [1.86, 13.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 SF36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [‐7.90, 13.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 CFQ‐R respiratory domain at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.40 [‐2.45, 17.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Feeling of cleared chest (using a subjective visual analogue scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 At up to Week 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.35, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Average number of pulmonary exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Number requiring antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Number of visits not requiring antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Average number of hospital admissions per participant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Mean adherence rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Change in log10 colony forming units (CFU)/g from baseline at final visit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 P. aeruginosa </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 S. aureus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Mean time (years) to first detection of CF pathogens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 First detection of S aureus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 First detection of H influenzae </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 First isolation of P aeruginosa </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Adverse events: acute fall in lung function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Acute fall in FEV₁ % predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Acute fall in FEV₁ mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Adverse events 2 to 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.59, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.3 Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [0.36, 26.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.4 Chest tightness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [0.12, 65.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.5 Haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.21, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.6 Wheezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 4.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.7 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.09, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.8 Increased sputum production</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.09, 19.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Adverse events 48 to 52 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 All adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.42, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.4 Chest tightness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.5 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.13, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.6 Wheezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.38, 11.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.7 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.53, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.8 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.63, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.9 Ear infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.74, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.10 Acquisition of Burkholderia cepacia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.15, 7.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.11 Abdominal distension / flatulence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.71, 5.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.12 Rhinorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.04, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.13 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.30, 2.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001506-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline in acute lung disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Change in FEV<sub>1</sub> from baseline (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 At day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 At day 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 At discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Change in FVC from baseline (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 At day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 At day 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 At discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Shuttle walk test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 At day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hypertonic saline 3% to 7% versus isotonic saline in acute lung disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001506-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Hypertonic saline versus rhDNase</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Change in FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 At 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Improvement in FEV<sub>1</sub> &gt;10% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 At 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Change in FVC (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Exercise tolerance ‐ oxygen saturation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Exercise tolerance ‐ VAS for breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Exercise tolerance ‐ FCS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Mean percentage change in quality of life score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Treatment difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Delivery time (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Hypertonic saline versus rhDNase</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001506-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Hypertonic saline versus mannitol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Delivery time (mins) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Hypertonic saline versus mannitol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001506-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Hypertonic saline 7% versus xylitol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 FEV<sub>1</sub> % predicted mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 At 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [‐0.80, 4.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 FVC % predicted mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 At 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Adherence to treatment ‐ mean number of doses taken <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Density of colonisation of pathogens ‐ change from baseline log CFU/mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 P aeruginosa </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [‐0.90, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 P aeruginosa mucoid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐3.48, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.3 S aureus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐1.03, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 15.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.07 [0.47, 35.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.3 Gastrointestinal disorders (bowel obstruction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.23 [0.39, 134.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.4 Hepatobiliary disorders (abnormal lab results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.38, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.5 Bronchospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.6 Haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.20, 21.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.7 Vascular disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Hypertonic saline 7% versus xylitol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001506-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Hypertonic saline 7% versus hypertonic saline 3%</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 FEV<sub>1</sub> % predicted (absolute value) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 At 28 days (endpoint)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 FEV<sub>1</sub> % predicted mean percentage change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 At 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 FVC % predicted (absolute value) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 At 28 days (endpoint value)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 FVC % predicted mean percentage change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 At 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Exercise capacity ‐ PEFR (L/min) via a 3‐minute step test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 PEFR endpoint values at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Exercise capacity ‐ SaO<sub>2</sub> via a 3‐minute step test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 SaO2 % at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Exercise capacity ‐ heart rate (bpm) via a 3‐minute step test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 At 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Breathlessness via a 3‐minute step test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.1 VAS of perceived breathlessness at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Hypertonic saline 7% versus hypertonic saline 3%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001506.pub5/references#CD001506-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001506.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001506-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001506-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001506-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD001506-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD001506-note-0015">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001506-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001506\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001506\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001506\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001506\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001506\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001506.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001506.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001506.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001506.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001506.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720271934"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001506.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720271938"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001506.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfd137a7c9377',t:'MTc0MDcyMDI3Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 